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About this Thesis
Congenital diaphragmatic hernia (CDH) is a 
severe congenital anomaly of the diaphragm 
and both lungs, which occurs in approximately 
1 per 2,500 births. Most CDH patients will 
have difficulty breathing directly after birth, 
and need immediate mechanical ventilatory 
support. Advanced postnatal treatment op-
tions with standardized treatment improved 
the survival outlook, even of CDH patients 
with most severe pulmonary hypoplasia and 
pulmonary hypertension. 
This thesis describes the postnatal risks and 
short- and long-term outcomes of CDH 
patients from neonatal age until school age. 
Early outcomes include the risk of disturbed 
thyroid hormone concentrations during the 
neonatal period and the risk of persistent pul-
monary hypertension in the first year of life. 
Long-term outcomes include the risk of neu-
ropsychological problems and growth failure 
until school age. Six studies were performed 
in the Sophia Children’s Hospital in Rotter-
dam, the Netherlands (chapters 2, 3, 4, 7, and 
8), and two in the Westmead Children’s Hos-
pital in Sydney, Australia (chapters 5 and 6). 
Congenitale hernia diafragmatica ofwel een 
aangeboren middenrifbreuk, in het Engels 
‘congenital diaphragmatic hernia’ (CDH), is 
een ernstige aangeboren afwijking van het 
middenrif en de longen die bij 1 op de 2.500 
pasgeborenen voorkomt. De meeste kin-
deren met deze aandoening hebben direct 
na de geboorte moeite met ademen waar-
door ze meteen beademd moeten worden. 
Dankzij nieuwe behandelmethoden en ge-
standaardiseerde behandeling zijn hun over-
levingskansen in de afgelopen jaren echter 
sterk verbeterd. 
Dit proefschrift beschrijft onderzoek naar 
diverse uitkomsten van CDH patiënten, waar-
onder de schildklierfunctie, de aanwezigheid 
van pulmonale hypertensie (verhoogde bloed-
druk in de longvaten), de groei en neuropsy-
chologische ontwikkeling. Zes studies werden 
verricht in het Erasmus MC-Sophia Kinder-
ziekenhuis in Rotterdam (hoofdstukken 2, 3, 
4, 7 en 8) en twee studies in het Westmead 
Children’s Hospital in Sydney (hoofdstukken 
5 en 6). 
Do you ever think about the importance of our breathing? 
Life starts from the first breath we take in when we are born and continues until our 
last breath. Breathing is something we do naturally, most often without thinking about 
it, and without appreciating it. However, we cannot live without breathing: breath is life.
For children born with a diaphragmatic hernia, breathing is not so simple and self-
evident. They will have difficulty breathing immediately after birth due to the lung 
problems associated with the defect in their diaphragm. Consequently, from the first 
breath of life, these children are at a high risk of mortality and morbidity. Fortunately, 
more and more of them now survive. Little is known, however, about the risks and 
consequences of this condition when children grow up. 
This thesis describes the postnatal risks and outcomes of children with congenital 
diaphragmatic hernia from neonatal age until school age.
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Congenital diaphragmatic hernia (CDH) is a congenital anomaly of the diaphragm and both 
lungs, which occurs in approximately 1 per 2,500 births.1 Normally in humans, the diaphragm 
starts to develop around four weeks of gestation and is fully formed by the twelfth week of 
gestation.2 In infants with CDH, the diaphragm does not form properly creating a defect that 
allows abdominal viscera to enter into the thoracic cavity. Multiple factors including genetic 
and environmental factors as well as compression by the abdominal organs impede the 
normal development of the lungs. Maldevelopment of the terminal bronchioles, alveoli and 
pulmonary vessels is the result,3, 4 and most patients experience severe respiratory failure 
soon after birth because of pulmonary hypoplasia and pulmonary hypertension. 
Postnatal management
As long ago as 1701, Holt reported the first case of CDH in a child.5 The first success-
ful repair of the diaphragmatic defect was performed in 1902 by Heidenhain.5 As it was 
hypothesized that early repair could improve survival of the child, the aim was to perform 
surgery at an early age. In 1946, Gross et al.5 reported the first successful surgical repair 
of a diaphragmatic defect in a neonate within the first 24 hours after birth. From then on, 
CDH was considered a surgical emergency, and immediate surgical repair after birth was the 
cornerstone of treatment. Over the years, however, the idea developed that this may not 
be the best treatment option. Indeed, several studies found that delayed surgery, allowing 
physiologic stabilization of the patients, improved their outcome.6, 7 Other studies, in contrast, 
did not find a difference in outcome between acute and delayed surgical repair.8, 9 Despite 
the lack of clear evidence, surgeons have embraced the concept of delayed surgical repair 
increasingly since the 1980s, and this is now considered as standard of care.10 
Other advances in surgical treatment include the use of minimally invasive techniques 
and closure of the defect with a patch. The method of closure depends on the size of the 
diaphragmatic defect. Standardized classification of the defect size is advocated by using the 
letters A to D, with ‘A’ reflecting the smallest and ‘D’ the largest defect size.11 Small defects 
(A and B) are repaired primarily, whereas large defects require closure with a patch. Now-
adays, surgical repair can be accomplished by open and minimally invasive techniques. Large 
defects are repaired using the open technique whereas smaller defects can be repaired by 
laparoscopy or thoracoscopy. Benefits of the latter techniques are a lesser need of surgery 
for early adhesive small bowel disease and a shorter hospital stay.12 On the other side, a 
higher rate of diaphragmatic hernia recurrence with minimally invasive techniques can be 
considered a disadvantage.12 
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The ventilation strategy for CDH is based on the principle of gentle ventilation, whereby 
the peak inflation pressure is controlled by limiting the pressure of ventilation while tolerating 
an oxygen saturation of 85% and a rise of the arterial pressure of carbon dioxide (permissive 
hypercapnia).13 Apart from stimulating spontaneous ventilation, this approach achieves ade-
quate oxygenation while it avoids injury to the lungs by volutrauma, shear forces, and oxygen 
free radicals. Another ventilation strategy that is increasingly used for CDH patients is high 
frequency oscillation ventilation (HFOV). HFOV allows adequate oxygenation and carbon 
dioxide elimination at low ventilation pressures thereby decreasing iatrogenic barotrauma.14 
A trial in 171 CDH patients treated with conventional (gentle) ventilation or HFOV as the 
initial ventilation mode found no difference in mortality or chronic lung disease between 
the treatment groups.15 Still, the group initially treated with conventional ventilation were 
ventilated for fewer days, were treated with vasoactive medication for a shorter time, and 
a smaller proportion required extracorporeal membrane oxygenation (ECMO) and med-
ication to treat pulmonary hypertension.15 Therefore, the CDH EURO Consortium now 
recommends conventional mechanical ventilation as the initial ventilation strategy, and HFOV 
should be used as rescue therapy when conventional ventilation fails.10 
Pulmonary hypertension associated with CDH is a major cause of mortality.16, 17 A reduced 
number of pulmonary arteries in combination with altered vasoreactivity and abnormal 
pulmonary vascular remodeling in CDH contribute to the development of pulmonary hyper-
tension.18 The optimal treatment is unknown; currently, inhaled nitric oxide (iNO) is the most 
used acute treatment for pulmonary hypertension in CDH infants,19 although its beneficial 
effects on oxygenation and survival have been questioned.20 Another treatment option for 
persistent pulmonary hypertension in CDH patients is sildenafil, which appears to be more 
effective than iNO.21 However, both the efficacy and safety of iNO and sildenafil have not 
been studied in a large trial. Other treatment options include other vasodilators such as 
prostacyclins, milrinone and bosentan, which have been even less studied.22, 23 Therefore, 
further studies are necessary to clarify the efficacy and safety of medication for pulmonary 
hypertension in CDH patients.
ECMO is reserved as a life-saving treatment option for CDH patients with severe revers-
ible respiratory failure when other treatment options fail. Still the use of ECMO for CDH 
patients is controversial, and a Cochrane systematic review in 2008 concluded: ‘the benefit of 
ECMO for babies with CDH is unclear’.24 While some studies have shown increased survival 
rates with ECMO treatment,25, 26 other studies have demonstrated no improved survival.27 
Recently, the Extracorporeal Life Support Organization Registry reported a survival rate of 
51% in CDH patients who require ECMO treatment.28 In addition to this low survival rate, 
adverse long-term outcomes such as impaired neurodevelopmental outcome, increased 
respiratory morbidity and growth failure have been found in these patients.29-31 We should 
not forget, however, that they represent a subgroup of CDH patients with more severe 




do not know whether ECMO is beneficial in CDH patients and how candidates for ECMO 
should be selected.10
In summary, current postnatal management of CDH is based on the standardized and 
revised guidelines of the CDH EURO Consortium protocol,10 and this includes gentle ven-
tilation with permissive hypercapnia, delayed surgical repair after stabilization, with the use of 
iNO, HFOV and ECMO as rescue therapies. A timeline showing when these therapy options 
were introduced in the Erasmus MC-Sophia Children’s Hospital is presented in figure 1.
Figure 1. Timeline showing the introduction of new postnatal treatment strategies for congenital dia-


















Abbreviations: CDH=congenital diaphragmatic hernia; ECMO=extracorporeal membrane oxygenation; HFOV=high frequency 
oscillation ventilation; iNO=inhaled nitric oxide.
Mortality
Reported mortality rates for CDH patients vary considerably in the literature. One of the 
reasons for this difference in reported mortality rates is the presence of ‘hidden mortality’.32 
The term ‘hidden mortality’ accounts for intrauterine deaths because of CDH and CDH 
patients who die before arriving at the reporting institution and who, therefore, are not 
reported by institution-based studies. Nevertheless, it appears that advances in treatment, 
such as delayed surgical repair, ‘gentle ventilation’, and the use of HFOV and ECMO have 
decreased mortality rates occurring during initial hospital stay in CDH patients. Especially, 
the beneficial effects of standardized evidence-based management on survival have been 
acknowledged in recent years. With standardized treatment, institutions report a survival 
between 82% and 88%.33-35 With this in mind, it is important that CDH research also focuses 





As mentioned above, the improved survival has made the long-term outcomes and quality 
of life of CDH survivors increasingly important issues. During initial hospital stay, patients are 
at risk for morbidities related to their critical illness, their underlying diagnosis as well as their 
medical treatment. Furthermore, CDH survivors are at risk for long-term sequelae including 
pulmonary disease, gastro-intestinal morbidity, poor growth, and neurological impairment.36 
The high prevalence of long-term morbidities among CDH survivors emphasizes the impor-
tance of close follow-up and long-term care. 
Endocrine morbidity
Neonates with CDH are considered as critically ill: they are treated with mechanical ven-
tilation, and most of them require vasoactive medication and treatment for pulmonary 
hypertension. As pointed out above, ECMO is offered to those with severe reversible 
respiratory failure.10, 37 Critical illness may be associated with endocrine dysfunction such 
as non-thyroidal illness syndrome (NTIS), which is characterized by low thyroxine and low 
triiodothyronine, increased reverse triiodothyronine, and normal or low thyroid-stimulating 
hormone.38 Low thyroid hormone levels have been reported in critically ill neonates with 
various diseases such as congenital heart disease, sepsis, persistent pulmonary hypertension, 
hyaline membrane disease, pneumonia, and CDH.39-41 These low thyroid hormone levels can 
be detected during neonatal screening for congenital hypothyroidism. As thyroid hormones 
are essential for normal development of the central nervous system,42 NTIS could have 
important consequences for neurodevelopmental outcome. Information on the incidence 
and clinical consequences of NTIS in CDH patients is not yet available. It is also unknown 
whether disturbed thyroid hormone concentrations persist.
Pulmonary morbidity
CDH patients are immediately intubated after birth and ventilated for a varying period of 
time. Approximately 30% of CDH survivors develop chronic lung disease.10 Lung function is 
also affected in the first year of life, with decreased expiratory flows and increased functional 
residual capacity.30 Lung function appears to gradually improve to normal or near-normal 
during childhood.43 Although in a follow-up study by Spoel et al.44 CDH survivors who had 
received ECMO treatment had compromised lung function at the ages of 5, 8, and 12 years, 
with deterioration over time. A recent study likely showed that airflow obstruction and diffu-
sion capacity of CDH survivors deteriorated mildly from childhood into adulthood.45 Spoel et 
al.46 additionally found ventilation abnormalities in six out of nine patients on hyperpolarized 
helium-3 MRI imaging at adult age. They also found structural changes indicative of enlarged 
alveolar dimensions in the ipsilateral lung. These findings demonstrate the importance of 




As described in a previous section, pulmonary hypertension is common among CDH 
infants and is a major cause of early death. Its persistence after the first days of life is associ-
ated with worse outcome.17, 47 Studies have found that pulmonary hypertension persisted in 
half of CDH patients at 3 weeks of age,47 and in 18% at 3 months of age.17, 36 No study has 
as yet routinely assessed pulmonary hypertension in the follow-up of CDH patients after 
the age of 3 months.17 It is therefore hard to tell which CDH patients qualify for long-term 
follow-up of pulmonary hypertension.
Growth failure and nutritional morbidity
Many CDH survivors show poor growth during early life. Reported prevalence rates of wast-
ing, which reflects acute malnutrition, at 1 year of age range from 8% to 69%.48, 49 The cause for 
poor growth in CDH patients is probably multifactorial, including increased catabolic stress in 
the neonatal period, gastroesophageal reflux disease, and persistent pulmonary impairment.50 
A contributing factor is oral aversion, which has been found in about one quarter of CDH 
infants.50 While one study has reported catch-up growth after the first 6 months,49 a recent 
longitudinal study showed that growth failure still persisted in 13.5% of patients at 6 years.51 
Adequate nutritional intake is important as malnutrition in infancy has been associated with 
adverse long-term outcomes such as impaired neurodevelopment in otherwise healthy 
children.52, 53 Currently it is unknown whether poor growth in CDH patients persists during 
childhood. Additionally, it is unknown whether physical growth affects neurodevelopmental 
outcomes of CDH patients at all.
Neurodevelopmental and neuropsychological morbidity
Neurodevelopmental dysfunction is considered one of the most significant morbidities 
among CDH survivors. Neurodevelopmental problems seem to vary with age and widely 
varying outcomes have been reported. Danzer et al.54 reported mildly and severely delayed 
neurocognitive and language scores in 17% and 15%, respectively, of 41 CDH patients at 
the median age of 24 months. Psychomotor development was mildly and severely delayed 
in 23% and 31%, respectively.54 However, Gischler et al.55 found normal mental development 
scores in 12 CDH patients at 24 months of age, but psychomotor development scores were 
also delayed in this cohort. Neurocognitive and motor problems have also been found at 
school age. While Danzer et al.56 reported normal intelligence quotient scores and normal 
academic achievement sores in 35 CDH patients at 5 years of age, visual-motor-integration 
scores of these children were lower than those of the norm population. Further, more of 
them had reactive (23%) or pervasive developmental problems (27%) compared with the 
norm population.56 Madderom et al.57 likewise found a normal intelligence in a cohort of 
35 CDH patients at 8 years of age, whereas the proportions of patients with concentration 
and behavioral attention problems were higher than the norm population. Currently, we do 
not know which specific neuropsychological domains are most affected in CDH patients 
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at school age. Worse still, we do not know which patients are most at risk of long-term 
impairments and neither do we know whether severity of illness scores or early growth 
parameters are predictive of neuropsychological outcome at this age.
Conclusion 
Advanced postnatal treatment options have led to improved survival of CDH patients, 
even of those who have severe pulmonary hypoplasia and pulmonary hypertension. These 
CDH survivors seem to carry a high but varying risk of developing postnatal morbidities. 
An increasing number of institutions in different countries now acknowledge long-term 
longitudinal follow-up of CDH patients is needed. Currently, little is known about the devel-
opment and persistence of postnatal morbidities including thyroid hormone disturbances, 
growth failure, and adverse neurodevelopmental outcomes in this group of CDH patients 
who received modern treatment strategies including HFOV, ECMO and medication for 
pulmonary hypertension. Further, the evidence in the current literature on risk factors for 




Outline of this thesis
The aim of this thesis is to evaluate the postnatal risks and outcomes of CDH patients both 
at the short-term and long-term, and to identify possible risk factors associated with out-
comes. The reported studies included CDH patients treated and followed in the Erasmus 
MC-Sophia Children’s Hospital in Rotterdam, the Netherlands (chapters 2, 3, 4, 7, and 8) 
and the Westmead Children’s Hospital in Sydney, Australia (chapters 5 and 6). The outline 
of this thesis is schematically shown in figure 2.
Chapter 2 describes the incidence and consequences of aberrant screening results for 
congenital hypothyroidism in ECMO-treated CDH patients and other ECMO-treated neo-
nates. Additionally, we determine associations between clinical variables and an aberrant 
congenital hypothyroidism screening result, as well as the association between congenital 
hypothyroidism screening results and mortality.
Chapter 3 describes the disturbances in thyroid hormone levels during neonatal ECMO for 
CDH and other life-threatening conditions requiring ECMO. Further, the neuropsychological 
outcome at 2 years of age is assessed.
Chapter 4 reports the prevalence of persistent pulmonary hypertension in CDH patients 
during the first year of life. Further, we compare characteristics of patients with persistent 
pulmonary hypertension with patients without persistent pulmonary hypertension, and give 
advice about the follow-up of pulmonary hypertension.
Chapter 5 describes the physical growth during the first year of life of CDH patients. Risk 
factors for failure to thrive are also determined.
Chapter 6 assesses the neurodevelopmental outcome at 1 year and 3 years of age of CDH 
patients. Neurodevelopmental outcomes of CDH patients are compared with a healthy 
age-matched control group.
Chapter 7 describes the neuropsychological outcomes at 8 years of age of patients with 
CDH and patients treated with neonatal ECMO following other diagnoses. Further, associ-
ations between neuropsychological outcomes and early physical growth as well as severity 
of illness are determined.
Chapter 8 describes physical growth of CDH patients until 12 years of age. Further, associ-
ations between physical growth and clinical variables are investigated. Potential causes of poor 
growth are identified through dietary consultations with indirect calorimetry measurements 
in a subset of patients with growth failure.
In chapter 9 the study results are discussed and put into perspective. 
The results of all studies are summarized in English (chapter 10) and Dutch (chapter 11). 
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Figure 2. Schematic overview of the chapters in this thesis showing which studies were performed at 
the different follow-up ages
Chapter 2: A nationwide evaluation of congenital hypothyroidism screening during neonatal extracorporeal membrane oxygenation 
Chapter 3: Changes in thyroid hormone levels during neonatal extracorporeal membrane oxygenation
Chapter 4: Characteristics of infants with congenital diaphragmatic hernia who need follow-up of pulmonary hypertension
Chapter 5: Growth in children with congenital diaphragmatic hernia during the first year of life
Chapter 6: Neurodevelopmental outcome in congenital diaphragmatic hernia survivors during the first three years
Chapter 7: Risk factors of impaired neuropsychological outcome in school-aged survivors of neonatal critical illness
Chapter 8: Congenital diaphragmatic hernia and growth to 12 years
Neonatal age Pre-school age School age
0 - 2 weeks of age
0 - 3 years of age
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Background: Thyroid hormone concentrations may deviate from normal values during critical 
illness. This condition is known as non-thyroidal illness syndrome (NTIS), and it can influence 
the results of screening for congenital hypothyroidism (CH) during neonatal extracorporeal 
membrane oxygenation (ECMO).
Objectives: To determine the incidence of aberrant CH screening results in ECMO-treated 
neonates, to identify possible determinants, and to follow up patients with abnormal thyroid 
hormone concentrations.
Methods: In this retrospective cohort study, we included 168 ECMO-treated neonates 
admitted from 2004 to 2014 and screened by protocol and divided them into the following 
3 groups: group 1 (screened during ECMO, n=107), group 2 (screened shortly before ECMO, 
n=26), and group 3 (screened shortly after ECMO, n=35).
Results: CH screening results were aberrant in 67.3% (72/107) of the neonates screened 
during ECMO, in 73.1% (19/26) of the neonates screened before ECMO, and in 31.4% 
(11/35) of the neonates screened after ECMO (p<0.001). Of the neonates with an aber-
rant screening result, all but 2 (i.e. 98%) had a low thyroxine concentration with a normal 
thyrotropin concentration at screening, as is seen in NTIS. None was diagnosed with CH. 
Mortality did not significantly differ between neonates with an aberrant screening result 
(32.4%) and neonates with a normal screening result (22.7%; p=0.18). Screening before 
ECMO (odds ratio: 5.92; 95% confidence interval: 1.93-18.20), screening during ECMO 
(odds ratio: 4.49; 95% confidence interval: 1.98-10.19), and a higher Pediatric Logistic Organ 
Dysfunction-2 score (odds ratio: 1.31; 95% confidence interval: 1.04-1.66) were associated 
with an aberrant screening result.
Conclusions: Aberrant CH screening results were found in most ECMO-treated neonates 
screened before or during ECMO, which is likely due to NTIS. Follow-up of thyroid hormone 
concentrations is best started after recovery from critical illness. Our results suggest that 
thyroxine therapy is not required during ECMO.




As thyroid hormones are essential for normal brain development, children with congenital 
hypothyroidism (CH) are at risk for intellectual disability.1 CH screening and early treatment 
have almost eliminated intellectual disabilities caused by untreated CH. In the Netherlands, 
CH screening is primarily based on thyroxine (T4) screening with supplementary thyrotropin 
(TSH) and thyroxine-binding globulin measurements aimed at identifying not only children 
with primary hypothyroidism but also children with central hypothyroidism.2 However, inter-
pretation of the screening results can be complicated by factors that can transiently reduce 
thyroid hormone concentrations, such as prematurity,3 drug use,4 cardiac surgery,5 and crit-
ical illness.6 This condition of disturbed thyroid hormone concentrations (low T4 and low 
triiodothyronine, increased reverse triiodothyronine, and normal or low TSH) during critical 
illness is referred to as non-thyroidal illness syndrome (NTIS) or euthyroid sick syndrome. It 
is important to distinguish between CH and NTIS because CH therapy should be initiated 
as soon as possible, whereas treatment for NTIS is not recommended.6 In previous studies 
critically ill neonates have had lower thyroid hormone concentrations than healthy neo-
nates,7-9 and this has been associated with a prolonged hospital stay and a higher mortality.7, 
9 Low thyroid hormone concentrations consistent with NTIS have been found in neonates 
on extracorporeal membrane oxygenation (ECMO).10 However, it is unknown whether 
ECMO exerts an influence on CH screening results and whether there are any implications 
of a positive CH screening result during ECMO. 
We therefore wanted to determine the incidence of aberrant CH screening results in 
ECMO-treated neonates, identify possible determinants of aberrant screening results, and 





In this retrospective cohort study, we included ECMO-treated neonates admitted between 
January 1, 2004, and December 31, 2014, who underwent CH screening in either of the 
two pediatric ECMO centers in the Netherlands (i.e. the Erasmus MC-Sophia Children’s 
Hospital, Rotterdam and the Radboud UMC-Amalia Children’s Hospital, Nijmegen). These 
centers use the same entry criteria and treatment protocols, but the prime fluid is different: 
erythrocyte concentrate is used in the Erasmus MC-Sophia Children’s Hospital, and eryth-
rocyte concentrate with fresh frozen plasma (FFP) is used in the Radboud UMC-Amalia 
Children’s Hospital. ECMO was initiated in case of reversible severe respiratory failure with 
an estimated mortality risk >80% as described by Stolar et al.11 The exclusion criteria were: 
screening not in conformity with the Dutch neonatal screening protocol, incomplete or no 
screening results available, no registration in the Dutch civil registry (not invited for screening), 
and ECMO initiated after 8 days of life (not critically ill at the scheduled time of screening). 
We created the following 3 groups: group 1 (screened during ECMO), group 2 (screened 
shortly before ECMO), and group 3 (screened shortly after ECMO). Neonates in groups 2 
and 3 were considered critically ill at screening, but they did not receive ECMO at that time. 
CH screening results were obtained from the National Institute for Public Health and Envi-
ronment (RIVM). In the Netherlands, CH screening is primarily based on T4 measurements by 
immunochemical blood spots sampled 72-168 hours after birth. The method is described in 
detail in the supplementary material. We classified the initial screening results as either normal 
or aberrant (abnormal or borderline result on the first heel puncture). In neonates with an 
aberrant result, the pattern of changes in thyroid hormone concentrations was classified into 
3 categories: abnormally low T4 (≤-3.0 standard deviation score (SDS)) with normal TSH (≤7.0 
mU/l), mildly lowered T4 (-3.0< T4≤-1.6 SDS) with normal TSH (≤7.0 mU/l), and mildly low-
ered T4 (-3.0<T4≤-1.6 SDS) with mildly elevated TSH (7.0<TSH≤21.0 mU/l). Relevant clinical 
data were collected. The primary diagnosis was defined as the underlying diagnosis requiring 
ECMO support. Illness severity was estimated using the Pediatric Risk of Mortality III (PRISM 
III) score,12 calculated for the first 24 hours of pediatric intensive care unit (PICU) stay, and the 
Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score,13 computed for the 24 hours prior 
to the first heel puncture. Povidoneiodine and radiocontrast materials were not used. 
Ethical approval was obtained from the local ethics committees (CMO 2005/253).
Follow-up of neonates with abnormal thyroid hormone concentrations
Follow-up serum free T4 (FT4) and TSH concentrations were obtained from the medical 
charts of neonates with an abnormal CH screening result. FT4 and TSH were compared to 
the reference values established by Lem et al.14 An abnormal value was defined as <-2 SDS 
or >+2 SDS compared to the reference values. 




Data are expressed as means±standard deviation, medians (interquartile range), or num-
bers (%), as appropriate. Categorical variables were compared using the chi-square test or 
Fisher’s exact test. Student’s t-test or a one-way analysis of variance was used for normally 
distributed variables, and the Mann-Whitney U test or the Kruskal-Wallis test was applied 
for non-normally distributed variables. To correct for multiple testing, the Bonferroni cor-
rection was used, and adjusted p-values are given. Univariate logistic regression analyses 
served to identify associations between clinical variables (primary diagnosis, time of screening 
(before/during/after ECMO), PRISM III score, PELOD-2 score, and drug usage) and aber-
rant screening results. Use of the following intravenous drugs ≤8 hours prior to screening 
was recorded: dopamine, dobutamine, furosemide, morphine, fentanyl, and hydrocortisone. 
From a few hours after administration, these drugs can temporarily affect thyroid hormone 
concentrations; pretreatment levels are reached within hours after discontinuation of the 
drug.4, 15-19 Variables with p≤0.20 were included in the multiple logistic regression analysis. 
Multicollinearity was not found. 
Data were analyzed using SPSS 21.0 for Windows (IBM Corporation, Armonk, New York, 





ECMO was initiated in 318 neonates (figure 1). We included 168 neonates divided into 3 
groups. Table 1 shows the patient characteristics. In group 3, ECMO was started later, and CH 
screening was performed later. Further, the duration of ECMO therapy was shorter in group 
3. The median PELOD-2 score was higher in group 1 than in group 3 (adjusted p=0.045). 
Eight patients received levothyroxine therapy (supplementary table 2). Three of them had a 
normal initial screening result and developed hypothyroxinemia later, which was identified 
by routine laboratory tests. One patient was diagnosed with thyroid dyshormonogenesis 
and required lifelong treatment.










Screening not conform protocol1: n=83
Deceased prior to screening: n=27
No/incomplete data: n=8
No Dutch civil registration: n=2




1 Screening performed too early: n=1; Screening performed too late: n=82.
Abbreviation: ECMO=extracorporeal membrane oxygenation.
Congenital hypothyroidism screening results
Table 2 shows the screening results. The incidence of aberrant results was higher in group 1 
(67.3%) and group 2 (73.1%) than in group 3 (31.4%; both adjusted p<0.001). At the initial 
screening, the combination of low T4 and normal TSH was found in 100 of 102 neonates 
(table 2). Neonates with an aberrant screening result were treated longer with ECMO and 
had higher PELOD-2 scores than those with a normal screening result (supplementary table 
3). The incidence of aberrant screening results in group 1 in both centers was similar and 
thus irrespective of the use of FFP in the prime fluid (67.2% with FFP versus 67.3% without 
FFP; p=1.00). The proportion of aberrant screening results in group 1 was not dependent 
on the time elapsed between the start of ECMO and blood sampling for CH screening 
(data not shown).
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Gestational age (weeks) 39.9 (38.1-41.0) 40.0 (37.0-41.0) 40.4 (39.0-41.1) 0.21
Birth weight (grams) 3247±631 3256±704 3541±595 0.06
Male 62 (57.9%) 17 (65.4%) 20 (57.1%) 0.77
Primary diagnosis
 Meconium aspiration syndrome
 Congenital diaphragmatic hernia
 Sepsis


















Age at start ECMO therapy (day of life) 1 (0-2) 6 (5-7) 1 (0-1) <0.001
Duration of ECMO therapy (days) 7 (5-9) 6 (4-7) 3 (2-4) <0.001
PRISM III score (first 24 hours of PICU admission) 17 (15-23) 17 (9-21) 17 (12-21) 0.12
Age at CH screening (day of life) 4 (4-5) 4 (4-4) 6 (5-7) <0.001
PELOD-2 score (24 hours prior to CH screening) 6 (6-7) 5 (5-7) 6 (5-7) 0.03
Data are expressed as mean±standard deviation, median (interquartile range) or number (percentage), as appropriate. 
1 Other: congenital heart disease; congenital cystic adenomatoid malformation; recurrent pneumothoraces; infant respiratory 
distress syndrome in combination with pneumothorax; meconium peritonitis; respiratory failure of unknown cause.
Abbreviations: CH=congenital hypothyroidism; ECMO=extracorporeal membrane oxygenation; PELOD-2=Pediatric Logistic 
Organ Dysfunction-2; PICU=pediatric intensive care unit; PRISM III=Pediatric Risk of Mortality III.







Initial screening: normal screening result  no further action 35 (32.7%) 7 (26.9%) 24 (68.6%)
Initial screening: abnormal screening result  referral1
 Pattern of changes in thyroid hormone concentrations







Initial screening: dubious screening result  second screening
 Pattern of changes in thyroid hormone concentrations
 Mildly lowered T4; normal TSH3










Second screening: died before second screening
Second screening: normal screening result  no further action
Second screening: abnormal screening result  referral1
 Pattern of changes in thyroid hormone concentrations
 Abnormally low T4; normal TSH2
 Mildly lowered T4; normal TSH3



















1 Referral=referral to pediatrician for further analysis.
2 T4≤-3.0 SDS and TSH≤7.0 mU/l.
3 -3.0<T4≤ -1.6 SDS and TSH≤7.0 mU/l. 
4 -3.0<T4≤ -1.6 SDS and 7.0<TSH≤21.0 mU/l.
Abbreviations: ECMO=extracorporeal membrane oxygenation; SDS=standard deviation score; T4=thyroxine; TSH=thyrotropin.
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Figure 2. Flowchart: follow-up of neonates with an abnormal congenital hypothyroidism screening result
Group 1 (screened during ECMO)










Normal FT4 with high TSH: n=6
Low FT4 with high TSH: n=1
Low FT4 with normal TSH: n=2
Group 2 (screened before ECMO)





Group 3 (screened after ECMO)






Normal FT4 with high TSH: n=1
1 Deceased before follow-up of thyroid hormone concentrations was performed.
2 Transferred to another hospital.
Abbreviations: ECMO=extracorporeal membrane oxygenation; FT4=free thyroxine; TSH=thyrotropin.
Follow-up of neonates with abnormal thyroid hormone concentrations
The follow-up results are shown in figure 2. Sixteen neonates died before the follow-up was 
initiated, and 1 neonate was transferred to another hospital. Thyroid hormone concentrations 
normalized in 37 neonates at the median age of 10 days (interquartile range: 8-17.5). In 29 
of those neonates, this happened before 28 days of life; thyroid hormone concentrations 
normalized in the other 8 neonates between 30 and 108 days of life. Normalization of 
thyroid hormone concentrations could not be confirmed in 10 children (figure 2). At the 
last follow-up, low FT4 values ranged from 12.0 to 12.7 pmol/l and high TSH values ranged 
from 5.7 to 14.9 mU/l in these children.
Aberrant congenital hypothyroidism screening results and mortality
The mortality rate before hospital discharge was 28.6% (48/168). The mortality rate was not 
significantly higher in children with an aberrant CH screening result (32.4%) than in children 
with a normal screening result (22.7%; p=0.18).
Associations between clinical variables and an aberrant screening result
In the univariate logistic regression analyses, screening before ECMO, screening during ECMO, 
and a higher PELOD-2 score were significantly associated with an aberrant screening result 
(table 3). In the multivariate model, screening before and during ECMO remained associated 
with an aberrant screening result.
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PELOD-2 score 1.31 (1.04-1.66) 0.02 1.27 (0.99-1.63) 0.06
Primary diagnosis
 Meconium aspiration syndrome (ref) 




































1 adjusted for all other variables shown in the table. 
Abbreviations: aOR=adjusted odds ratio; CI=confidence interval; ECMO=extracorporeal membrane oxygenation; OR=odds 




More than two thirds of the initial CH screening results were aberrant in ECMO-treated 
neonates screened before and during ECMO. Low T4 in combination with a normal TSH 
concentration was found in all but two neonates with an aberrant screening result, which 
normalized rapidly without treatment in most cases. None of these children was diagnosed 
with CH. This suggests that aberrant screening results are due to NTIS, and that T4 therapy 
during ECMO is not required. The incidence of aberrant screening results in the group of 
neonates screened after ECMO was significantly lower than that in the two other groups, 
possibly reflecting that clinical recovery occurs during ECMO. 
Reduced thyroid hormone concentrations have been found in critically ill term neonates 
treated with or without ECMO.7-10 The effect of neonatal ECMO on thyroid hormone 
concentrations has been studied only by Stewart et al.10 They found a decline in all thyroid 
hormone concentrations directly after the start of ECMO in a cohort of 14 neonates, which 
suggests a dilutional effect.  Additionally,  Agus and Jaksic20 reported that thyroid hormone 
concentrations in ECMO prime fluid were significantly below normal. They suggested that 
these concentrations would be even lower in prime fluid without FFP.20 However, in the 
present study the incidence of aberrant screening results was not higher in the center with-
out FFP in the prime fluid. Although we acknowledge that the occurrence of hemodilution 
after ECMO cannulation plays a role in the lowering of thyroid hormone concentrations, we 
think that NTIS contributes more to this, and that hemodilution may further lower thyroid 
hormone concentrations in critically ill neonates. This assumption is supported by our finding 
that the incidences of aberrant screening results did not significantly differ between screening 
before (73.1%) and during (67.3%) ECMO. 
Screening before and during ECMO and a higher PELOD-2 score were associated with 
an aberrant screening result. Further, neonates with an aberrant screening result had higher 
PELOD-2 scores than neonates with a normal screening result, suggesting an influence of 
illness severity. Nevertheless, the use of the PELOD-2 score has some limitations. Though 
validated for a broad group of PICU patients,13 its performance in ECMO-treated neonates 
is unknown.  Further,  the PELOD-2 score is affected by treatment. Therefore, we cannot 
firmly conclude that illness severity plays a role in causing aberrant screening results. 
Dopamine has been found to suppress TSH in previous studies,17, 19 but we did not find an 
association between dopamine and an aberrant screening result. Therefore, dopamine does 
not seem to be the main cause of aberrant CH screening results. However, our study does 
not allow pinpointing of the exact effect of dopamine on thyroid hormone concentrations. 
Now, clinicians will be most concerned with the implications of aberrant CH screening 
results. As we found a lower risk of aberrant screening results in neonates screened after 
ECMO, follow-up of thyroid hormone concentrations should be started after ECMO and 
ideally after recovery from critical illness. However, because T4 treatment should not be 
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started later than the first two weeks of life to prevent intellectual disabilities,21 we recom-
mend that thyroid function tests should be repeated before this age. 
The consequences of low thyroid hormone concentrations during critical illness remain 
controversial. Correlations between low thyroid hormone concentrations and adverse out-
comes have been found, including increased mortality.8, 9, 22 We did not find a significant 
difference in mortality rates between neonates with an aberrant screening result and neo-
nates with a normal screening result. However, it should be noted that our sample size was 
small, and the results could have been biased by the lack of screening results for the 27 
neonates who died before screening was performed.
As thyroid hormones are essential for early brain development, transiently reduced thyroid 
hormone concentrations during early life could affect neurodevelopment, which has been 
shown in premature infants.23, 24 In that case, supplementation of thyroid hormones during 
NTIS could be beneficial. On the other hand, a recent study in young adults did not confirm 
this association between transient hypothyroxinemia of prematurity and adverse neurode-
velopmental outcomes.25 Furthermore, neonatal T4 supplementation was not beneficial 
in premature infants.26 As T4 therapy has not been proven to be beneficial, and thyroid 
hormone concentrations normalized rapidly in most cases, we do not advise starting T4 
therapy in ECMO-treated neonates based on an aberrant screening result in the first two 
weeks of life. 
To our knowledge, this is the first study reporting on CH screening results in ECMO-
treated neonates with follow-up of thyroid function. A strength is the use of an efficient CH 
screening method. Further, this is the largest cohort study investigating CH screening results 
in ECMO-treated neonates. Limitations are its retrospective design, its small sample size, and 
the lack of a strict schedule to follow-up abnormal thyroid hormone concentrations. The 
small sample size does not allow drawing of a strong conclusion about the influence of the 
time of sampling during ECMO on screening results. Further, the exact date of normalization 
in some patients with abnormal thyroid hormone levels remains uncertain.
In conclusion, we found a higher incidence of aberrant CH screening results in neonates 
screened before (73.1%) or during (67.3%) ECMO than in neonates screened after (31.4%) 
ECMO.  All but two neonates (i.e. 98%) with an aberrant screening result had low T4 con-
centrations with normal TSH, as is seen in NTIS. Thyroid hormone concentrations normalized 
rapidly in most, and none of these children was diagnosed with CH. Our results suggest that 
T4 therapy is not required during ECMO. Follow-up of abnormal thyroid hormone concen-
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Supplementary methods. Dutch neonatal screening method
In the Netherlands, congenital hypothyroidism screening is primarily based on thyroxine 
(T4) measurement by immunochemical assay in blood spots sampled 72 to 168 hours after 
birth. The concentration of  T4 is compared with the day mean, and expressed as a standard 
deviation score (SDS). If T4 is >-0.8 SDS, the result is normal. If T4 is ≤-0.8 SDS, the thy-
rotropin (TSH) concentration (expressed in mU/l blood) is additionally measured. If  T4 is 
≤-1.6 SDS, the thyroxine-binding globulin (TBG) concentration (expressed in nmol/l blood) 
is additionally measured. A T4/TBG ratio is calculated as follows: ((T4 SDS+5.1)x1,000)/
TBG. If  T4 is ≤-3.0 SDS and TBG is >40.0 nmol/l or TSH is >21.0 mU/l, the screening result 
is abnormal, and referral to a pediatrician is indicated (supplementary table 1). Before July 
2012, a T4≤-3.0 SDS was considered as abnormal and in that case TBG was not determined. 
Since July 2012, TBG is always determined if  T4≤-1.6 SDS. A result indicating TBG deficiency 
(T4≤-3.0 SDS and TBG≤40 nmol/l) is considered as normal. In case of a borderline result 
(-3.0<T4≤-0.8 SDS in combination with a T4/TBG ratio≤17 or 7<TSH≤21 mU/l), a second 
heel puncture is performed. If the second screening result is abnormal or borderline again, 
the result is considered as abnormal, and referral is indicated.
The referral criterion for premature neonates born ≤36.0 weeks gestation or with a birth 
weight of ≤2500 grams is based on TSH.
Supplementary table 1. Interpretation of the Dutch screening procedure for congenital hypothyroidism
TSH >21.0 mU/l 7.0<TSH≤21.0 mU/l TSH≤7.0 mU/l
T4 ≤-3.0 SDS and TBG >40.0 nmol/l Abnormal: referral2 Abnormal: referral2 Abnormal: referral2
-3.0<T4≤-1.6 SDS and T4/TBG ratio≤ 17.01 Abnormal: referral2 Borderline: repeat3 Borderline: repeat3
-3.0<T4≤-1.6 SDS and T4/TBG ratio>17.01 OR
T4≤-3.0 SDS and TBG≤40.0 nmol/l OR T4>-1.6 SDS
Abnormal: referral2 Borderline: repeat3 Normal: no action
1 T4/TBG ratio = ((T4 SDS+5.1)x1,000)/TBG.
2 Referral: referral to pediatrician for further analysis.
3 Repeat: repeat screening.
Abbreviations: SDS=standard deviation score; T4=thyroxine; TBG=thyroxine-binding globulin; TSH=thyrotropin.





































































































































































































































































































































































































































































































Gestational age (weeks) 39.9 (38.1-41.0) 40.3 (38.3-41.2) 0.37
Birth weight (grams) 3311±611 3310±694 1.00
Male 66 (64.7%) 33 (50.0%) 0.06
Primary diagnosis
 Meconium aspiration syndrome
 Congenital diaphragmatic hernia
 Sepsis













Age at start ECMO therapy (day of life) 3 (2-4) 2 (1-3) 0.06
Duration of ECMO therapy (days) 6 (4-8) 5 (3-6) 0.001
PRISM III score (first 24 hours of PICU admission) 18±6.4 17±7.2 0.32
Age at CH screening (day of life) 4 (4-5) 4 (4-5) 0.32
PELOD-2 score (24 hours prior to CH screening) 6 (6-8) 6 (5-7) 0.02
Data are expressed as mean±standard deviation, median (interquartile range) or number (percentage), as appropriate. 
1 Other: congenital heart disease; congenital cystic adenomatoid malformation; recurrent pneumothoraces; infant respiratory distress 
syndrome in combination with pneumothorax; meconium peritonitis; respiratory failure of unknown cause.
Abbreviations: CH=congenital hypothyroidism; ECMO=extracorporeal membrane oxygenation; PELOD-2=Pediatric Logistic Organ 
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Objective: Thyroid hormone concentrations can be disturbed during critical illness. Our aim 
was to determine changes in thyroid hormone concentrations during neonatal extracorpo-
real membrane oxygenation (ECMO).
Methods: We included 21 ECMO-treated neonates. Age-specific standard deviation scores 
(SDS) of free and total thyroxine (FT4; TT4), reverse and total triiodothyronine (rT3; TT3), 
thyroid-stimulating hormone (TSH) and thyroxine-binding globulin (TBG) were determined 
at six fixed time-points. Data were analyzed using general linear models.
Results: At baseline, mean SDS FT4 (-0.78, 95% confidence interval: -1.37 to -0.19), TT4 
(-1.97, 95% confidence interval: -2.76 to -1.18),  TT3 (-0.88, 95% confidence interval: -1.13 to 
-0.63), TSH (-2.14, 95% confidence interval: -2.93 to -1.35) and  TBG (-3.52, 95% confidence 
interval: -4.55 to -2.50) were low with high mean SDS rT3 (0.53, 95% confidence interval: 
0.28 to 0.78). One hour after start ECMO,  TT4, TSH and TBG had further declined; 12 
hours after start ECMO TT3 had declined (all p<0.05).  After this decline, mean SDS  TSH 
increased to the baseline level 12 hours after start ECMO (-2.50, 95% confidence interval: 
-3.22 to -1.79), and was higher than baseline 48 hours after start ECMO (-0.56, 95% confi-
dence interval: -1.29 to 0.17). This TSH increase was followed by increases in TT4 and TT3. 
FT4 remained constant within the normal range during ECMO.
Conclusions: Thyroid hormone concentrations before ECMO were suggestive of non-thy-
roidal illness syndrome. During ECMO, increases in TSH,  TT4 and  TT3 after an initial decline 
possibly reflect spontaneous restoration of the hypothalamic–pituitary–thyroid axis. FT4 
remained constant within the normal range. This suggests that thyroxine therapy is not 
required during ECMO.




Thyroid hormone concentrations can be affected by several factors including gestational age,1 
cardiac surgery,2, 3 use of drugs such as dopamine,4 and critical illness.5-7 Critically ill patients 
typically present with lower concentrations of total triiodothyronine (TT3) and total thyrox-
ine (TT4), increased reverse triiodothyronine (rT3) and low to normal thyroid-stimulating 
hormone (TSH) concentrations, which is known as non-thyroidal illness syndrome (NTIS) 
or euthyroid sick syndrome.5-7 The magnitude of changes in TT3 and TT4 concentrations 
has been related to the severity of illness. Both low TT3 and low TT4 have been associated 
with adverse patient outcomes such as increased mortality in neonatal, pediatric and adult 
patients.8-14 
Recently we reported that 67.3% of neonates screened during extracorporeal membrane 
oxygenation (ECMO) had an aberrant screening result for congenital hypothyroidism.15  The 
one study so far on thyroid hormone concentrations during neonatal ECMO found a decline 
in all thyroid hormone concentrations in 14 critically ill neonates directly after the start of 
ECMO.16 It is not known, however, whether and how thyroid hormone concentrations 
change during and after neonatal ECMO, and whether there are any potential therapeutic 
consequences of changes. Therefore, we determined longitudinal changes in thyroid hormone 





We included 21 neonates with a diagnosis of meconium aspiration syndrome (MAS) or 
congenital diaphragmatic hernia (CDH), which are the two most common indications for 
neonatal ECMO treatment.17 Neonates were admitted to either of the two ECMO centers 
in the Netherlands (the Erasmus MC-Sophia Children’s Hospital, Rotterdam or the Radboud 
University Medical Center-Amalia Children’s Hospital, Nijmegen), both level III university 
hospitals. ECMO therapy was initiated in case of reversible severe respiratory failure with 
an estimated mortality risk of >80% as described by Stolar et al. and on the standardized 
CDH EURO Consortium Consensus treatment protocol.18, 19  
Relevant clinical data were collected including gestational age, birth weight, gender, age at 
start ECMO, duration of ECMO, neonatal screening results for congenital hypothyroidism and 
survival. Severity of illness was estimated with the Pediatric Risk of Mortality III (PRISM III) score 
and the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score.20, 21 PRISM III is a physiolo-
gy-based score for predicting the mortality risk in pediatric intensive care unit (PICU) patients. 
It is calculated from the most abnormal values of 17 physiologic variables obtained in the first 
24 hours of PICU care (score range: 0-74).20 The PELOD-2 is a descriptive score that allows 
daily assessment of the severity of multiple organ dysfunction syndrome in PICU patients. It 
includes 10 variables involving five organ dysfunctions with a score range of 0-33.21 PELOD-2 
scores were calculated for the 24 hours prior to blood sampling. Use of dopamine ≤8 hours 
prior to blood sampling was recorded because dopamine affects thyroid hormone concen-
trations within the first hours after initiation of treatment, and pre-treatment concentrations 
are reached within hours after discontinuation.22 None of the patients received supplemental 
levothyroxine at any time-point. At 2 years of age, the Bailey Scales of Infant Development 
-Second Edition- Dutch version was used to assess cognitive outcomes of patients using the 
mental development index score. The mean score of the mental development index is 100 with 
a standard deviation of 15.23 Informed consent was obtained from parents. Ethical approval for 
this study was obtained from both local Ethics Committees (CMO 2005/253).
ECMO procedure
In the Erasmus MC-Sophia Children’s Hospital, the ECMO circuit was primed with erythro-
cyte concentrate, Ringer’s solution, albumin, Tris buffer, sodium bicarbonate, calcium gluconate 
and heparin. In the Radboud University Medical Center-Amalia Children’s Hospital, the 
ECMO circuit was primed with erythrocyte concentrate, fresh frozen plasma (FFP), sodium 
bicarbonate and heparin. The total prime volume was approximately 350 ml in both cen-
ters. Once the circuit was fully primed, ECMO cannulation was performed. The pediatric 
intensivist or neonatologist and pediatric surgeon decided on the choice of ECMO modality 
(veno-venous or veno-arterial).




Blood was taken from an arterial catheter at six fixed time-points: 1 hour prior to ECMO 
(baseline value); 1, 12, 48 and 72 hours after start of ECMO; >24 hours after cessation 
of ECMO. Plain tubes were centrifuged and serum was stored at -20 °C. Free thyroxine 
(FT4), TT4, TT3 and TSH concentrations were determined using chemiluminescence assays 
(Vitros ECI; Ortho Clinical-Diagnostics, Rochester, New York, USA). rT3 was measured by 
radioimmunoassay (ZenTech S.A., Liége, Belgium). Thyroxine-binding globulin (TBG) was 
measured on an Immulite XPi system (Siemens Healthcare Diagnostics B.V., Los Angeles, 
California, USA). The intra- and interassay coefficients of variation were <5.4% for FT4, 
<6.4% for TT4, <8.7% for rT3, <4.3% for TT3, <4.1% for TSH and <6.4% for TBG.  Thyroid 
hormone concentrations and TBG were calculated into standard deviation scores (SDS) 
using age-specific reference values.24 The normal range was considered between -2 SDS 
and +2 SDS compared to the reference values, which are shown in supplementary table 1.
Statistical analyses
Baseline characteristics of MAS and CDH patients were compared using the Fisher’s exact 
test for categorical variables. The independent samples t-test was used for normally distrib-
uted variables, and the Mann-Whitney U-test for continuous variables that were not normally 
distributed. Differences in thyroid hormone concentrations at baseline between survivors 
and non-survivors were compared using the Mann-Whitney U-test. We used general linear 
models to describe the longitudinal changes in thyroid hormone concentrations and TBG. 
The dependent variables in these general linear models were the SDS of FT4,  TT4, rT3, 
TT3, TSH and TBG. The independent variables were gestational age, diagnosis, use of dopa-
mine ≤8 hours prior to the laboratory measurement, treatment center (use of FFP) and 
time-point (treated as a categorical variable). A random intercept was used in the general 
linear models to account for the within-subject correlations. Multicollinearity was assessed 
by calculating correlations between independent variables. The results of the general linear 
models are presented using the estimated marginal means, which are the predicted values 
of the dependent variable adjusted for covariates in the model, and the associated 95% 
confidence interval. To estimate the effect of critical illness, the PELOD-2 score and survival 
were added as independent variables in subsequent analyses. The statistical tests were two-
sided and used a significance level of 0.05.  All analyses were performed using SPSS 21.0 for 





We included 21 ECMO-treated neonates diagnosed with either MAS (n=11) or CDH 
(n=10). The CDH patients had a significantly lower gestational age than the MAS patients, 
and were all treated with veno-arterial ECMO (table 1). The CDH patients had a significantly 
higher PRISM III score than the MAS patients. Mental development index scores of CDH and 
MAS patients were within the normal range of the Dutch norm population (within 1 SDS 
of the mean). One MAS patient could not be tested because of severe mental disabilities 
due to perinatal asphyxia. Eighteen patients were screened for congenital hypothyroidism in 
accordance with the Dutch neonatal screening protocol (others: screening too late (n=2); 
screening result missing (n=1)). Two of the three patients (66.7%) screened before ECMO 
had an aberrant initial screening result. Seven of the 12 patients (58.3%) screened during 
ECMO had an aberrant initial screening result. None were diagnosed with congenital hypo-
thyroidism. The three patients screened after ECMO all had a normal screening result. Three 
(14.3%) patients died from pulmonary hypertension after ECMO decannulation: two CDH 
patients at the age of 9 and 11 days, respectively; one MAS patient at the age of 9 days.






Gestational age (weeks) 40.7±0.6 37.6±1.6 <0.001
Birth weight (grams) 3.38±0.37 3.00±0.62 0.10
Male 6 (54.5%) 5 (50.0%) 1.00
PRISM III score (first 24 hours of PICU admission) 13±6 21±7 0.01
Veno-arterial ECMO 4 (36.4%) 10 (100%) 0.004
Age start ECMO (days) 3 (1-4) 1 (1-2) 0.31
Duration of ECMO therapy (hours) 146±80 165±65 0.56
MDI1 92±82 93±163 0.97
Data are expressed as mean±standard deviation, median (interquartile range) or number (percentage). 
1 The Bailey Scales of Infant Development -Second Edition- Dutch version was used to assess mental development index in 
survivors.
2 Nine MAS patients were tested: one patient died and one patient could not be tested because of severe mental disabilities 
due to perinatal asphyxia.
3 Seven CDH patients were tested: two patients died and one patient was lost to follow-up
Abbreviations: CDH=congenital diaphragmatic hernia; ECMO=extracorporeal membrane oxygenation; MAS=meconium aspi-
ration syndrome; MDI=mental development index; PICU=pediatric intensive care unit; PRISM III=Pediatric Risk of Mortality III.
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Thyroid hormone and thyroxine-binding globulin concentrations at baseline
Mean baseline values of FT4,  TT4,  TT3,  TSH and TBG were significantly below the reference 
norm (SDS=0), and rT3 was significantly higher than the norm (table 2). Mean baseline 
values of  TSH and TBG were abnormally low before ECMO. Baseline values did not differ 
between MAS patients and CDH patients or between patients in the two different treatment 
centers (data not shown).  At baseline, the three non-survivors had lower median TT3 SDS 
(-1.32, interquartile range (IQR): -1.46 to -1.29 versus -0.85, IQR: -1.10 to -0.63) and lower 
median TBG SDS (-5.70, IQR: -6.17 to -4.90 versus -2.71, IQR: -3.89 to -1.69) than survivors 
(both p=0.03).
Table 2. Thyroid hormone and thyroxine-binding globulin concentrations at baseline compared with the 
reference norms
SDS of ECMO patients 
n=21
p-value
FT4 -0.78 (-1.37 to -0.19) 0.01
TT4 -1.97 (-2.76 to -1.18) <0.001
TT3 -0.88 (-1.13 to -0.63) <0.001
rT3  0.53 ( 0.28 to  0.78) <0.001
TSH -2.14 (-2.93 to -1.35) <0.001
TBG -3.52 (-4.55 to -2.50) <0.001
Data are presented using the estimated marginal means (associated 95% confidence interval).
Abbreviations: ECMO=extracorporeal membrane oxygenation; FT4=free thyroxine; rT3=reverse triiodothyronine; SDS=stan-
dard deviation score; TBG=thyroxine-binding globulin; TSH=thyroid-stimulating hormone; TT3=total triiodothyronine; TT4=total 
thyroxine.
Thyroid hormone and thyroxine-binding globulin concentrations during neonatal ECMO
Figure 1 shows the changes in thyroid hormone concentrations. One hour after start of 
ECMO, all thyroid hormone concentrations and  TBG showed a downward slope. Mean 
TT4, rT3, TSH and TBG significantly declined 1 hour after start of ECMO (p=0.003, p=0.002, 
p=0.02, p<0.001, respectively). Mean TT3 was significantly lower than baseline 12 hours after 
start of ECMO (p=0.02). After this initial decline, first TSH increased to baseline 12 hours 
after start of ECMO. TT4, rT3, TT3 and TBG reached their baseline values 48 hours after 
start of ECMO. After the cessation of ECMO,  TT3 and  TSH concentrations were signifi-
cantly higher than baseline (p=0.009, p<0.001, respectively). Mean TBG was still abnormally 
low after cessation of ECMO. FT4 concentrations did not significantly change during ECMO 
(p=0.53), and remained within the normal range.
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Figure 1. Changes in thyroid hormone and thyroxine-binding globulin concentrations during neonatal 
extracorporeal membrane oxygenation
A. Changes in FT4, TT4 and TSH concentrations 
Pre-
ECMO +1 +12 +48 +72 
Post-
ECMO 
B. Changes in rT3, TT3 and TSH concentrations
Pre-
ECMO +1 +12 +48 +72 
Post-
ECMO 




C. Changes in TBG concentration
Pre-
ECMO +1 +12 +48 +72 
Post-
ECMO 
Estimated marginal means with error bars representing the 95% confidence intervals were plotted. Pre-ECMO: 1 hour prior to 
ECMO (baseline value); +1: 1 hour after start of ECMO; +12: 12 hours after start of ECMO; +48: 48 hours after start of ECMO; 
+72: 72 hours after start of ECMO; Post-ECMO: >24 hours after cessation of ECMO.
* Indicates a significant change compared with the baseline value.
Abbreviations: ECMO=extracorporeal membrane oxygenation; FT4=free thyroxine; rT3=reverse triiodothyronine; TBG=thyrox-
ine-binding globulin; TSH=thyroid-stimulating hormone; TT3=total triiodothyronine; TT4=total thyroxine.
Clinical variables associated with thyroid hormone and thyroxine-binding globulin
The estimated coefficients of time-point, gestational age, diagnosis of CDH, dopamine use 
and treatment center (use of FFP) on thyroid hormone concentrations are given in supple-
mentary table 2. The numbers of children that used dopamine are shown in supplementary 
table 3. Time-point had a significant effect on all thyroid hormone and TBG concentrations, 
except FT4. Use of FFP was positively associated with TSH and  TBG, but was negatively 
associated with FT4.  A diagnosis of CDH was negatively associated with TSH. PELOD-2 
score or survival had no significant associations with thyroid hormone concentrations or TBG 
(data not shown).  Assessment of multicollinearity revealed a strong correlation between 
gestational age and diagnosis (r=0.85). Excluding diagnosis as a covariate in the general linear 




We found that the concentrations of  FT4,  TT4,  TT3,  TSH and TBG were already low 
and the rT3 concentration already high in critically ill neonates prior to the start of ECMO, 
resembling the pattern described in NTIS.5-7 The biologically active hormone FT4 was statis-
tically significantly below the reference norm, but it remained within the normal range. After 
an initial decline directly after start ECMO, first TSH increased to a value above baseline 48 
hours after ECMO. This TSH increase was followed by increases in TT4 and TT3, possibly 
reflecting clinical recovery with restoration of the hypothalamic–pituitary-thyroid axis. 
Stewart et al.16 studied thyroid hormone concentrations during ECMO in 14 neonates 
with severe respiratory failure from different causes, and also found a decline in all thyroid 
hormone concentrations directly after the start of ECMO. Further, a recent study in pediatric 
patients undergoing cardiac surgery with cardiopulmonary bypass specifically addressed the 
thyroid response in a subgroup of 57 neonates.3 Similar to our results, TSH strongly declined 
after surgery. However, they also found a small drop in FT4. Agus et al.25 found that low 
concentrations of thyroid hormones are present in ECMO prime fluid. In the current study, 
the prime volume was 350 ml. We think that the immediate decline of thyroid hormone 
concentrations can be ascribed to a dilutional effect. Based on the average birth weights in 
our study, we estimated that the dilutional factor in MAS patients was 55% (350/(350+287)
x100%) and in CDH patients was 58% (350/(350+255)x100%). We think that this small 
difference in dilutional factor did not cause a significant difference in the decline of thyroid 
hormone levels between both groups. However, a larger difference in dilutional factor could 
lead to a different response.  Agus et al.25 suggested that concentrations of thyroid hormones 
would be higher when FFP is used in the prime fluid. Indeed we found a positive association 
between TSH and  TBG and the use of FFP. However, this positive association was not found 
for TT4, rT3 and TT3, and contrary to this suggestion, we found that the use of FFPs was 
associated with lower FT4 levels. From this study, we cannot make a definite conclusion about 
the effect of the use of FFP in prime fluid on thyroid hormone levels. 
Hemodilution may not be the only explanation for this decline in thyroid hormone con-
centrations. The severe decline in TBG concentration could also be explained by a global 
inflammatory response with consequent capillary leakage, which occurs during the initial 
phases of cardiopulmonary bypass and ECMO.26-28 This capillary leak allows plasma proteins 
to move from the intravascular to the extravascular space, which lowers plasma protein 
concentrations.
Other factors contributing to the changes in thyroid hormone concentrations may be the 
severity of critical illness and use of dopamine. Previous studies in neonates have found a 
relation between low TT3 and low TT4 and adverse patient outcomes such as increased 
mortality, longer duration of mechanical ventilation and longer hospital stay.12-14 Therefore, we 
expected thyroid hormone concentrations to be lower in neonates with a greater severity of 
Thyroid function during neonatal ECMO
 49
3
illness. Indeed, we found lower concentrations of  TT3 and TSH at baseline in non-survivors. 
However, we did not find an association between the PELOD-2 score or survival and thyroid 
hormone concentrations in the general linear model.  This could be due to the relatively small 
sample size. Secondly, although the PELOD-2 score has been validated for PICU patients,21, 
29 the score is affected by treatment such as ventilator settings and use of vasoactive drugs. 
Therefore, it does not solely reflect the severity of illness. Possibly, the PELOD-2 score does 
not distinguish enough between treatment effects and severity of illness in this specific group 
of ECMO-treated neonates. Furthermore, dopamine could have played a role, as it has been 
found to suppress TSH concentrations.22 Dopamine could be discontinued in most patients 
during ECMO, and we think this indeed played a role in the TSH increase during ECMO. 
However, we did not find a significant association between dopamine and thyroid hormone 
concentrations, which may be due to the influence of other factors that potentially affect 
thyroid hormone concentrations during ECMO. In the present study, the combination of low 
TT3, TT4 and TSH concentrations prior to the start of ECMO indicates an aberrant feedback 
regulation of the hypothalamic–pituitary–thyroid axis, as has been previously described during 
NTIS.5-7 During ECMO, however, first the TSH concentration significantly increased, which 
was later followed by an increase in TT4 and TT3. Other studies have found the same pattern 
of  TSH,  TT4 and TT3 increases at the start of restoration of the hypothalamic-pituitary–thy-
roid axis.30, 31  Therefore, we think these changes in thyroid hormone concentrations during 
ECMO suggest clinical recovery with restoration of the hypothalamic–pituitary–thyroid axis.
Therefore, we think these changes in thyroid hormone concentrations during ECMO suggest 
clinical recovery with restoration of the hypothalamic–pituitary–thyroid axis. 
In a previous study we found a higher incidence of aberrant screening results for congen-
ital hypothyroidism in neonates screened before (73.1%) or during ECMO (67.3%) than in 
neonates screened after (31.4%) ECMO.15 In the present study, aberrant screening results 
were found only in neonates screened before or during ECMO. None of the children with an 
aberrant screening result had congenital hypothyroidism. Because thyroid hormone concen-
trations significantly changed during ECMO, we recommend to repeat thyroid function tests 
after ECMO. Thyroid function tests should be repeated before the age of 14 days, however, 
because thyroxine treatment started later than this age can lead to intellectual disabilities.32 
Treatment of low thyroid hormone concentrations during NTIS remains a matter of 
debate. As thyroid hormone is important for neurodevelopment during early life, a low 
concentration during this period could possibly affect neurodevelopmental outcomes. Yet, 
studies on thyroid supplementation therapy in infants with hypothyroxinemia of prematurity 
found no beneficial effect.33 Further, a recent study found that transient hypothyroxinemia of 
prematurity was not associated with adverse neurodevelopmental outcomes at the age of 19 
years.34 A randomized controlled trial in pediatric patients undergoing cardiac surgery found 
that T3 supplementation in patients <5 months of age was associated with reduced time of 
mechanical ventilation.35 However,  T3 supplementation in pediatric patients undergoing car-
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diopulmonary bypass has not been found to improve their long-term neurodevelopmental 
outcomes.36 We found a constant FT4 concentration during ECMO, which was only slightly 
lower than the reference norm. Further, cognitive outcomes of MAS and CDH patients 
were similar to cognitive outcomes of the norm population, except for one MAS patient 
with severe perinatal asphyxia. This, in combination with the lack of evidence for thyroid 
replacement therapy and the increases in thyroid hormone concentrations occurring during 
ECMO suggest that early treatment is not required during ECMO. However, larger studies 
with long-term follow-up of neurodevelopmental outcomes should be performed to draw 
definite conclusions. 
A strength of this study is the determination of all thyroid hormone concentrations and 
TBG at fixed time-points before, during and after neonatal ECMO. Furthermore, it is the first 
study that calculated these concentrations into SDS using recently established age-specific 
reference values.24 A limitation of this study is that we did not measure thyroid hormone 
concentrations in the prime fluid used during ECMO. Thyroid hormone concentrations in 
prime fluid could have varied, and measurements of thyroid hormone concentrations in the 
prime fluid would have given more information about the hemodilution effect during ECMO. 
In conclusion, we found that thyroid hormone disturbances similar to NTIS were present 
in critically ill neonates prior to the start of ECMO. After an initial decline directly after the 
start of ECMO, first TSH increased, followed by TT4 and TT3. This may reflect restoration 
of the hypothalamic–pituitary–thyroid axis during ECMO. FT4 remained constant within 
the normal range during the ECMO course. These results suggest that thyroid hormone 
replacement therapy is not required during ECMO.
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Supplementary table 1.  Age-specific reference values for thyroid hormone and thyroxine-binding globulin 
levels in neonates published by Lem et al.24
Age -2 SDS -1 SDS 0 SDS +1 SDS +2 SDS
FT4 (pmol/l) Day of birth 12.12 15.81 21.78 32.65 56.54
1 day-7 days 12.32 15.91 21.61 31.65 52.54
8 days-1 month 12.81 16.12 21.12 29.28 44.33
TT4 (nmol/l) Day of birth 75.26 99.44 132.38 177.64 240.37
1 day-7 days 75.90 99.96 132.64 177.36 239.10
8 days-1 month 77.93 101.62 133.44 176.47 235.16
TT3 (nmol/l) Day of birth 0.30 1.23 2.18 3.13 4.09
1 day-7 days 0.32 1.25 2.18 3.13 4.08
8 days-1 month 0.39 1.29 2.21 3.13 4.06
rT3 (nmol/l) Day of birth 0.30 0.48 0.87 1.88 5.51
1 day-7 days 0.30 0.48 0.86 1.82 5.20
8 days-1 month 0.30 0.47 0.83 1.67 4.36
TSH (mU/l) Day of birth 2.43 3.84 6.44 11.75 24.03
1 day 1.90 3.21 5.54 9.76 17.58
2 days 1.40 2.61 4.64 7.94 13.10
3 days 0.94 2.03 3.75 6.24 9.65
4 days 0.60 1.48 2.85 4.63 6.82
5 days-7 days 0.58 1.18 2.14 3.57 5.58
8 days-1 month 0.58 1.18 2.14 3.57 5.57
TBG (mg/L) Day of birth 19.17 23.34 28.68 35.61 44.70
1 day-7 days 19.16 23.34 28.67 35.59 44.68
8 days-1 month 19.12 23.28 28.61 35.51 44.59
24 Lem AJ, de Rijke YB, van Toor H, de Ridder MA, Visser TJ, Hokken-Koelega AC. Serum thyroid hormone levels in healthy chil-
dren from birth to adulthood and in short children born small for gestational age. J Clin Endocrinol Metab. 2012;97:3170-3178.
Abbreviations: FT4=free thyroxine; rT3=reverse triiodothyronine; SDS=standard deviation score; TBG=thyroxine-binding globulin; 
TSH=thyroid-stimulating hormone; TT4=total thyroxine; TT3=total triiodothyronine.
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Supplementary table 2.  Associations between thyroid hormone and thyroxine-binding globulin concen-
trations and clinical variables





FT4 Time-point (compared to baseline): 
1 hour after start ECMO
12 hours after start ECMO
48 hours after start ECMO













Gestational age (weeks) 0.20 -0.07 to 0.47 0.15
Diagnosis of CDH 0.44 -0.58 to 1.46 0.37
Use of dopamine -0.26 -0.84 to 0.31 0.36
Center that used FFP -0.67 -1.26 to -0.07 0.03
TT4 Time-point (compared to baseline): 
1 hour after start ECMO
12 hours after start ECMO
48 hours after start ECMO













Gestational age (weeks) 0.26 -0.09 to 0.62 0.13
Diagnosis of CDH -0.38 -1.69 to 0.93 0.55
Use of dopamine -0.20 -0.96 to 0.57 0.61
Center that used FFP 0.67 -0.10 to 1.43 0.08
rT3 Time-point (compared to baseline): 
1 hour after start ECMO
12 hours after start ECMO
48 hours after start ECMO













Gestational age (weeks) -0.02 -0.15 to 0.11 0.74
Diagnosis of CDH 0.18 -0.30 to 0.66 0.44
Use of dopamine 0.07 -0.18 to 0.31 0.58
Center that used FFP -0.21 -0.50 to 0.07 0.13
TT3 Time-point (compared to baseline): 
1 hour after start ECMO
12 hours after start ECMO
48 hours after start ECMO













Gestational age (weeks) 0.10 -0.002 to 0.20 0.05
Diagnosis of CDH -0.02 -0.39 to 0.34 0.90
Use of dopamine -0.19 -0.43 to 0.04 0.11
Center that used FFP 0.11 -0.11 to 0.32 0.30
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Supplementary table 2. Continued





TSH Time-point (compared to baseline): 
1 hour after start ECMO
12 hours after start ECMO
48 hours after start ECMO













Gestational age (weeks) -0.38 -0.88 to 0.12 0.13
Diagnosis of CDH -2.25 -4.10 to -0.40 0.02
Use of dopamine -0.50 -1.23 to 0.24 0.18
Center that used FFP 1.37 0.27 to 2.46 0.02
TBG Time-point (compared to baseline): 
1 hour after start ECMO
12 hours after start ECMO
48 hours after start ECMO













Gestational age (weeks) 0.12 -0.49 to 0.74 0.68
Diagnosis of CDH -1.33 -3.60 to 0.94 0.24
Use of dopamine -0.32 -1.29 to 0.65 0.52
Center that used FFP 1.63 0.29 to 2.97 0.02
Abbreviations: CDH=congenital diaphragmatic hernia; ECMO=extracorporeal membrane oxygenation; FFP=fresh frozen plasma; 
FT4=free thyroxine; rT3=reverse triiodothyronine; TBG=thyroxine-binding globulin; TSH=thyroid-stimulating hormone; TT3=total 
triiodothyronine;.TT4=total thyroxine.
Supplementary table 3. Patients that used dopamine during extracorporeal membrane oxygenation
Time-point Use of dopamine
1 hour before start ECMO (baseline) 94.7% (18/19)
1 hour after start ECMO 94.7% (18/19)
12 hours after start ECMO 55% (11/20) 
48 hours after start ECMO 52.6% (10/19) 
72 hours after start ECMO 50.0% (8/16)
Post-ECMO 42.9% (6/14)
Abbreviation: ECMO=extracorporeal membrane oxygenation.
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Objective: Pulmonary hypertension (PH) is one of the main causes of mortality and morbid-
ity in patients with congenital diaphragmatic hernia (CDH). Currently, it is unknown whether 
PH persists or recurs during the first year of life. 
Design: Prospective longitudinal follow-up study.
Setting: Tertiary university hospital.
Patients: Fifty-two CDH patients admitted between 2010 and 2014.
Measurements: PH was measured using echocardiography and electrocardiography at 6 
and 12 months of age. Characteristics of patients with persistent PH were compared with 
those of patients without persistent PH.
Main results: Persistent PH was found in four patients. At 6 months of age, in three patients 
(patients A-C), and at 12 months of age, in two patients (patients C and D). Patients with 
persistent PH had a longer duration of mechanical ventilation (median 77 days (interquartile 
range: 49-181) versus median 8 days (interquartile range: 5-15; p=0.002) and hospital stay 
(median 331 days (interquartile range: 198-407) versus median 33 days (interquartile range: 
16-59; p=0.003) than patients without persistent PH.  The proportion of patients with per-
sistent PH (n=4) treated with inhaled nitric oxide (100% vs. 31%; p=0.01), sildenafil (100% 
vs. 15%; p=0.001) and bosentan (100% vs. 6%; p<0.001) during initial hospital stay was higher 
than that of patients without persistent PH (n=48).  A higher proportion of patients with 
persistent PH required tube feeding and treatment with supplemental oxygen and sildenafil 
at follow-up.  The diagnosis of PH would have been missed in two patients with PH on 
echocardiography, if only electrocardiography had been performed. 
Conclusions: Less than 10% of CDH patients had persistent PH at ages 6 and 12 months. 
Follow-up for PH should be reserved for CDH patients with echocardiographic signs of 
persistent PH at hospital discharge and those treated with medication for PH at hospital 
discharge.




Congenital diaphragmatic hernia (CDH) is a severe birth defect associated with significant 
mortality and morbidity due to pulmonary hypoplasia and pulmonary hypertension (PH). 
Although survival rates have improved, overall mortality remains high.1 Increased survival 
rates have also led to increased comorbidity. A recent study found that 74% of CDH survi-
vors had pulmonary, gastrointestinal, or neurological morbidities at hospital discharge.2 One 
of the most important causes of mortality and morbidity in CDH patients is persistent PH. 
The development of persistent PH is complex. A reduced number of pulmonary arteries 
in combination with altered vasoreactivity and abnormal pulmonary vascular remodeling 
contribute to the development of PH in neonates with CDH.3 In approximately half of CDH 
patients PH resolves at 3 weeks of age.4, 5 Nevertheless, a recent study showed that PH still 
persisted in 18% of 113 CDH patients at 3 months of age.6 
Current guidelines advise to treat severe PH with pulmonary vasodilators such as inhaled 
nitric oxide (iNO), sildenafil and/or bosentan,7 although there is no evidence from properly 
designed randomized controlled trials in this specific group of patients. Management of 
PH in CDH patients remains challenging, and persistence of PH is associated with a worse 
outcome including higher mortality and respiratory morbidity.1, 4-6 In 2008, the American 
Academy of Pediatrics recommended screening for PH at follow-up when echocardiography 
was previously abnormal or when the child required supplemental oxygen therapy.8 More 
recently, Hollinger et al.9 advised to routinely follow up PH only in high risk CDH patients at 
3 and 6 months of age. Still, little is known about the course of PH in CDH survivors after 
hospital discharge. 
In this study, we determined the prevalence of persistent PH at 6 and 12 months of age 
in CDH patients who received standardized postnatal treatment.10 Furthermore, we evalu-






This prospective longitudinal study was conducted within the framework of our structured 
follow-up program for CDH patients monitoring growth, lung function and neurodevelop-
ment until 18 years of age.11 We included children admitted between January 2010 and 
October 2014. Exclusion criteria were: CDH diagnosed after 7 days of age, a paraesoph-
ageal diaphragmatic defect, or a congenital heart defect with known increased pulmonary 
vascular resistance. Postnatal management was performed according to the guidelines of 
the standardized CDH EURO Consortium Consensus treatment protocol.10 Echocardiog-
raphy was performed within the first 24 hours of pediatric intensive care unit admission. 
The treatment of PH was as follows: If preductal saturations fell below 85% with signs of 
poor organ perfusion, blood pressure support was given to maintain arterial blood pressure 
levels at normal levels for gestational age. Inhaled nitric oxide (iNO) was started in case of 
extra-pulmonary right-to-left shunting and if the oxygenation index was above 20 and/or 
the saturation difference was more than 10%. Sildenafil was started when severe PH per-
sisted after the use of iNO. Bosentan was started in case of persistent PH despite the use 
of iNO and sildenafil. Sildenafil and/or bosentan were continued after discharge in patients 
with severe PH during hospital admission with the need for supplemental oxygen therapy 
at hospital discharge. CDH patients were discharged with supplemental home oxygen if 
they were unable to maintain an oxygen saturation above 92% on room air.  At follow-up, 
sildenafil and/or bosentan were weaned if children had no signs of PH on echocardiography 
and no supplemental oxygen therapy. The Erasmus MC Medical Ethical Review Board stated 
that ‘the Medical Research in Human Subjects Act does not apply to this study’, and waived 
institutional review board approval (MEC-2017-256). 
Data collection
The following baseline data were collected: gestational age, birth weight, gender, ethnicity, 
side of diaphragmatic defect, prenatal diagnosis, in case of prenatal diagnosis observed-to-
expected lung-to-head ratio (LHR) and liver position at third prenatal ultrasound (30-32 
weeks gestational age), age at repair of the diaphragmatic defect, surgical technique for 
repair (laparotomy or thoracoscopy), requirement of patch repair, need for extracorporeal 
membrane oxygenation (ECMO) treatment, age at start of ECMO treatment, duration of 
ECMO treatment, duration of initial mechanical ventilation, presence of chronic lung disease 
(oxygen dependency at 28 days of life),12 treatment with iNO, sildenafil, and/or bosentan 
during hospital stay, duration of initial hospital stay, presence of cardiac anomalies, and need 
for supplemental oxygen, diuretics, sildenafil and/or bosentan at discharge and follow-up. 




Echocardiograms and electrocardiographs (ECGs) were performed at 6 and 12 months of 
age (or >12 months of age when indicated).  An experienced pediatric cardiologist obtained 
standard echocardiographic views using a GE Vivid S6 ultrasound system with a 6S or 10S 
MHz transducer or a Philips iE 33 ultrasound system with a S8 or S12 MHz transducer 
according to the ECS/ERS guidelines.13 Echocardiographic images were stored electronically. 
The following echocardiographic criteria were assessed to determine the presence of PH: 
peak tricuspid regurgitation (TR) gradient estimated by the modified Bernoulli equation, 
peak pulmonary regurgitation gradient, shunt direction across a patent ductus arteriosus, 
interventricular septum position (normal, flattened, or D-shaped interventricular septum), 
global right and left ventricular function (normal, moderately decreased, severely decreased), 
dilation of the vena cava inferior, and collapse of the vena cava inferior during inspiration. 
The diagnosis of PH was made if one of the following criteria were present: elevated TR 
gradient, right-to-left or bidirectional shunt across the patent ductus arteriosus, flattened or 
D-shaped interventricular septum position, impaired right ventricular function and/or dilation. 
ECGs were assessed for the presence of sinus rhythm, heart rate and the following signs 
of PH: right QRS axis deviation of ≥110° or right ventricular hypertrophy. Right ventricular 
hypertrophy was defined by the presence of either R-wave amplitude in lead  V1≥98th per-
centile of age or S-wave amplitude in lead V6≥98th percentile of age.14 Right atrial enlargement 
was defined as  ≥2.5 mV.  On available chest x-rays, the heart position was determined on 
chest x-rays (normal or dextroposition defined as heart located primarily in the right chest). 
A second pediatric cardiologist who was blinded to the clinical outcomes independently 
assessed all echocardiograms and ECGs.  There was 100% concordance in diagnosing PH 
on echocardiograms and ECGs between the two pediatric cardiologists. Lastly, we evaluated 
results of two patients with persistent PH who underwent cardiac catheterization during 
follow-up.
Statistical analyses
To evaluate differences between characteristics of included and non-included patients and 
between patients with and without persistent PH at 6 or 12 months of age, we performed 
chi-square or Fisher’s exact tests for categorical variables, as appropriate. Independent sam-
ples t-tests were used for normally distributed variables, and Mann-Whitney U tests for 
continuous variables that were not normally distributed. Analyses were performed using 
SPSS 21.0 for Windows (IBM Corporation, Armonk, New York, USA). The statistical tests 





During the study period, 112 CDH patients were admitted.  Twenty-three (21%) died before 
hospital discharge (figure 1). Eleven patients met exclusion criteria (late diagnosis: n=9; par-
aesophageal hernia: n=2). Twenty-six patients were excluded because they did not have an 
echocardiogram at follow-up (n=25) and one patient was lost to follow-up. Comparison 
of data of the included 52 patients (67%) with those of the 26 eligible nonparticipants 
revealed no important differences in patient characteristics (supplementary table 1). Included 
patients were more frequently born in our institution than non-included patients, and a 
higher proportion of included patients required supplemental oxygen at discharge. Other 
patients’ characteristics did not differ. Forty-nine (94%) of the 52 included patients had an 
echocardiogram at hospital admission at the median age of 1 day.  This revealed PH in 37 
cases (71%). Four infants (8%) had PH at 6 and/or 12 months of age. Patient characteris-
tics are shown in table 1. Patients with persistent PH had a significantly longer duration of 
mechanical ventilation and hospital stay than patients without persistent PH.  All patients 
with persistent PH underwent a laparotomy for repair of the diaphragmatic defect, and all 
were treated with iNO, sildenafil and bosentan during initial hospital stay.
Follow-up of pulmonary hypertension in CDH patients during infancy
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Figure 1. Flowchart of the study population
CDH survivors 
n=89 (79%) 




Lost to follow-up: n=1
No echocardiogram: n=252
Echo at 12 months
n=32 (62%)
CDH patients admitted between 





Echo at 6 months
n=35 (67%)
Echo only at 6 months
n=203
Echo at 6+12 months
n=154




1 Died before hospital discharge.
2 Reasons for no echocardiogram at 6 and 12 months of age (n=25): logistic (n=23); MRSA infection (n=2). 
3 Reasons for no echocardiogram at 12 months of age (n=17): logistics (n=14); poor image quality of echocardiogram (n=2); 
uncooperativeness (n=1).
4 Two children died after hospital discharge. One patient, without pulmonary hypertension at 6 and 12 months follow-up, died 
at the age of 15 months due to sepsis. One patient, with pulmonary hypertension at ages 6 and 12 months, died at the age of 
14 months due to a cyanotic spell.
5 Reasons for no echocardiogram at 6 months of age (n=20): logistics (n=16); hospital admission (n=2); poor image quality of 
echocardiogram (n=1); echocardiography in other center (n=1).
6 Reasons for echocardiogram >12 months of age (n=2): small atrial septal defect (n=1); refusal of follow-up at 6 and 12 months 
of age (n=1). 
Abbreviation: CDH=congenital diaphragmatic hernia.
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Gestational age (weeks) 38.4 (38.1-38.8) 38.3 (37.5-38.9) 0.62
Birth weight (kilograms) 3.0 ( 2.8-3.1) 3.0 (2.6-3.3) 0.95
Male 3 (75%) 27 (56%) 0.632
Ethnicity
     Dutch






Inborn 4 (100%) 39 (81%) 1.002
Left sided hernia 4 (100%) 42 (88%) 1.002
Prenatally
Prenatal diagnosis 4 (100%) 38 (79%) 0.582
Prenatal liver position
     Up
     Down







Observed-to-expected LHR 44.0% (34.0-44.6) 47.6% (41.6-56.7) 0.29
Surgery
Age at surgery (days) 5 (4-7) 3 (2-4) 0.13
Thoracoscopic repair 0 (0%) 29 (60%) 0.032
Patch repair 4 (100%) 35 (73%) 0.562
ECMO 
ECMO use 2 (50%) 4 (8%) 0.062
Age start ECMO (days) 10 (8-11) 3 (3-5) 0.06
Hours on ECMO 321 (315-327) 97 (91-237) 0.36
Hospital admission
Duration of mechanical ventilation (days) 77 (49-181) 8 (5-15) 0.002
Presence of chronic lung disease 4 (100%) 23 (51%)3 0.112
Duration of initial hospital stay (days) 331 (198-407) 33 (16-59) 0.003
Inhaled nitric oxide use 4 (100%) 15 (31%) 0.012
Sildenafil use 4 (100%) 7 (15%) 0.0012
Bosentan use 4 (100%) 3 (6%) <0.0012
Hospital discharge 
Supplemental oxygen at discharge 4 (100%) 4 (8%) <0.0012
Diuretics at discharge 4 (100%) 8 (17%) 0.0022
Sildenafil at discharge 4 (100%) 5 (10%) <0.0012
Bosentan at discharge 3 (75%) 1 (2%) 0.0012
Data are presented as median (interquartile range ) or number (percentage), as appropriate.
P-value=significant difference between the groups.
1 Pulmonary hypertension at 6 and/or 12 months of age.
2 Fisher’s exact test was used.
3 Missing: n=3.
Abbreviations: ECMO=extracorporeal membrane oxygenation; LHR=lung-to-head ratio; PH=pulmonary hypertension at 6 
and/or 12 months of age.
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Echocardiography at 6 months
At 6 months follow-up, 35 patients underwent echocardiography (figure 1). A higher pro-
portion of the 35 patients with echocardiography at 6 months were treated with sildenafil 
at hospital discharge compared with the 17 included patients who did not receive echocar-
diography at 6 months (26% versus 0%; p=0.02). Other patient characteristics did not differ 
significantly (data not shown).  Three patients (patients A-C, see supplementary table 2) had 
PH at 6 months with flattening of the interventricular septum and/or right ventricular dila-
tion. The ductus arteriosus had closed in all. TR was only found in patient A, with a gradient 
of 30 mm Hg. Patient B was diagnosed with a partial anomalous pulmonary venous return 
(PAPVR) with an atrial septal defect patients PH at 6 months follow-up required supplemen-
tal oxygen, tube feeding, diuretics, sildenafil and bosentan at 6 months of age, which differed 
from patients without PH (table 2). 






Supplemental oxygen use 3 (100%) 3 (9%) 0.0031
Tube feeding 3 (100%) 8 (25%) 0.031
Diuretics 3 (100%) 5 (16%) 0.0091
Sildenafil 3 (100%) 3 (9%) 0.0031
Bosentan 3 (100%) 2 (6%) 0.0021
Data are presented as number (percentage).
P-value=significant difference between the groups. 
1 Fisher’s exact test was used.
Abbreviation: PH=pulmonary hypertension.
Echocardiographic at 12 months and later
Echocardiographic data at 12 months of age were available for 32 patients (figure 1).  A higher 
proportion of the 32 patients with echocardiography at 12 months underwent a laparotomy 
for CDH repair compared with the 20 patients without echocardiography (56% versus 25%; 
p=0.03), while other patient characteristics did not differ significantly (data not shown). PH 
was found in two patients (6%; patients C and D, see supplementary table 2). Both patients 
with persistent PH at 12 months received sildenafil at 12 months of age (table 3). Patient C 
had PH at the ages of 6 months and 12 months.  At 12 months of age, the echocardiogram 
showed signs of severe right ventricular failure despite the use of sildenafil and bosentan. 
This patient died at 14 months of age due to a cyanotic spell in combination with severe 
PH. Parents did not agree to autopsy. Patient D had a normal echocardiogram at 6 months 
of age under sildenafil treatment, which was continued because this patient still required 
supplemental oxygen therapy at that time.  At 12 months of age, this patient had slight right 
ventricular dilation without TR and a closed ductus arteriosus.  Sildenafil was discontinued at 
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18 months of age. Two weeks later and 6 months after stopping sildenafil, echocardiographic 
evaluation confirmed that PH had not recurred in these patient. Under treatment with silde-
nafil, PH had disappeared at 12 months of age in patients A and  B. In patient A, sildenafil 
and bosentan were stopped at 3 years of age, and an echocardiogram made 2 weeks later 
confirmed absence of PH. In patient B, sildenafil and bosentan were stopped at 2.9 years of 
age, and an echocardiogram made 2 months later confirmed absence of PH.  Two patients 
received sildenafil until 14 months of age but they had no echocardiographic signs of PH at 
6 and 12 months of age (Table 3). 






Supplemental oxygen use 1 (50%) 2 (7%) 0.181
Tube feeding 2 (100%) 8 (26%) 0.101
Diuretics 1 (50%) 3 (10%) 0.241
Sildenafil 2 (100%) 3 (10%) 0.021
Bosentan 1 (50%) 2 (7%) 0.181
Data are presented as number (percentage).
P-value=significant difference between the groups. 
1 Fisher’s exact test was used.
Abbreviation: PH=pulmonary hypertension.
Cardiac catheterization at follow-up
During follow-up, cardiac catheterization was performed in two patients who had PH after 
the neonatal period (patients A and B). In patient A, cardiac catheterization evaluating pul-
monary vascular reactivity at 4.5 months of age found a right ventricular pressure of 55-60% 
of the left ventricular pressure, and PH did not change with the use oxygen or iNO. Patient 
B underwent cardiac catheterization three times (at 9, 10 and 36 months of age). The first 
confirmed the diagnosis of a PAPVR with a median sized atrial septal defect with a left-to-
right shunt ratio of 1.7. During the second time, an atrial septal defect device could not be 
placed. The third cardiac catheterization showed a slight right atrium dilation due to PAPVR 
with an atrial septal defect without signs of PH.
ECG at follow-up
Twenty-nine of 35 patients had an ECG at 6 months of age (including patients A and C with 
PH). Patient C had right ventricular hypertrophy on the ECG. All other patients (including 
patient A and one patient with dextroposition on the chest x-ray) had no signs of PH on 
ECG. At 12 months of age, an ECG was performed in 29 of 32 patients (including patient 
D with PH). All these patients had no signs of PH on ECG (including patient D and two 
patients with cardiac dextroposition).




Routine echocardiography showed persistence of PH in a minority (8%) of included CDH 
patients, while 71% of surviving CDH patients had PH at hospital admission. Patients with 
persistent PH had a longer duration of mechanical ventilation and hospital stay than patients 
without persistent PH, and they were all treated with iNO, sildenafil and bosentan. This 
indicates that persistent PH is associated with a greater severity of illness during early life.
As stated earlier, the development of PH in CDH patients is a complex matter, with 
involvement of reduction in the number of pulmonary arteries in combination with altered 
vasoreactivity and abnormal pulmonary vascular remodeling.3 Patients with most severe lung 
hypoplasia requiring prolonged ventilatory support and hospitalization seem most at risk of 
persistent PH, as is seen in infants with bronchopulmonary dysplasia.15 In addition to abnor-
mal lung and pulmonary vessel development, the iatrogenic lung injury due to prolonged 
mechanical ventilation may be a contributing factor to persistence of PH. In our study, 94% 
and 96% of CDH patients had a normal echocardiogram at 6 and 12 months of age, respec-
tively. The persistence of PH in CDH patients has been studied previously (supplementary 
table 3). Most of the previous studies on persistence of PH in CDH patients were retrospec-
tive cohort studies assessing PH with echocardiography. Interpretation and comparison of 
the study results is hindered by to the use of different definitions for PH resulting in varying 
prevalence rates of PH (supplementary table 3). Lusk et al.5 found a prevalence of 57% at 
4 weeks of age, and Wynn et al.6 reported a prevalence of 49% at 1 month of age. In other 
studies, the reported prevalence of persistent PH at 6 to 7 months of age varied between 
0% and 27%.16, 17 Selection bias due to different patient populations and loss to follow-up 
seems also involved in these varying prevalence rates. 
Although cardiac catheterization is the gold standard for assessing PH,13, 18 echocardiography 
is more frequently used in children. Cardiac catheterization carries the risk of complications 
such as hypotension requiring intervention, hypertensive crisis, and cardiac arrest, which occur in 
10% of patients.19 Still, the reliability of echocardiography in CDH has been questioned because 
of the risk of false-negative results. Using cardiac catheterization, Zussman et al.20 found an 
elevated mean pulmonary artery pressure and pulmonary vascular resistance in three (38%) 
of eight children with CDH, whereas they had no signs of PH on the echocardiogram. The 
authors argue that early consideration of cardiac catheterization may be warranted in CDH 
patients. All these patients had a clinical indication for cardiac catheterization, however, which 
makes it impossible to extrapolate these results. In our series, two patients with persistent 
PH underwent cardiac catheterization on clinical indication, which confirmed the diagnosis 
of PH in both. In addition to cardiac catheterization and echocardiography, ECG may provide 
supportive evidence of PH, although a normal ECG cannot exclude PH.13, 21 Indeed, we think 
echocardiography should be the diagnostic tool of choice for follow-up of PH in CDH patients 
as two patients with persistent PH on echocardiography would have been missed if only an 
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ECG had been performed. 
Echocardiography can be challenging in CDH patients as the heart is often shifted to an 
abnormal position, and no single reliable quantitative measure of pulmonary artery pressure 
and/or right ventricular function exists. In our study, one patient who received sildenafil treat-
ment had echocardiographic signs of PH at 12 months of age, but not at 6 months of age. 
We assume that the echocardiogram at 6 months of age had underestimated the pulmonary 
artery pressure, which led to a false-negative diagnosis.  To improve diagnostic accuracy, more 
recent echocardiographic studies in CDH patients have used more advanced techniques 
such as tissue Doppler.5, 6, 16, 17, 22 Estimation of pulmonary artery pressures is mainly based 
on the existence of  TR, and qualitative assessment including position of the interventricular 
septum and/or signs of right ventricular dilation. Yet, TR is often not present in CDH patients 
with PH. Lusk et al.5, for example, found that TR was present in only 38% of patients with 
PH. We found TR in only two of the four patients with PH. So far, there is no standardized 
echocardiography protocol for CDH patients that minimizes the risk of missing PH. More 
advanced techniques such as tissue Doppler may improve diagnostic accuracy of PH in CDH 
patients, and as mentioned above, this technique is increasingly being used in more recent 
studies.5, 6, 16, 17, 22 A standardized protocol with more advanced echocardiographic methods 
may improve diagnostic accuracy and follow-up of PH in the future. 
As echocardiography is both time-consuming and costly, ideally the risk of missing PH 
should be minimal. Our results indicate that routine follow-up of PH with echocardiography 
is not useful during infancy because PH was only found in a small subset of patients who 
were treated with sildenafil.  The American Academy of Pediatrics recommends follow-up of 
PH when echocardiography was previously abnormal or when the child is on supplemental 
oxygen.8 More recently, Hollinger et al.9 advised to routinely follow up PH only in high risk 
CDH patients (defect size type C or D, requirement of patch repair, ECMO and/or supple-
mental oxygen) until 6 months of age, and after this age on indication. Nowadays, sildenafil 
and bosentan are increasingly being prescribed after hospital discharge, and follow-up of PH 
is important in these patients.  Therefore, we recommend using risk stratification on the basis 
of presence or absence of PH on echocardiography at hospital discharge and/or the need 
for PH treatment at hospital discharge to guide follow-up of PH. 
Little is known about the efficiency and safety of sildenafil and bosentan in the treatment 
of PH in CDH patients, and valid data or international guidelines are lacking.23, 24 Research 
addressing the reactivity of the pulmonary vasculature to medication is needed to assess 
the effectiveness of treatment. So far, only one study has addressed the weaning off silde-
nafil in 17 infants with CDH. Sildenafil could be ceased in ten patients after a long period 
(median 343 days) but no echocardiographic results were presented.25 In our study, three 
patients without PH were still treated with sildenafil and/or bosentan at 6 months of age, 
and two patients with resolved PH at 12 months of age received sildenafil until 2.7 years 
and 3.0 years of age, respectively. These patients may have been treated with sildenafil and 
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bosentan longer than needed, especially considering that PH did not recur. Although we did 
not address this issue in our study, we propose that sildenafil and bosentan can be weaned 
much faster than described by Behrsin et al.25 Based on our experience we recommend a 
control echocardiogram one month after discontinuation of sildenafil and/or bosentan to 
confirm that PH has not recurred. 
Another important question is whether PH recurs when CDH patients get older, which 
may affect their exercise capacity. A previous study found only a mildly reduced exercise 
capacity without echocardiographic evidence of PH at rest in 23 CDH patients at the median 
age of 13.3 years.26 These patients had been born in the period 1985-1991, in which survival 
and treatment were different than in our study period. More recently, Van der Cammen-Van 
Zijp et al.27 showed that exercise capacity was below the norm in CDH patients at 5 years 
of age and had deteriorated over time in ECMO-treated CDH patients. However, echo-
cardiography was not performed in this study. Based on our data and current literature 
we cannot exclude that altered vasoreactivity and abnormal growth of pulmonary vessels 
in CDH patients affects their exercise capacity. Future multicenter studies should focus on 
evaluating the course of PH in CDH patients later in life. Further in the future, exercise echo-
cardiography can possibly be used to assess pulmonary vascular function during exercise.28 
This is the first prospective study assessing routine follow-up for PH during infancy in CDH 
patients. All echocardiograms were performed by an experienced pediatric cardiologist and 
assessed by a second pediatric cardiologist, which showed 100% concordance in diagnosing 
PH. This is also the first mid-term follow-up study that focuses on the follow-up of PH in 
patients treated with sildenafil and/or bosentan. Some limitations need to be addressed 
as well. First, echocardiographs made within the first year of life were not available for 26 
patients, and not all included patients had an echocardiogram at both time-points. Second, 
the limited number of patients with PH did not allow for regression analyses. Multicenter 
studies using the same standard of care should further investigate risk factors for persistence 
of PH as well as the consequences of persistent PH.
In conclusion, echocardiographic follow-up of PH during infancy should not be advocated 
for all CDH patients. It should be reserved for patients with persistent PH on echocardiog-
raphy at hospital discharge and/or those who still require treatment with sildenafil and/or 
bosentan at hospital discharge. Outcomes of studies on the efficacy of medication such as 
sildenafil and/or bosentan in lowering the pulmonary artery pressure might be helpful for 
developing guidelines on PH treatment in CDH patients. Development of a standardized pro-
tocol prescribing validated echocardiography measures for the accurate echocardiographic 
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Gestational age (weeks) 38.3 (37.6-38.9) 38.6 (38.1-39.7) 0.11
Birth weight (kilograms) 3.0 (2.6-3.2) 3.2 (2.9-3.5) 0.48
Male 30 (58%) 15 (58%) 1.00
Ethnicity
     Dutch






Inborn 43 (83%) 16 (62%) 0.04
Left sided hernia 46 (89%) 22 (85%) 0.721
Prenatally
Prenatal diagnosis 42 (81%) 16 (62%) 0.07
Prenatal liver position
     Up
     Down








Observed-to-expected LHR 44.9% (41.3-56.3) 43.0% (37.1-59.8) 0.88
Surgery
Age at surgery (days) 3 (2-5) 4 (3-5) 0.23
Thoracoscopic repair 29 (56%) 17 (65%) 0.42
Patch repair 39 (75%) 15 (58%) 0.12
ECMO
ECMO use 6 (12%) 3 (12%) 1.001
Age start ECMO (days) 5 (3-8) 2 (2-5) 0.30
Hours on ECMO 207 (96-327) 264 (190-293) 0.80
Hospital admission
Duration of mechanical ventilation (days) 8 (5-19) 8 (5-16) 0.53
Presence of chronic lung disease2 27 (52%)3 12 (46%) 0.48
Duration of initial hospital stay  (days) 34 (16-93) 35 (22-57) 0.55
Inhaled nitric oxide use 19 (37%) 9 (35%) 0.87
Sildenafil use 11 (21%) 2 (8%) 0.201
Bosentan use 7 (14%) 1 (4%) 0.261
Hospital discharge
Supplemental oxygen at discharge 8 (15%) 0 (0%) 0.0471
Diuretics at discharge 12 (23%) 5 (19%) 0.70
Sildenafil at discharge 9 (17%) 1 (4%) 0.151
Bosentan at discharge 4 (8%) 0 (0%) 0.301
Data are presented as median (interquartile range) or number (percentage), as appropriate.
P-value=significant difference between the groups.
1 Fisher’s exact test was used.
2 Presence of chronic lung disease (oxygen dependency at 28 days of life)12
3 Missing: n=3.
Abbreviations: ECMO=extracorporeal membrane oxygenation; LHR=lung-to-head ratio.
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Supplementary table 2. Characteristics of the four patients with pulmonary hypertension at follow-up
Patient A Patient B Patient C Patient D
Hospital admission
PH on echo Yes Yes Yes Yes
Duration of mechanical ventilation (days) 2581 48 104 49
Duration of initial hospital stay (days) 274 388 426 122
6 months follow-up
PH on echo Yes Yes Yes No
PH on ECG No Missing Yes No
Supplemental oxygen Yes Yes Yes Yes
Tube feeding Yes Yes Yes Yes
Diuretics Yes Yes Yes Yes
Sildenafil Yes Yes Yes Yes
Bosentan Yes Yes Yes No
12 months follow-up
PH on echo No No Yes Yes
PH on ECG No Missing Missing No
Supplemental oxygen No Yes Yes No
Tube feeding Yes Yes Yes Yes
Diuretics Yes Yes Yes No
Sildenafil Yes Yes Yes Yes
Bosentan Yes Yes Yes No
1 Use of tracheostomy tube
Abbreviations: ECG=electrocardiography; PH=pulmonary hypertension.
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Supplementary table 3. Overview of echocardiographic studies assessing pulmonary hypertension at 
follow-up in congenital diaphragmatic hernia patients published from 2000 onwards
Study Study design Number of patients Year of 
birth
Time frame of 
follow-up
Definition PH Most important results





PH: ≥2/3 of systemic systolic pressure. 12% of survivors had persistence of PH prior to discharge.
PH was associated with ECMO and prolonged ventilatory support. 




PH: TR jet velocity of ≥2.6 m/sec or evidence of 
ventricular-septal flattening with one or more of the 
following: right atrial enlargement, right ventricular 
hypertrophy, or right ventricular dilation.
27% had PH assessed at the median age of 7 (5.7-13.3) months of 
age. 
Wynn et al. 2013 Prospective cohort study 220 2009-2010 -1 month 
-3 months
PH: ≥1/2 of systemic systolic pressure. 49% had PH at 1 month of age.
Worse PH at 1 month of age was associated with prenatal diagnosis, 
patch repair, post-operative complications, low birth weight and 
ECMO.
18% had PH at 3 months of age. 
Worse PH at 3 months of age was associated with patch repair, non-
isolated CDH, a genetic diagnosis, and a lower birth weight.
Datta et al. 2012 Retrospective cohort study 31 1992-2007 -90 days Chronic PH: evidence of right ventricular systolic 
pressure above normal <90 days of life with 
requirement of oxygen or vasodilatory medication on 
follow-up at 90 days of life.
32% had chronic PH.
Chronic PH was associated with higher ventilatory pressure after 
ECMO decannulation, need for high-frequency oscillation ventilation, 
prolonged duration of ventilation and hospital stay.
Egan et al. 2012 Case control study 7 CDH patients versus 
16 controls
Unknown -Mean 6.2±1.7 years PH: flattened interventricular septum or a TR jet >2.5 
m/sec.
None of the patients had persistence of PH.
Zussman et al. 2012 Case control study 8 CDH patients versus 
10 controls with a patent 
ductus arteriosus
2006-2009 -Mean 16.9±9.3 
months 
PH: TR or patent ductus arteriosus gradient 
estimating right-sided pressure >40% of systemic 
pressure.
38% had persistence of PH on echocardiogram.
At cardiac catheterization, mean pulmonary artery pressure and 
pulmonary vascular resistance was significantly higher in CDH 
patients than in controls. 
Trachsel et al. 2006 Case control study 23 CDH patients versus 
23 controls
1985-1991 -Mean 13.3±2.2 years PH: not defined. None of the patients had persistence of PH. 
Kamata et al. 2005 Retrospective cohort study 33 1986-2000 -Mean 4.1±2.5 years PH: not defined. None of the patients had persistence of PH.
Dillon et al. 2004 Retrospective cohort study 47 1991-2002 -1 week
-2 weeks
-3 weeks
PH: estimated pulmonary artery pressure to systemic 
arterial pressure ratio ≥0.5
33% of survivors had persistence of PH.
Stefanutti et al. 2004. Cross-sectional cohort study 24 1985-1994 -Mean 8.15±2.80 years PH: not defined. None of the patients had persistence of PH.
Abbreviations: CDH=congenital diaphragmatic hernia; ECMO=extracorporeal membrane oxygenation; PH=pulmonary hyper-
tension; TR=tricuspid regurgitation.
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PH was associated with ECMO and prolonged ventilatory support. 




PH: TR jet velocity of ≥2.6 m/sec or evidence of 
ventricular-septal flattening with one or more of the 
following: right atrial enlargement, right ventricular 
hypertrophy, or right ventricular dilation.
27% had PH assessed at the median age of 7 (5.7-13.3) months of 
age. 
Wynn et al. 2013 Prospective cohort study 220 2009-2010 -1 month 
-3 months
PH: ≥1/2 of systemic systolic pressure. 49% had PH at 1 month of age.
Worse PH at 1 month of age was associated with prenatal diagnosis, 
patch repair, post-operative complications, low birth weight and 
ECMO.
18% had PH at 3 months of age. 
Worse PH at 3 months of age was associated with patch repair, non-
isolated CDH, a genetic diagnosis, and a lower birth weight.
Datta et al. 2012 Retrospective cohort study 31 1992-2007 -90 days Chronic PH: evidence of right ventricular systolic 
pressure above normal <90 days of life with 
requirement of oxygen or vasodilatory medication on 
follow-up at 90 days of life.
32% had chronic PH.
Chronic PH was associated with higher ventilatory pressure after 
ECMO decannulation, need for high-frequency oscillation ventilation, 
prolonged duration of ventilation and hospital stay.
Egan et al. 2012 Case control study 7 CDH patients versus 
16 controls
Unknown -Mean 6.2±1.7 years PH: flattened interventricular septum or a TR jet >2.5 
m/sec.
None of the patients had persistence of PH.
Zussman et al. 2012 Case control study 8 CDH patients versus 
10 controls with a patent 
ductus arteriosus
2006-2009 -Mean 16.9±9.3 
months 
PH: TR or patent ductus arteriosus gradient 
estimating right-sided pressure >40% of systemic 
pressure.
38% had persistence of PH on echocardiogram.
At cardiac catheterization, mean pulmonary artery pressure and 
pulmonary vascular resistance was significantly higher in CDH 
patients than in controls. 
Trachsel et al. 2006 Case control study 23 CDH patients versus 
23 controls
1985-1991 -Mean 13.3±2.2 years PH: not defined. None of the patients had persistence of PH. 
Kamata et al. 2005 Retrospective cohort study 33 1986-2000 -Mean 4.1±2.5 years PH: not defined. None of the patients had persistence of PH.
Dillon et al. 2004 Retrospective cohort study 47 1991-2002 -1 week
-2 weeks
-3 weeks
PH: estimated pulmonary artery pressure to systemic 
arterial pressure ratio ≥0.5
33% of survivors had persistence of PH.
Stefanutti et al. 2004. Cross-sectional cohort study 24 1985-1994 -Mean 8.15±2.80 years PH: not defined. None of the patients had persistence of PH.




Growth in children with congenital diaphragmatic 










Purpose: Infants with congenital diaphragmatic hernia (CDH) have high rates of mortality 
and long-term morbidity, including poor growth and failure to thrive. The aim of this study 
was to describe growth patterns during the first year of life in infants with CDH not treated 
with extracorporeal membrane oxygenation. 
Methods: Medical records of infants with CDH admitted to our center between January 
2005 and December 2011 were reviewed. Infants with anthropometric measurements at 
3, 6 and 12 months were included. Anthropometric measurements were obtained for the 
first year of life. Logistic regression analyses were performed to find predictive associations 
with failure to thrive (weight-for-age and/or weight-for-length z-score <-2). 
Results: Of the 45 survivors, 38 were seen twice (84%) and 24 (53%) were seen on three 
occasions to age 12 months. Poor growth was observed with weight being most affected. 
Failure to thrive was present in 63% during the first 6 months of life. Days of mechanical ven-
tilation were the only predictor of failure to thrive. Besides poor weight gain, height and head 
circumference were also reduced. However, catch-up growth occurred during the second 
half of infancy and at age 12 months failure to thrive had reduced by two thirds to 21%.
Conclusions: Poor growth is a common early finding in CDH patients, which improves 
during infancy.  This emphasizes the importance of close follow-up and aggressive nutritional 
management in CDH patients.




Infants with congenital diaphragmatic hernia (CDH) have significant rates of mortality and 
long-term morbidity, which are primarily related to lung hypoplasia and associated pulmonary 
hypertension.1, 2 In recent years, the survival of CDH infants has progressively improved with 
survival rates now approaching 90% at some centers.3, 4 Advances in treatment, like extracor-
poreal membrane oxygenation (ECMO), have been thought to be partly responsible for the 
improved survival rates in CDH infants.5, 6 However, the beneficial effect of ECMO on survival 
remains controversial,7, 8 and the use of ECMO therapy has been found to be associated 
with adverse outcomes in CDH survivors.9-11 With increased survival, however, the long-term 
prognosis and quality of life of CDH survivors have become an increasingly important issue. 
Failure to thrive (FTT) is a significant comorbidity that has been reported in up to 69% of 
CDH survivors.12-16 Catch-up growth in children with CDH has been reported in the second 
year of life,15 although this finding is not universal. Contributing to poor growth are feeding 
difficulties and oral aversion, which are reported to occur in up to 27% of CDH infants.12-14 
However, growth over time has been poorly studied in CDH survivors, and as such growth 
patterns during the early years remain unclear. 
The aim of this study was to describe the effect of CDH on growth in children during 




In this study, medical records of all infants with CDH admitted to the Children’s Hospital at 
Westmead between 1 January 2005 and 31 December 2011 were reviewed. Infants were 
treated according to a standardized protocol including gentle ventilation and delayed surgical 
repair following stabilization. Synchronized conventional ventilation with tidal volume moni-
toring was the preferred initial ventilator strategy. Inhaled nitric oxide, vasopressor support 
and high frequency ventilation were used if infants could not be stabilized with conventional 
ventilation (table 1). ECMO was not offered as a routine treatment modality in our center. 
Table 1. Postnatal management protocol for congenital diaphragmatic infants
Treatment with synchronized 
conventional ventilation
PIP max <26 cm H2O; PEEP: 2-5 cm H2O1 
Adapt FiO2 to obtain preductal saturation between 85% and 88% and postductal 
saturations above 70%
Ventilator breath rate: 40-60/min to allow permissive hypercapnia (pCO2 45-65 
mm Hg) with a pH of 7.25-7.352
Aim for 3-4 ml/kg tidal volume
Indications for inhaled nitric oxide Presence of pulmonary hypertension confirmed by echocardiography
Indications for vasopressor support Mean blood pressure <10th percentile for gestational age
Indications for high-frequency ventilation Preductal saturation <85%
Respiratory acidosis: pH <7.25 and/or pCO2 >65 mm Hg 
1 If oxygenation is a problem consider trialing increased PEEP if chest x-ray reveals underinflation. Also consider a longer inspiratory 
time and an inspiration:expiration ratio of 1:1 to maintain airway pressure.
2 Maintain spontaneous respiration if possible.
Abbreviations: CO2=carbon dioxide; FiO2=inspiratory oxygen fraction; PEEP=positive end expiratory pressure; PIP=peak inspi-
ratory pressure.
After hospital discharge, follow-up visits were scheduled in the infant lung clinic on a reg-
ular basis. All infants with anthropometric measurements at 3, 6 and 12 months of age were 
included. Anthropometric measurements were plotted on the World Health Organization 
2006 growth charts (http://www.who.int/childgrowth/en/) and z-scores were calculated. A 
z-score of 0 represents the mean for the reference population.  All anthropometric mea-
surements were adjusted for gestation in children born <37 weeks.
FTT was defined as having a z-score <-2 for weight-for-age and/or weight-for-length.  After 
identification of FTT, we searched for variables associated with FTT including prenatal diag-
nosis, prematurity, birth weight, gender, side of hernia, type of repair, presence of congenital 
anomalies, presence of moderate to severe pulmonary hypertension (arterial pressures 
greater than half systemic on echocardiography together with the need for inhaled nitric 
oxide and/or sildenafil postoperatively), days of mechanical ventilation, supplemental oxygen 
at discharge, duration of hospital stay and presence of gastroesophageal reflux disease 
(GERD).
Data were analyzed using SPSS version 20.0 for Windows (SPSS Inc., Chicago, Illinois, USA). 
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Categorical variables were compared using chi-square test or Fisher’s Exact test. Student’s 
t-tests were used for continuous normally distributed variables and nonparametric tests for 
non-normally distributed continuous variables. Growth parameters over time were com-
pared with the Wilcoxon signed-ranks test. Logistic regression analyses were performed to 




Fifty-five infants with CDH were admitted to the Children’s Hospital at Westmead during 
the 7-year period of data collection. The overall survival rate during the entire follow-up was 
82%. Nine children died in hospital owing to a combination of respiratory failure, pulmonary 
hypoplasia and persistent pulmonary hypertension. Five children died before undergoing 
surgical repair and four patients died postoperatively before hospital discharge (age of death: 
11, 21, 26, and 112 days). One child died from viral pneumonia after hospital discharge at 
10 weeks of age in the emergency department of a regional hospital. 
Of the 45 survivors, 38 (84%) were seen twice, between 3 and 12 months of age. A subset 
of 24 infants (53%) was seen on three occasions (3 months, 6 months and 12 months). Seven 
patients were lost to follow-up. Infant characteristics are shown in table 2. 
Table 2. Characteristics of congenital diaphragmatic hernia infants
Characteristics CDH patients (n=24)
Gestational age (weeks) 37.5±3.1
Birth weight (kilograms) 2.96±0.73
Gender
     Male




     1 min
     5 min
6 (1-9)
8 (5-9)
Time of diagnosis 
     Prenatal




     Left




     Primary repair
     Patch
14 (58%)
10 (42%)
Age at surgery (days) 3 (1-14)
Associated congenital anomalies 10 (42%)
Congenital heart disease 7 (29%)
Moderate to severe pulmonary hypertension 9 (38%)
Data are presented as mean±standard deviation, median (range) or number of patients (percentage).
Structural heart disease was the most commonly associated congenital anomaly noted in 
CDH survivors. Minor structural heart disease (atrial septal defect, ventricular septal defect 
and atrioventricular septal defect) was present in six children and one child had tetralogy 
of Fallot. Other associated congenital anomalies were malformation of both upper limbs, 
imperforate anus and a balanced translocation of chromosome 1:16. Moderate to severe 
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pulmonary hypertension was defined by pulmonary arterial pressures greater than half sys-
temic on echocardiography together with the need for inhaled nitric oxide and/or sildenafil 
postoperatively. Moderate to severe pulmonary hypertension was present in 9/24 (38%) 
of infants. Pulmonary hypertension, as assessed by echocardiography, had resolved in all by 
the age of 13 months.
After hospital discharge, 14/24 (58%) of children received supplemental calories with 
polyjoule, 10/24 (42%) of patients required gastric tube feeding, and 2/24 (8%) of children 
required gastrostomy placement. Poor growth was observed in many infants, especially in 
early infancy with weight being most affected (figure 1). 
Figure 1. Growth of congenital diaphragmatic hernia infants during the first year of life



































































































The figure presents error bars, indicating mean values and 95% confidence intervals.
Catch-up growth was observed in a significant proportion of children during infancy. 
Weight improved from a mean±standard deviation (SD) z-score of -2.07±1.17 at 3 months 
of age to -0.85±1.32 at 12 months of age (p=0.001).  FTT was present in 15/24 (63%) of 
the children during the first 6 months of life, however, considerable catch-up growth was 
observed over the latter part of infancy (figure 1). At the age of 12 months, FTT remained 
in only 5/24 (21%) of the children (p=0.01). When the 38 subjects seen on only two occa-
sions were considered, FTT was present in a similar proportion of the cohort with 50% at 
3 to 6 months of age and in 19% at 12 months of age. Days of mechanical ventilation were 
the only variable predictive of FTT at 6 months of age (p=0.03). We found no predictors 
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for FTT at 12 months of age. Linear growth was reduced but also improved over time with 
a mean±SD z-score of -1.36±1.43 at 3 months of age and -0.39±1.30 at 12 months of 
age (p=0.04). As a consequence of improved weight gain as well as linear growth, weight-
for-length scores remained relatively stable during the first year of life. Weight-for-length 
mean±SD z-scores were -1.10±0.97 and -1.12±1.37, at respectively 3 and 12 months of age 
(p=0.86). Head circumference was the growth parameter best preserved with mean±SD 
z-scores of -0.98±1.08 and -0.03±1.13 at respectively 3 and 12 months of age (p=0.001).
Twenty-one percent of patients required additional visits to a multidisciplinary feeding clinic 
owing to persistent feeding difficulties. Oral aversion was observed in 1/24 (4%) of children. 
Other feeding difficulties reported were: poor suck-swallowing reflex, immature oral skills, 
feeding difficulties owing to increased work of breathing and GERD. The number of children 
treated for symptomatic GERD during infancy was 9/24 (38%).  Almost all of these children 
were successfully managed with antireflux medication, however, only one (4%) child required 




Our survival rate of 82% is consistent with recent studies showing improved survival in 
CDH patients.3, 4, 17 Despite our encouraging survival outcomes, this study indicates that 
poor growth and FTT are frequent findings in CDH survivors during the first year of life. 
The cause for poor growth in CDH patients is multifactorial, including increased catabolic 
stress in the neonatal period, GERD, and persistent pulmonary impairment.13 Poor growth 
is similarly seen in infants with bronchopulmonary dysplasia during the early months after 
initial hospitalization, which is caused by their increased work of breathing and higher meta-
bolic rates.18, 19 The number of children with poor growth and FTT in the present cohort is 
consistent with the findings of others.13 However, some studies have reported even higher 
numbers of patients with growth failure.12, 15 
Most children in our cohort demonstrated catch-up growth during the first year of life. 
FTT was present in 63% of children during the first 6 months of life but remained in only 
21% at 12 months of age. Other studies have also reported improved growth with time, 
but mainly after the first year of life.13, 14 The early follow-up visits in the infant lung clinic and 
regular medical review together with the elaborate use of calorie-enhanced feeds may have 
contributed to the faster catch-up growth observed in our patients. Besides poor weight gain, 
length was reduced in many children during the follow-up period. Linear growth in CDH 
patients is infrequently described in the literature, and the finding of reduced length in CDH 
patients has only been reported in one other study.12 
In this study, days of mechanical ventilation were the only predictor of FTT in the first 6 
months of life. This is interpreted to reflect a more severe pulmonary disease phenotype 
of CDH with poor growth as a consequence of increased respiratory effort or work of 
breathing, which is consistent with the current literature. One study found an association 
between FTT and duration of mechanical ventilation as well as hospital stay.20 Muratore et 
al.13 have also demonstrated ECMO and the need for oxygen at discharge as predictors of 
FTT. GERD has also been associated with FTT.13, 21 However, we did not find an association 
between GERD and FTT as was consistent with another study.22 These differences could be 
owing to the variable severity of GERD present in CDH infants and diagnostic methods of 
GERD. The importance of optimizing early nutrition is likely to improve respiratory status, 
reduce the metabolic cost of an elevated work of breathing, both in terms of respiratory 
effort and rate, and allow the utilization of calories for growth.  
Oral aversion is another difficult problem that is reported in up to 27% of CDH infants,12-14 
however, only one (4%) child in our cohort was diagnosed with oral aversion. Our restrictive 
approach towards gastrostomy tube placements and early stimulation of oral feeding could 
be an explanation for the low rate of oral aversion seen. 
The incidence of GERD found in this study was lower (38%) than reported in most other 
studies (45% to 89%).12, 23 Further, only one (4%) child required fundoplication in contrast 
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with 19% in another study.13 This variability in incidence is also likely related to the different 
diagnostic methods used in studies including pH monitoring, upper gastrointestinal contrast 
studies or clinical diagnosis of GERD, as well as thresholds for initiating treatment. 
The strengths of this study are the early follow-up of all four growth parameters in CDH 
patients during review in the follow-up clinic. Limitations of our study are the retrospective 
study design and relatively small sample size. Multicenter studies should be encouraged to 
recruit a sufficient number of CDH patients into a randomized trial of more aggressive 
feeding initiatives overseen by a dietician to improve growth in early infancy.
Conclusion
Poor growth continues to be a common finding in infants with CDH during the first year of 
life. Close follow-up of growth and nutrition with early aggressive nutritional management is 
essential. Additional calories should be provided in the first year of life to optimize growth 
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Neurodevelopmental outcome in 
congenital diaphragmatic hernia survivors 









Objective: To determine neurodevelopmental outcome in congenital diaphragmatic hernia 
(CDH) survivors during the first 3 years of life.
Methods: Admitted CDH patients were assessed at the ages of 12 (n=18) and 36 months 
(n=15) using the Bayley scales of infant and toddler development-third edition. Neurodevel-
opmental results of CDH patients were compared with published norms and with a healthy 
matched control group.
Results: At 12 months of age, receptive language was mildly delayed in 6% of patients, and 
6% of patients demonstrated mildly delay in expressive language and gross motor skills at this 
age. Eighteen percent of CDH patients had severely delayed scores for gross motor skills. At 
36 months of age, expressive language scores were mildly delayed in 21% of patients. When 
compared to the control group, CDH patients had similar neurodevelopmental scores at 
12 and 36 months of age.
Conclusion: CDH is not necessarily associated with impaired neurodevelopmental outcomes 
during the first 3 years of life.




Neurodevelopmental outcomes of congenital diaphragmatic hernia (CDH) survivors are 
a major cause for concern, with studies reporting a significantly increased risk of impaired 
neurodevelopmental outcomes.1-3  The incidence of impaired neurodevelopmental outcomes 
in CDH patients during the first years of life has varied considerably in the literature ranging 
from 12% to 77%.4, 5  Three recent longitudinal studies reported adverse neurodevelopmental 
and neuromotor outcomes in CDH patient during the first years of life.6-8 It appears that 
infants requiring extracorporeal membrane oxygenation (ECMO) have the highest risk for 
adverse neurodevelopmental outcomes.1-3 However, reports of neurodevelopmental out-
comes in CDH patients are generally based upon small cohorts without control subjects 
for comparison. 
The aim of this study was to determine the neurodevelopmental outcomes in CDH 




In this study, neurodevelopmental outcome was assessed in CDH patients admitted to 
the Children’s Hospital at Westmead between 1 January 2006 and 31 December 2009. 
Neurodevelopmental assessments were performed at the corrected age of 12 months 
and at 36 months using the Bayley scales of infant and toddler development-third edition 
(Bayley-III). The Bayley-III is a standardized test that assesses neurodevelopment across five 
distinct scales: cognition, receptive language, expressive language, fine motor and gross motor. 
Neurodevelopmental results of CDH patients were compared with published norms and a 
locally recruited, contemporary control group. The Bayley-III scaled scores have a mean of 
10 with a standard deviation (SD) of 3. A Bayley-III scaled score <1 SD below the mean was 
considered as normal, a score of 1-2 SD below the mean as mildly delayed and a score of 
>2 SD below the mean as severely delayed. Additionally, audiology assessments using tym-
panometry were performed annually as part of routine follow-up. All neurodevelopmental 
measurements were adjusted for preterm delivery. Each infant with CDH was matched 
with two healthy control infants of the same gestational age and gender.  The control group 
comprised healthy infants born during the same time period, who did not have any surgery 
up to the time of their assessment. The healthy controls were recruited from the co-located 
tertiary maternity units. Controls were the children born in one of the three tertiary mater-
nity units, whose date and time of birth was closest to that of the CDH patient. Informed 
consent was directly obtained from parents. 
Data were analyzed using SPSS version 20.0 for Windows (SPSS Inc., Chicago, Illinois, USA). 
Student’s t-test was used for continuous normally distributed variables and non-parametric 
tests for non-normally distributed continuous variables. A p-value <0.05 was considered 
statistically significant. 
Ethical approval for this study was obtained from the Ethics Committee of  The Children’s 
Hospital at Westmead (Activity N4060).




During the study period, 34 CDH patients were admitted to our center.  The overall survival 
rate was 85%. Of 29 survivors, 11 patients could not be included due to refusal of parents to 
join the study or loss to follow-up. Eighteen CDH patients were matched with 36 controls 
and assessed with the Bayley-III at the corrected age of 12 months and 15 of these children 
were tested again at 36 months of age. One child was later diagnosed with a chromosomal 
abnormality and was excluded from the analyses. Therefore, results for 17 CDH patients 
at 12 months and 14 CDH patients at 36 months of age are shown. Patient characteristics 
of CDH patients and controls are shown in table 1. Structural heart disease was the most 
commonly associated congenital anomaly noted in CDH survivors, other associated congen-
ital anomalies were Pentalogy of Cantrell, an imperforate anus and a balanced translocation 
of chromosome 1:16. Minor structural heart disease (atrial septal defect, ventricular septal 
defect, moderate pulmonary valve stenosis) was present in six children and the child with 
Pentalogy of Cantrell was diagnosed with Tetralogy of Fallot. 





Gestational age (weeks) 38.8±1.6 38.8±1.5
Birth weight (grams) 3344±644 3348±555
Gender
     Male





Time of diagnosis 
     Prenatal




     Left




     Primary repair
     Patch
13 (76.5%)
4 (23.5%)
Associated congenital anomalies 9 (52.9%)
Congenital heart disease 7 (41.2%)
Moderate to severe pulmonary hypertension1 5 (29.4%)
Data are presented as mean±standard deviation or number of patients (percentage).
1 Pulmonary arterial pressures greater than half systemic on echocardiography together with the need for inhaled nitric oxide 
and/or sildenafil post-operatively.
Abbreviation: CDH=congenital diaphragmatic hernia.
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At 12 months of age, all CDH patients scored within the normal range on the cognitive 
and fine motor scale. Receptive language was mildly delayed in one patient (6%), and one 
patient (6%) demonstrated mild delay in expressive language and gross motor skills. Three 
patients (18%) had severely delayed scores for gross motor skills at the age of 12 months. 
All children with mildly or severely delayed scores at 12 months of age were reassessed at 
36 months of age. At 36 months of age, expressive language scores were mildly delayed in 
three children (21%), and one child (7%) had a mildly delayed score on the receptive language 
scale as well. All the other outcome scores were normal at 36 months of age. 
We found no difference in neurodevelopmental outcomes between CDH patients and 
the control group at 12 months and 36 months of age (table 2). However, there was a 
trend toward a significant difference for expressive language at 36 months of age, with 
CDH patients having lower scores. There was no difference in maternal or paternal educa-
tion between the CDH patients and the control group. No sensorineural hearing loss was 
diagnosed in our cohort during the follow-up period. 
Our study did not find any predictors for delayed neurodevelopmental outcome on any 
of the subscales.
Table 2. Neurodevelopmental outcome scores at 12 months and 36 months of age
Scale









Cognitive 11.41 (10.13-12.70) 11.14 (10.34-11.94) 0.76 10.36 (9.43-11.28) 10.73 (9.79-11.68) 0.97
Receptive language 10.18 (9.11-11.24) 11.17 (10.28-12.05) 0.14 10.42 (8.95-11.89) 11.23 (10.56-11.91) 0.25
Expressive language 9.35 (8.25-10.46) 10.06 (9.33-10.78) 0.22 9.33 (8.21-10.46) 10.87 (9.88-11.85) 0.06
Fine motor 9.82 (8.91-10.74) 9.97 (9.23-10.71) 0.77 10.64 (9.61-11.67) 11.00 (10.22-11.78) 0.39
Gross motor 8.24 (6.57-9.90) 8.97 (8.13-9.81) 0.61 9.86 (9.08-10.64) 10.21 (9.30-11.12) 0.93
Data are presented as mean (95% confidence interval).
Abbreviation: CDH=congenital diaphragmatic hernia.




We did not find any differences in neurodevelopmental outcomes in CDH patients when 
compared with healthy controls at 12 months and 36 months of age. Three other longitudinal 
studies evaluated neurodevelopmental and neuromotor outcomes in CDH patients.6-8  In 
our study, grossmotor skills were severely delayed in 18% of CDH patients at 12 months of 
age with all of these children achieving normal scores for grossmotor skills at 36 months of 
age. Friedman et al.6 showed considerably higher rates of motor problems in CDH patients 
compared with our cohort. Similarly to our study, Danzer et al.8 and Gischler et al.7 demon-
strated poor psychomotor outcomes in CDH patients during infancy. CDH survivors may 
require prolonged recovery periods in hospital. As a consequence, they have little physical 
activity and therefore fewer opportunities to obtain motor skills early in the first year of life. 
Nonetheless, our results demonstrate that CDH patients with delays in grossmotor skills 
catch-up with their peers after the first year of life. The two other studies also observed an 
improvement of psychomotor scores after 12 months of age.7, 8 At 12 months of age, our 
control group scored one point below the mean score of the general population on the 
gross motor scale, which was still in the normal range within one standard deviation from 
the mean score. 
At 36 months of age, 21% of CDH patients demonstrated mild delay on the expressive 
language scale compared to 6% of children at 12 months of age. Furthermore, there was 
a trend toward a difference for expressive language at 36 months of age between CDH 
patients and controls that did not reach statistical significance. Friedman et al.6 also found lan-
guage problems to be increased at 3 years of age compared to age 1 year, whereas the other 
two longitudinal studies did not show a decline in language scores.7, 8 A possible explanation 
for these differences at 12 and 36 months of age is that subtle neurocognitive problems will 
become more evident with age. Therefore, problems are more likely to be diagnosed at 36 
months of age. This emphasizes the importance of long-term follow-up of CDH survivors. 
ECMO is frequently found to be associated with adverse neurodevelopmental outcome 
in CDH patients.1-3 None of the CDH survivors in our cohort were treated with ECMO, 
which could be a contributing factor toward favorable neurodevelopmental outcome in our 
cohort of CDH patients. 
Sensorineural hearing loss is another neurological disability that has been associated with 
CDH.9 No sensorineural hearing loss was diagnosed in our cohort during the follow-up 
period, which could have contributed to the encouraging results in our cohort. 
The most important limitation of this study includes the small sample size of CDH patients. 
However, we did assess our subjects in relation to contemporary controls from the same 
geographic population. Larger numbers of patients should be recruited to further explore 




In this study, neurodevelopmental outcomes of CDH patients born since 2006 were no 
different to healthy matched controls at 12 and 36 months of age. This suggests that CDH 
is not necessarily associated with impaired neurodevelopmental outcomes during the first 
3 years of life.
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Purpose: Until now, long-term outcome studies have focused on general cognitive functioning 
and its risk factors following neonatal extracorporeal membrane oxygenation (ECMO) and/
or congenital diaphragmatic hernia (CDH). This study aimed to identify affected neuropsy-
chological domains and its clinical determinants in survivors of neonatal ECMO and/or CDH. 
Design: Prospective follow-up study.
Setting: Tertiary university hospital.
Patients: Sixty-five eight-year-old survivors of neonatal ECMO and/or CDH. 
Interventions: None.
Measurements and Main Results: Intelligence, attention, memory, executive functioning and 
visuospatial processing were evaluated using validated tests and compared to Dutch refer-
ence data. Assessed risk factors of outcome were illness severity indicators (need for ECMO, 
type of ECMO, maximum vasoactive-inotropic score, sepsis, ventilator-free days during the 
neonatal period, and duration of initial hospital stay), number of anesthetic procedures in 
the first year of life and growth at 1 year of age. 
Patients had an average intelligence (mean IQ±standard deviation (SD): 95±16), but a 
significantly poorer sustained attention (mean z-score±SD: -2.73±2.57), verbal (immediate: 
-1.09±1.27; delayed: -1.14±1.86) and visuospatial memory (immediate: -1.48±1.02; delayed: 
-1.57±1.01; recognition: -1.07±3.10) than the norm. ECMO-treated CDH patients had a 
significantly lower mean IQ (84±12) than other neonatal ECMO patients (94±10) and 
CDH patients not treated with neonatal ECMO (100±20). Maximum vasoactive-inotropic 
score was negatively associated with delayed verbal (B=-0.02; 95% confidence interval: -0.03 
to -0.002, p=0.026) and visuospatial memory (B=-0.01; 95% confidence interval: -0.02 to 
-0.001, p=0.024).
Conclusions: We found memory and attention deficits in eight-year-old neonatal ECMO and 
CDH survivors. The maximum dose of vasoactive medication was negatively associated with 
verbal and visuospatial memory, which may suggest an effect of early cerebral hypoperfusion 
in determining these abnormalities. 




The majority of children growing up following neonatal extracorporeal membrane oxy-
genation (ECMO) and/or congenital diaphragmatic hernia (CDH) have a generally average 
intelligence quotient (IQ), yet show impaired neurodevelopmental outcome and school 
problems.1-3 Until now, most long-term outcome studies of school-aged survivors have 
focused on IQ and attention, hampering our understanding of the specific neuropsycholog-
ical problems after neonatal critical illness.1-3 Furthermore, it remains largely unclear which 
patients are at risk of impaired outcome and why. For early identification and intervention 
of those patients at risk, it is crucial to increase our understanding of the neuropsychological 
domains most frequently affected and the risk factors determining impaired outcome. 
Earlier studies have found that markers of illness severity, such as ECMO requirement 
and the presence of chronic lung disease, were predictive of neuropsychological deficits in 
CDH patients.2 Still, clinically useful risk factors of such deficits following neonatal critical 
illness remain unknown. Our group has recently shown specific hippocampal volume alter-
ations that were related to verbal memory impairments in school-aged neonatal ECMO 
survivors.4, 5 The hippocampus appears specifically vulnerable to hypoxic-ischemic injuries.6, 
7 Using measures of hypoperfusion could possibly aid in predicting neuropsychological out-
comes following neonatal critical illness, as hypoperfusion may result in hypoxic-ischemic and 
eventually reperfusion injury in the hippocampus. Additionally, growth during early life may 
affect neurodevelopment. Poor growth in the first year of life has been reported in CDH 
and ECMO-treated patients,8, 9 and has been associated with worse neurodevelopmental 
outcome both in CDH patients and in premature infants.10, 11 However, the effects of poor 
growth on specific neuropsychological functions in school-aged survivors of neonatal critical 
illness remain unknown.
In this study, neuropsychological outcome was evaluated in school-aged CDH survivors 
treated or not treated with neonatal ECMO and in neonatal ECMO-treated survivors 
following other diagnoses. We hypothesized that children would mainly have attention and 
memory deficits, despite a generally average IQ.  We expected markers of increased severity 
of illness and hypoperfusion as well as poor growth in the first year of life to have negatively 





We included CDH and neonatal ECMO patients born between January 2006 and March 
2009. All participants were routinely seen at 8 years of age as part of a structured prospec-
tive longitudinal follow-up program that includes regular physical and neurodevelopmental 
assessments until 18 years of age.12 ECMO treatment had been applied in case of severe 
respiratory failure using the entry criteria described by Stolar et al.13 Since November 
2007, CDH patients were treated according to the standardized CDH EURO Consortium 
treatment protocol.14 In case of persistent poor tissue perfusion and/or hypotension (arte-
rial blood pressure below normal levels for gestational age and not improving after fluid 
boluses), treatment with dobutamine and/or dopamine was initiated, followed by norepi-
nephrine, epinephrine or milrinone in case of persistent hypotension. Exclusion criteria were: 
genetic syndromes known to affect neurodevelopment, severe neurologic or developmental 
impairments preventing standardized assessments, late CDH diagnosis (>7 days of life), or a 
paraesophageal hernia. We used a protocol with extended neuropsychological assessments, 
implemented in January 2014 (Supplemental File 1).1, 2 Included children were divided into 
three groups: neonatal ECMO patients following other diagnoses than CDH (‘ECMO-other’), 
CDH patients treated with neonatal ECMO (‘CDH-ECMO’) and CDH patients not treated 
with neonatal ECMO (‘CDH non-ECMO’). This post-ECMO/CDH follow-up program is stan-
dard of care, therefore Institutional Review Board approval was waived (MEC-2017-185).2, 15
Data collection 
Relevant clinical data were collected at the time of hospitalization (supplementary methods). 
The Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score16 was collected in the first 24 
hours of pediatric intensive care unit (PICU) stay (or up to ECMO cannulation in ECMO-
treated patients if ECMO was initiated within the first 24 hours of PICU stay), the maximum 
vasoactive-inotropic score (VIS)17 was recorded up until ECMO cannulation for the ECMO-
treated patients or up until hernia repair for the CDH non-ECMO patients. 
Follow-up data included growth measurements (height, weight, head circumference) at 6 
months and 1 year, which were converted into z-scores (individual score minus the norm 
score divided by the norm standard deviation).19 Height-corrected-for-target height z-score 
was calculated as follows: height-for-age z-score minus target height z-score.20 
Neuropsychological evaluation was performed by an experienced pediatric psychologist. 
Socioeconomic status was assessed from maternal education level (referring to highest level 
of completed education by the mother).21 




Validated neuropsychological tests were administered in their Dutch versions to assess skills 
in six domains (see brief descriptions of the tests in supplementary methods): 
1 IQ: two-subtest short-form (block design and vocabulary) of the Wechsler intelligence 
scale for children (WISC-III-NL).22
2 Attention: 
a. Processing speed: trail making test section A (TMT A).23, 24
b. Selective attention and cognitive flexibility: Stroop color word test (STROOP)23, 24 
and trail making test section B (TMT B).23, 24
c. Sustained attention: dot cancellation test (DCT).25
3 Verbal memory: 
a. Working memory: subtest digit span of the WISC-III-NL.22
b. Immediate and delayed recall: Rey auditory verbal learning test (RAVLT).26
4 Visuospatial memory: 
a. Working memory: subtest spatial span of the Wechsler nonverbal scale of ability 
(WNV).27
b. Immediate and delayed recall: Rey complex figure test (RCFT).28
5 Executive functioning: key search and modified six elements of the Behavioral assess-
ment of the dysexecutive syndrome for children (BADS-C-NL).29
6 Visuospatial processing: copy of the Rey complex figure test (RCFT copy).28 
Neuropsychological test scores were converted into z-scores. Scores were inverted where 
appropriate so that a higher score always indicated a better performance. Z-scores ≤-1 were 
regarded as likely to represent impaired functioning (general population (mean z-score=0; 
standard deviation=1)).23
Statistical analysis 
Differences in patient characteristics between the three groups (‘ECMO-other’, ‘CDH-
ECMO’ and ‘CDH-non-ECMO’) were evaluated with chi-square or Fisher’s exact tests for 
categorical variables, and with independent samples t-tests and one-way analysis of variance 
(ANOVA) for normally distributed variables. Mann-Whitney U tests and Kruskal-Wallis tests 
were used for continuous variables that were not normally distributed. Differences in neu-
ropsychological outcome between the three groups were assessed with one-way ANOVA. 
Univariable analyses were performed to assess the influence of clinical characteristics on 
the following neuropsychological outcomes of interest: intelligence, sustained attention, verbal 
memory immediate recall, verbal memory delayed recall, visuospatial memory immediate 
recall and visuospatial memory delayed recall. The independent variables included: maximum 
VIS, ECMO, type of ECMO(veno-arterial or veno-venous), sepsis, ventilator-free days in the 
first 28 days of life, duration of initial hospital stay, growth z-scores at 1 year (paired t-test 
showed largest growth deflection from 6 months to 1 year) and number of anesthetic pro-
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cedures during the first year of life. Next, multivariable linear regression analyses were used 
to identify which independent variables remained significant predictors in a multivariable 
model. The assumptions for linear regression analysis were checked with normal probability 
plots of the residuals. Multicollinearity was evaluated in the multivariable models using the 
criterion that variance inflation factors should not exceed 2.5.30
Analyses were performed with SPSS 21.0 (IBM, Chicago, Illinois, USA), a two-sided p-value 
of <0.05 was considered statistically significant.





Sixty-five patients aged 8.0±0.6 years were included: 25 ECMO-other patients, 10 CDH-
ECMO patients, and 30 CDH-non-ECMO patients (supplemental figure 1). Illness severity 
during hospital admission differed between the three groups (table 1). The CDH-ECMO 
patients had the highest PELOD-2 score, the highest maximum VIS, the highest rate of 
sepsis, and the longest duration of mechanical ventilation and hospital stay. Sepsis occurred 
in three ECMO-other patients (during ECMO: n=2; after ECMO: n=1), four CDH-ECMO 
patients (after ECMO: n=4), and one CDH-non-ECMO patient after hernia repair. Four 
(50%) patients required vasoactive medication during sepsis. The median maximum VIS 
during sepsis was lower than the median maximum VIS before the ECMO run and none 
of the patients had a higher maximum VIS during sepsis (table 1). Characteristics of eligible 
patients who were lost to follow-up or refused follow-up (n=14) did not differ from included 
patients (data not shown). None of the patients treated with ECMO (both ECMO-other and 
CDH-ECMO) had signs of cerebral hemorrhage or vessel occlusion on cranial ultrasounds 
performed before and after the ECMO run. 
Neuropsychological outcome 
IQ fell within the normal range for the group as a whole. Sustained attention, verbal memory 
(immediate and delayed recall) and visuospatial memory (immediate and delayed recall as 
well as recognition) were below average compared to the general population (table 2). The 
majority of patients had normal outcomes in working memory, executive functioning and 
visuospatial processing. However, over 50% had impaired outcomes (z-score≤-1) on one or 
more of the memory and attention tests (figure 1). 
When analyzing the three groups separately, we found that CDH survivors treated with 
ECMO had a significantly lower IQ compared to both other groups. However, no significant 












Gestational age (weeks) 40.9 (40.0-41.1) 39.2 (36.7-40.7) 38.5 (38.0-39.3) <0.001
Birth weight (kilograms) 3.5±0.5 3.1±0.8 2.9±0.4 0.001
Male 14 (56%) 5 (50%) 18 (60%) 0.842
Ethnicity
     Dutch
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Inborn 4 (16%) 4 (40%) 18 (60%) 0.0032
ECMO-related 
Highest oxygenation index prior to ECMO 33 (28-40) 38 (26-54) 0.72
Age start ECMO (days) 2 (1-4) 1 (1-2) 0.30
Duration of ECMO (hours) 92 (54-100) 172 (131-212) <0.001
ECMO mode
     VA
     VV converted to VA







Left sided hernia 8 (80%) 25 (83%) 1.002
Age at surgery (days) 4 (3-6) 3 (2-4) 0.32
Patch repair 9 (90%) 17 (57%) 0.072
Surgical technique
 Laparotomy 10 (100%) 20 (67%) 0.042
 Thoracoscopy  10 (33%)
Hospital admission-related




































CPR during initial hospital stay 2 (8%) 1 (10%) 0 (0%) 0.182
Sepsis during initial hospital stay5 3 (12%) 4 (40%) 1 (3%) 0.012
Days of mechanical ventilation 10 (7-11) 40 (16-51) 10 (5-18) 0.001
Ventilator-free days in the first 28 days of life 18 (17-21) 0 (0-12) 19 (10-23) 0.001
Days of initial PICU stay 13 (10-16) 70 (24-101) 21 (12-35) <0.001
Days of initial hospital stay 24 (21-29) 91 (48-156) 36 (20-53) 0.004

























Inhaled nitric oxide treatment 22 (88%) 10 (100%) 10 (33%) <0.0012















Number of anesthetic procedures first year of life 2 (2-3) 4 (3-4) 1 (1-2) <0.001
Weight-for-height z-score at 1 year -0.38±0.86 -1.80±0.76 -0.88±0.97 0.001
Height-corrected-for-target height z-score at 1 year -0.27±0.96 -0.36±0.69 -0.43±0.78 0.02
Head circumference-for-age z-score at 1 year -0.47±1.16 -0.50±1.31 -0.39±1.15 0.96
 Data are expressed as mean±standard deviation, median (interquartile range) or number (percentage), as appropriate.  
P-value=significant difference between the groups. 
1 ECMO treatment was given in case of meconium aspiration syndrome (n=18), persistent pulmonary hypertension of the 
newborn (n=2), congenital heart disease (monoventricular heart with transposition of the great vessels and total anomalous 
pulmonary venous return) (n=1), sepsis (n=1), respiratory insufficiency due to respiratory syncytial virus (n=1), infant respiratory 
distress syndrome with bilateral pneumothorax (n=1), pulmonary hypoplasia due to bilateral hydrothorax (n=1).
2 Fisher’s exact test was used.
3 PELOD-2 score in the first 24 hours of PICU stay or up to ECMO cannulation if ECMO was initiated in the first 24 hours of 
PICU stay was calculated.16
4The maximum VIS recorded during PICU stay up until ECMO cannulation for the ECMO-treated patients or up until hernia 
repair for the CDH non-ECMO patients.17 VIS was maximal at the median age of 1 (1-1) day in the ECMO patients, at the 
median age of 1 (0-1) day in the CDH-ECMO patients, and at the median age of 0 (0-1) days in the CDH non-ECMO patients.
5 Sepsis during initial hospital stay (clinical suspicion of sepsis with positive blood culture). ECMO-other: two patients had sepsis 
during ECMO; one patients after ECMO; maximum VIS during sepsis: 10 (5-15). CDH-ECMO: 4 patients had sepsis after ECMO; 
maximum VIS during sepsis: 2.5 (0-32.5). CDH non-ECMO: one patient had sepsis after hernia repair ; maximum VIS during sepsis: 0.
6 Chronic lung disease defined as oxygen dependency at 28 days of life.18
Abbreviations: CDH=congenital diaphragmatic hernia; CPR=cardiopulmonary resuscitation; ECMO=extracorporeal membrane 















 WISC-III-NL 95±16 94±10 84±12 100±20 0.029
Attention
 TMT A -0.33±0.86 -0.25±1.05 -0.45±0.53 -0.36±0.79 0.963
 TMT B -0.18±0.98 0.08±1.03 -0.28±1.08 -0.37±0.88 0.267
 STROOP -0.61±1.01 -1.00±0.76 -0.29±1.11 -0.39±1.10 0.081
 DCT -2.73±2.57 -2.88±2.09 -3.88±2.91 -2.25±2.76 0.173
Verbal memory
 WISC-III-NL digit span 0.06±1.09 -0.08±1.15 -0.34±0.94 0.31±1.07 0.706
 RAVLT immediate -1.09±1.27 -1.26±1.24 -1.55±1.03 -0.79±1.33 0.664
 RAVLT delayed -1.14±1.86 -1.38±1.46 -1.87±1.16 -0.70±2.24 0.117
Visuospatial memory
 WNV spatial span -0.31±0.99 -0.39±0.79 -0.85±0.76 -0.06±1.14 0.613
 RCFT immediate -1.48±1.02 -1.52±1.02 -1.86±0.69 -1.31±1.09 0.417
 RCFT delayed -1.57±1.01 -1.56±1.01 -1.89±0.77 -1.47±1.09 0.689
 RCFT recognition -1.07±3.10 -1.09±1.51 -0.62±0.95 -0.47±1.22 0.117
Executive functioning
 Key search -0.12±0.94 -0.26±0.98 -0.04±1.09 -0.05±0.89 0.694
 Modified six elements -0.60±0.87 -0.95±0.90 -0.46±0.47 -0.46±0.92 0.194
Visual spatial processing
 RCFT copy -0.26±1.02 -0.36±1.00 -0.69±1.02 -0.02±1.01 0.107
Mean (standard deviation)=average IQ score or average z-score of the neuropsychological test. 
One-way analysis of variance was used to identify differences between the groups on neuropsychological outcome.  
P-value=significant difference between the groups. 
1 ECMO treatment was given in case of meconium aspiration syndrome (n=18), persistent pulmonary hypertension of the 
newborn (n=2), congenital heart disease  (monoventricular heart with transposition of the great vessels and total anomalous 
pulmonary venous return) (n=1), sepsis (n=1), respiratory insufficiency due to respiratory syncytial virus (n=1), infant respiratory 
distress syndrome with bilateral pneumothorax (n=1), pulmonary hypoplasia due to bilateral hydrothorax (n=1).
Abbreviations: CDH=congenital diaphragmatic hernia; DCT=dot cancellation test; ECMO=extracorporeal membrane oxygen-
ation; RAVLT=Rey auditory verbal learning test; RCFT=Rey complex figure test; STROOP=Stroop color word test; TMT=trail 
making test; WISC-III-NL=Wechsler Intelligence Scale for Children-Dutch version; WNV=Wechsler nonverbal scale of ability. 
Please refer to supplementary file 1 for a description of the neuropsychological tests.
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Percentage of patients with a z-score ≤-1 (impaired; as shown by the dark colored bars) and >-1 (normal; as shown by the grey 
colored bars) on each of the neuropsychological tests. 
Abbreviations: WISC-III-NL=Wechsler intelligence scale for children-Dutch version; TMT=trail making test; STROOP=Stroop 
color word test;  DCT=dot cancellation test; RAVLT=Rey auditory verbal learning test; RCFT=Rey complex figure test. Please
refer to the supplementary file for a description of the neuropsychological tests; STROOP=Stroop color word test; TMT=trail
making test; WISC-III-NL=Wechsler intelligence scale for children-Dutch version.
Predictors of neuropsychological outcome 
Table 3 shows the results of the regression analyses. In the univariable analyses, severity of 
illness indicated by the need for ECMO, treatment with venoarterial-ECMO, maximum VIS, 
ventilator-free days during the neonatal period, and duration of initial hospital stay were 
associated with neuropsychological outcome, in particular with IQ. The number of anesthetic 
procedures during the first year of life was associated with IQ and sustained attention, and 
weight-for-height at 1 year was positively associated with IQ. 
In the multivariable analyses, a higher maximum VIS remained associated with worse verbal 
and visuospatial memory delayed recall, such that an increase in maximum VIS of 20 points 
would result in a decrease of the verbal and visuospatial memory delayed recall z-scores 
of 0.4 and 0.2, respectively. Patients with impaired verbal memory had a significantly higher 
mean±standard deviation maximum VIS (72±44) than patients with normal verbal memory 
(40±32; p=0.003). Patients with impaired visuospatial memory had a higher mean maximum 
VIS (64±45) than patients with normal visuospatial memory (44±33), although this difference 
did not reach significance (p=0.118). The VIS remained a significant predictor of verbal and 
visuospatial memory delayed recall when group (ECMO-other, CDH-ECMO, CDH-non-
ECMO) was added to the model (data not shown).
Growth or other indicators of severity of illness were no longer associated with neuropsy-
chological outcome at 8 years of age in the multivariable analyses (supplementary table 1).
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Table 3. Patient characteristics and neuropsychological outcome at 8 years of age
Intelligence Sustained attention Verbal memory 
immediate
Verbal memory delayed Visuospatial memory immediate Visuospatial memory delayed
Univariable analyses with medical predictors
CDH-non-ECMO1 B=9.84, p=0.031
(CI: 0.96 to 18.72)
B=1.73, p=0.016
(CI: 0.34 to 3.12)
B=0.70, p=0.068
(CI: -0.05 to 1.46)
B=0.86, p=0.145
(CI: -0.31 to 2.02)
B=0.31, p=0.257
(CI -0.23 to 0.86)
B=0.30, p=0.302
(CI: -0.28 to 0.88)
CDH-ECMO2 B=-14.11, p=0.016
(CI: -25.48 to -2.74)
B=-1.84, p=0.060
(CI: -0.08 to 3.76)
B=-0.73, p=0.144
(CI: -1.73 to 0.26)
B=-0.97, p=0.204
(CI: -2.48 to 0.54)
B=-0.45, p=0.205
(CI: -1.16 to 0.26)
B=-0.37, p=0.328
(CI: -1.12 to 0.38)
ECMO-other3 B=-1.59, p=0.745
(CI: -11.37 to 8.19)
B=-0.77, p=0.312
(CI: -2.30 to 0.75)
B=-0.29, p=0.475
(CI: -1.11 to 0.53)
B=-0.31, p=0.622
(CI: -1.55 to 0.94)
B=-0.48, p=0.868
(CI: -0.63 to 0.53)
B=-0.09, p=0.772
(CI: -0.70 to 0.53)
VA-ECMO4 B=-12.59, p=0.002
(CI: -19.97 to -5.20)
B=-0.42, p=0.670
(CI: -2.46 to 1.61)
B=-0.38, p=0.457
(CI: -1.41 to 0.66)
B=-0.25, p=0.677
(CI: -1.47 to 0.97)
B=-0.23, p=0.530
(CI: -0.97 to 0.51)
B=-0.26, p=0.499
(CI: -1.02 to 0.51)
Sepsis5 B=-12.36, p=0.064
(CI: -25.46 to 0.74)
B=-0.86, p=0.451
(CI: -1.42 to 3.15)
B=-0.52, p=0.363
(CI: -1.65 to 0.62)
B=-0.93, p=0.281
(CI: -2.63 to 0.78)
B=-0.23, p=0.565
(CI: -1.04 to 0.57)
B=-0.25, p=0.556
(CI: -1.10 to 0.60)
VIS6 B=-0.08, p=0.105
(CI: -0.17 to 0.02)
B=-0.01, p=0.217
(CI: 0.01 to -0.03)
B=-0.01, p=0.014
(CI: -0.02 to -0.002)
B=-0.02, p=0.004
(CI: -0.03 to -0.01)
B=-0.01, p=0.028
(CI: -0.01 to -0.001)
B=-0.01, p=0.006
(CI: -0.01 to -0.002)
Ventilator-free days7 B=0.70, p=0.006
(CI: 0.22 to 1.19)
B=0.07, p=0.098
(CI: 0.16 to -0.01)
B=0.04, p=0.035
(CI: 0.00 to 0.09)
B=0.08, p=0.025
(CI: 0.01 to 0.14)
B=0.03, p=0.040
(CI 0.00 to 0.06)
B=0.03, p=0.043
(CI: 0.01 to 0.07)
Initial hospital stay (days) B=-0.16, p=0.004
(CI: -0.27 to -0.06)
B=-0.01, p=0.133
(CI: 0.00 to -0.03)
B=-0.01, p=0.045
(CI: -0.02 to 0.000)
B=-0.01, p=0.133
(CI: -0.03 to 0.004)
B=-0.00, p=0.281
(CI: -0.01 to 0.003)
B=-0.00, p=0.347
(CI: -0.01 to 0.004)
Anesthetics8 B=-2.92,  p=0.027
(CI: -5.49 to -0.35)
B=-0.44, p=0.036
(CI: -0.03 to -0.85)
B=-0.15, p=0.179
(CI: -0.37 to 0.72)
B=-0.23, p=0.175
(CI: -0.57 to 0.11)
B=-0.04, p=0.615
(CI: -0.20 to 0.12)
B=-0.04, p=0.626
(CI: -0.21 to 0.13)
Univariable analyses with growth predictors
Weight-for-height z-score at 1 year B=6.41, p=0.002
(CI: 2.48 to 10.33)
B=0.42, p=0.275
(CI: -0.35 to 1.19)
B=0.35, p=0.053
(CI: -0.01 to 0.69)
B=0.29, p=0.323
(CI: -0.30 to 0.89)
B=0.23, p=0.087
(CI: -0.03 to 0.49)
B=0.22, p=0.112
(CI: -0.05 to 0.50)
Height-corrected-for-target height z-score at 
1 year
B=0.54, p=0.835
(CI: -4.70 to 5.79)
B=0.21, p=0.639
(CI: 0.68 to 1.10)
B=0.28, p=0.203
(CI: -0.16 to 0.71)
B=0.38, p=0.287
(CI: -0.33 to 1.09)
B=-0.01, p=0.936
(CI: -0.34 to 0.31)
B=-0.05, p=0.766
(CI: -0.39 to 0.29)
Head circumference-for-age z-score at 1 year B=3.98, p=0.060
(CI: -0.18 to 8.13)
B=0.27, p=0.413
(CI: -0.39 to 0.94)
B=0.21, p=0.237
(CI: -0.14 to 0.55)
B=0.23, p=0.445
(CI: -0.37 to 0.83)
B=0.13, p=0.351
(CI: -0.14 to 0.40)
B=0.11, p=0.423
(CI: -0.17 to 0.39)
Multivariable analyses9
VIS B=-0.02, p=0.026
(CI: -0.03 to -0.002)
B=-0.01, p=0.024
(CI: -0.02 to -0.001)
Maternal education level, ethnicity and gender were adjusted for in all models. 
Variables found to be significant predictors in the univariable analyses were added into the multivariable model. Only those variables 
found to be significant in the multivariable analyses are reported. 
Results indicate significant associations at p-value<0.05. 
1 CDH non-ECMO patients were compared to patients treated with ECMO. 
2 CDH-ECMO patients were compared to patients treated with ECMO following other diagnoses and to CDH patients not treated 
with ECMO. 
3 ECMO patients following other diagnosis were compared to CDH patients treated with and without ECMO.
4 Patients treated with VA-ECMO were compared to patients treated with VV-ECMO. 
5 Sepsis during initial hospital stay (clinical suspicion of sepsis with positive blood culture).
6 The maximum VIS recorded during pediatric intensive care unit stay up until ECMO cannulation for the ECMO-treated patients 
or up until hernia repair for the CDH non-ECMO patients. 
7 Ventilator-free days in the first 28 days of life. 
8 Number of anesthetic procedures in the first year of life.
9 Results of all variables added into the multivariable model are shown in supplementary table 1.
Abbreviations: CDH=congenital diaphragmatic hernia; CI=95% confidence interval; ECMO=extracorporeal membrane 
oxygenation; VA-ECMO=veno-arterial extracorporeal membrane oxygenation;  VIS=vasoactive-inotropic score;  VV-ECMO 
=veno-venous extracorporeal membrane oxygenation.
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Table 3. Patient characteristics and neuropsychological outcome at 8 years of age
Intelligence Sustained attention Verbal memory 
immediate
Verbal memory delayed Visuospatial memory immediate Visuospatial memory delayed
Univariable analyses with medical predictors
CDH-non-ECMO1 B=9.84, p=0.031
(CI: 0.96 to 18.72)
B=1.73, p=0.016
(CI: 0.34 to 3.12)
B=0.70, p=0.068
(CI: -0.05 to 1.46)
B=0.86, p=0.145
(CI: -0.31 to 2.02)
B=0.31, p=0.257
(CI -0.23 to 0.86)
B=0.30, p=0.302
(CI: -0.28 to 0.88)
CDH-ECMO2 B=-14.11, p=0.016
(CI: -25.48 to -2.74)
B=-1.84, p=0.060
(CI: -0.08 to 3.76)
B=-0.73, p=0.144
(CI: -1.73 to 0.26)
B=-0.97, p=0.204
(CI: -2.48 to 0.54)
B=-0.45, p=0.205
(CI: -1.16 to 0.26)
B=-0.37, p=0.328
(CI: -1.12 to 0.38)
ECMO-other3 B=-1.59, p=0.745
(CI: -11.37 to 8.19)
B=-0.77, p=0.312
(CI: -2.30 to 0.75)
B=-0.29, p=0.475
(CI: -1.11 to 0.53)
B=-0.31, p=0.622
(CI: -1.55 to 0.94)
B=-0.48, p=0.868
(CI: -0.63 to 0.53)
B=-0.09, p=0.772
(CI: -0.70 to 0.53)
VA-ECMO4 B=-12.59, p=0.002
(CI: -19.97 to -5.20)
B=-0.42, p=0.670
(CI: -2.46 to 1.61)
B=-0.38, p=0.457
(CI: -1.41 to 0.66)
B=-0.25, p=0.677
(CI: -1.47 to 0.97)
B=-0.23, p=0.530
(CI: -0.97 to 0.51)
B=-0.26, p=0.499
(CI: -1.02 to 0.51)
Sepsis5 B=-12.36, p=0.064
(CI: -25.46 to 0.74)
B=-0.86, p=0.451
(CI: -1.42 to 3.15)
B=-0.52, p=0.363
(CI: -1.65 to 0.62)
B=-0.93, p=0.281
(CI: -2.63 to 0.78)
B=-0.23, p=0.565
(CI: -1.04 to 0.57)
B=-0.25, p=0.556
(CI: -1.10 to 0.60)
VIS6 B=-0.08, p=0.105
(CI: -0.17 to 0.02)
B=-0.01, p=0.217
(CI: 0.01 to -0.03)
B=-0.01, p=0.014
(CI: -0.02 to -0.002)
B=-0.02, p=0.004
(CI: -0.03 to -0.01)
B=-0.01, p=0.028
(CI: -0.01 to -0.001)
B=-0.01, p=0.006
(CI: -0.01 to -0.002)
Ventilator-free days7 B=0.70, p=0.006
(CI: 0.22 to 1.19)
B=0.07, p=0.098
(CI: 0.16 to -0.01)
B=0.04, p=0.035
(CI: 0.00 to 0.09)
B=0.08, p=0.025
(CI: 0.01 to 0.14)
B=0.03, p=0.040
(CI 0.00 to 0.06)
B=0.03, p=0.043
(CI: 0.01 to 0.07)
Initial hospital stay (days) B=-0.16, p=0.004
(CI: -0.27 to -0.06)
B=-0.01, p=0.133
(CI: 0.00 to -0.03)
B=-0.01, p=0.045
(CI: -0.02 to 0.000)
B=-0.01, p=0.133
(CI: -0.03 to 0.004)
B=-0.00, p=0.281
(CI: -0.01 to 0.003)
B=-0.00, p=0.347
(CI: -0.01 to 0.004)
Anesthetics8 B=-2.92,  p=0.027
(CI: -5.49 to -0.35)
B=-0.44, p=0.036
(CI: -0.03 to -0.85)
B=-0.15, p=0.179
(CI: -0.37 to 0.72)
B=-0.23, p=0.175
(CI: -0.57 to 0.11)
B=-0.04, p=0.615
(CI: -0.20 to 0.12)
B=-0.04, p=0.626
(CI: -0.21 to 0.13)
Univariable analyses with growth predictors
Weight-for-height z-score at 1 year B=6.41, p=0.002
(CI: 2.48 to 10.33)
B=0.42, p=0.275
(CI: -0.35 to 1.19)
B=0.35, p=0.053
(CI: -0.01 to 0.69)
B=0.29, p=0.323
(CI: -0.30 to 0.89)
B=0.23, p=0.087
(CI: -0.03 to 0.49)
B=0.22, p=0.112
(CI: -0.05 to 0.50)
Height-corrected-for-target height z-score at 
1 year
B=0.54, p=0.835
(CI: -4.70 to 5.79)
B=0.21, p=0.639
(CI: 0.68 to 1.10)
B=0.28, p=0.203
(CI: -0.16 to 0.71)
B=0.38, p=0.287
(CI: -0.33 to 1.09)
B=-0.01, p=0.936
(CI: -0.34 to 0.31)
B=-0.05, p=0.766
(CI: -0.39 to 0.29)
Head circumference-for-age z-score at 1 year B=3.98, p=0.060
(CI: -0.18 to 8.13)
B=0.27, p=0.413
(CI: -0.39 to 0.94)
B=0.21, p=0.237
(CI: -0.14 to 0.55)
B=0.23, p=0.445
(CI: -0.37 to 0.83)
B=0.13, p=0.351
(CI: -0.14 to 0.40)
B=0.11, p=0.423
(CI: -0.17 to 0.39)
Multivariable analyses9
VIS B=-0.02, p=0.026
(CI: -0.03 to -0.002)
B=-0.01, p=0.024
(CI: -0.02 to -0.001)
Maternal education level, ethnicity and gender were adjusted for in all models. 
Variables found to be significant predictors in the univariable analyses were added into the multivariable model. Only those variables 
found to be significant in the multivariable analyses are reported. 
Results indicate significant associations at p-value<0.05. 
1 CDH non-ECMO patients were compared to patients treated with ECMO. 
2 CDH-ECMO patients were compared to patients treated with ECMO following other diagnoses and to CDH patients not treated 
with ECMO. 
3 ECMO patients following other diagnosis were compared to CDH patients treated with and without ECMO.
4 Patients treated with VA-ECMO were compared to patients treated with VV-ECMO. 
5 Sepsis during initial hospital stay (clinical suspicion of sepsis with positive blood culture).
6 The maximum VIS recorded during pediatric intensive care unit stay up until ECMO cannulation for the ECMO-treated patients 
or up until hernia repair for the CDH non-ECMO patients. 
7 Ventilator-free days in the first 28 days of life. 
8 Number of anesthetic procedures in the first year of life.
9 Results of all variables added into the multivariable model are shown in supplementary table 1.
Abbreviations: CDH=congenital diaphragmatic hernia; CI=95% confidence interval; ECMO=extracorporeal membrane 
oxygenation; VA-ECMO=veno-arterial extracorporeal membrane oxygenation;  VIS=vasoactive-inotropic score;  VV-ECMO 




This is the first study evaluating all major neuropsychological domains in school-aged 
survivors of neonatal ECMO and/or CDH. We found sustained attention and verbal and 
visuospatial memory deficits in over half of the patients, while other neuropsychological 
domains fell within the average range. CDH survivors treated with ECMO had a lower IQ 
than the other two groups, who had an average IQ. Nonetheless, the observed attention 
and memory problems were more severe than would be expected based on their IQ. This 
incongruity between attention and memory problems with IQ for all three groups indicates 
specific impairments in these domains. A higher dose of vasoactive medication (indicated 
by the maximum VIS recorded up until ECMO cannulation or hernia repair) was associated 
with lower scores on verbal and visuospatial memory delayed recall. Interestingly, impaired 
memory and attention were found in all diagnostic groups, except for better, although not 
significantly, verbal memory in the CDH non-ECMO group (within one standard deviation 
of the norm). Attention deficits have been reported in these patients previously, also despite 
generally average IQ.1-3, 15 However, other neuropsychological domains were not assessed 
in these studies. In the present study we evaluated all major neuropsychological domains, 
and thereby identified a specific neuropsychological profile following neonatal ECMO and/
or CDH. Our findings may serve as a starting point for intervention-based studies designed 
to improve cognitive functioning in these children.
As we found memory and attention deficits in the majority of patients, it is imperative 
to identify potential risk factors. Over the years, several severity of illness scoring systems 
have been developed including the VIS.17 In the univariable analyses, maximum VIS as well as 
veno-arterial ECMO, ventilator-free days during the neonatal period and duration of initial 
hospital stay were independently associated with neuropsychological outcome, mainly with 
IQ. This indicates that severity of illness plays an important role in determining cognitive 
outcome in these survivors. Interestingly, in the multivariable analyses, only the maximum 
VIS recorded up until ECMO cannulation or hernia repair remained associated with delayed 
verbal and visuospatial memory. The hippocampus is highly involved in memory and has 
previously been shown to be altered following neonatal ECMO and/or CDH.4, 5, 31, 32 The hip-
pocampus has been found to be particularly susceptible to cerebral hypoperfusion resulting 
in hypoxia-ischemia.6, 7, 33 Although this study does not show a causative effect of vasoactive 
medication regarding memory problems, we speculate that receiving high levels of vasoactive 
medication in the first period of life may be an indirect marker of temporarily (regional) 
inadequate brain perfusion. A high need for vasoactive medication could therefore be a useful 
component in estimating severity of illness and risk of memory impairments at school age 
in these survivors. Although we cannot make any recommendations based on our findings, 
the VIS may be valuable in determining the need for and timing of ECMO treatment in neo-
nates with severe respiratory failure, which should be investigated in future studies. As the 
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VIS has been validated to predict clinical outcomes in infants who require cardiac surgery,17, 
34 representing another group of critically ill children requiring circulatory support by vaso-
active drugs. Future studies are needed to further validate the usefulness of this score for 
long-term outcome in neonatal critical illness survivors, and to study the direct association 
between maximum VIS and brain areas susceptible to ischemic-reperfusion injury such as 
the hippocampus.
Attention and memory problems at school age have also been found in other groups of 
critically ill neonates such as premature infants and infants with congenital heart disease.31, 35 
Studies in premature infants have found that lower scores on executive functioning were 
associated with the severity of neonatal illness (indicated by presence of sepsis, meningitis, 
bronchopulmonary dysplasia or longer duration of hospital stay),36 although others have 
not confirmed this.37 Multicenter studies are needed to develop a multimodal prediction 
model which may be the key to earlier identification of critical illness survivors at risk of 
impaired neurodevelopmental outcome. Predictors of interest would be specific markers 
of illness severity, such as the maximum VIS, in combination with predetermined assessment 
of neurobiological correlates, such as imaging of the hippocampus.
We did not find any associations between growth at 1 year and long-term neuropsycholog-
ical outcome.  Although many CDH patients show poor growth during the first year of life,9 
only one study has found an association between growth (weight and head circumference) at 
2 to 3 years of age and general cognitive functioning, although not at the age of 5 years.11 In 
premature infants, several studies have demonstrated a positive association between weight 
gain and head growth and cognitive outcomes.10 However, a recent study in children with 
extremely low birth weight showed no effect of catch-up-growth in the first 2 years of life 
on neurocognitive outcome at 11 years.38 Most studies in premature infants did not take into 
account the difference in severity of illness. It is therefore uncertain whether poor growth 
itself or severity of critical illness leading to poor growth, is more important in determining 
adverse neuropsychological outcome in premature infants.  Although we cannot draw defin-
itive conclusions, our study indicates that in ECMO and CDH patients, the severity of illness 
has a greater impact on neuropsychological outcome than growth in the first year of life.
Our study has some limitations. First, the relatively small sample sizes of the three diagnos-
tic groups, especially of the CDH-ECMO group, is a frequent problem in follow-up studies 
including patients with rare diagnoses, but limits the interpretability of our regression analy-
ses. Multicenter collaborations with standardized management and standardized structured 
follow-up are important to increase sample sizes and get a better understanding of the 
pathophysiology underlying long-term outcome. Second, MRI data were not available in this 
study and we therefore could not examine whether maximum VIS was specifically associated 
with brain structures susceptible to cerebral hypoperfusion. Standardized neuroimaging stud-
ies both at neonatal age and school age will aid in understanding pathophysiologic concepts 
of early brain development as well as long-term outcome and are therefore important 
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in future studies.  Third, there are likely multiple factors involved in the development of 
long-term neuropsychological impairments following neonatal ECMO and/or CDH, such as 
exposure to inflammation7, anesthetics39, and endogenous and exogenous stressors40 in early 
life, or probably a complex interplay amongst these factors. As of now, techniques to reliably 
measure these mechanisms and their interactions are lacking. Future studies are needed to 
develop specific brain monitoring techniques that can be used during PICU stay for early 
identification of patients at risk of long-term impairments.
In conclusion, we found sustained attention, verbal and visuospatial memory deficits in 
eight-year-old survivors of neonatal ECMO and/or CDH.  These findings emphasize the need 
for standardized neuropsychological follow-up including attention and memory assessments 
until school age and beyond in these survivors. Maximum VIS in the first day(s) of PICU 
admission was negatively associated with verbal and visuospatial memory at eight years 
of age.  This suggests that this measure of severity of illness, possibly indicating (cerebral) 
hypoperfusion during early life, is related to specific neuropsychological functions in eight 
year-old neonatal ECMO and/or CDH survivors. Future studies using advanced neuroimaging 
techniques in combination with clinical characteristics and neuropsychological evaluation 
will aid in a better understanding of this finding and are needed for early identification and 
intervention of patients at risk. Our findings of specific attention and memory problems can 
serve as a starting point for developing and implementing early intervention strategies that 
focus on improving attention and memory in these patients.
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Supplementary methods. Description of data collection
Relevant clinical data were collected at the time of hospitalization, including: gestational age, 
birth weight, gender, ethnicity (Dutch/≥1 non-native Dutch parent), inborn, the need for 
extracorporeal membrane oxygenation (ECMO), Pediatric Logistic Organ Dysfunction-2 
(PELOD-2) score16 in the first 24 hours of pediatric intensive care unit (PICU) stay (or 
up to ECMO cannulation in ECMO-treated patients if ECMO was initiated in the first 
24 hours of PICU stay), the maximum vasoactive-inotropic score (VIS)17 was recorded 
up until ECMO cannulation for the ECMO-treated patients or up until hernia repair for 
the CDH-non-ECMO patients, calculated as follows: dopamine dose (ug/kg/min)+dobu-
tamine dose (ug/kg/min)+(100xepinephrine dose (ug/kg/min))+(10xmilrinone dose (ug/
kg/min))+(10,000xvasopressin dose (U/kg/min))+(100xnorepinephrine dose (ug/kg/min)), 
cardiopulmonary resuscitation(CPR) during initial hospital stay, sepsis during initial hospital 
stay (clinical suspicion of sepsis with positive blood culture), duration of initial mechanical ven-
tilation, ventilator-free days in the first 28 days of life, duration of PICU stay, duration of initial 
hospitalization, pulmonary hypertension on echocardiography during PICU admission, inhaled 
nitric oxide requirement, sildenafil requirement, the presence of chronic lung disease(oxygen 
dependency at 28 days of life),18 and number of anesthetic procedures in the first year of life 
(including CDH repair and/or ECMO (de)cannulation). Additional characteristics for ECMO 
patients included: highest oxygenation index before ECMO, age at start ECMO, type of 
ECMO (veno-arterial or veno-venous), ECMO duration, and cranial ultrasound result before 
and after ECMO. Additional data for CDH patients were: diaphragmatic defect side, surgical 
repair technique (thoracoscopy or laparotomy), age at surgery, and patch repair requirement.
Supplementary methods. Descriptions of the neuropsychological tests 
Intelligence 
Wechsler Intelligence Scale for Children (WISC-III-NL): the Wechsler intelligence scale for 
children was used. Both tests assessing verbal and non-verbal intelligence, have been shown to 
have good reliability and validity,1, 2 and have been used interchangeably by our group before.3 
For both tests, a normalized population mean of 100 with a standard deviation of 15 is used.1, 2
Attention 
Trail making test (TMT): this paper and pencil test consists of two parts. In the first part (part 
A), the subject must draw lines to consecutively connect numbered circles on a sheet. In the 
second part (part B), the subject must consecutively but alternately connect numbered and 
lettered circles on another worksheet. The goal of the test is to finish each part as quickly 
as possible.  The test can be administered to children and adults in the age range 6-89 years. 
This test measures visual conceptual and visuomotor tracking as well as divided attention.4, 5
Chapter 7
120
Stroop color word test (STROOP): the STROOP consists of three trials: in the first trial 
(Stroop 1) the subject must read color names, in the second trial (Stroop 2) name printed 
colors, and in the third trial (Stroop 3) name printed colors not denoted by the color name. 
The test can be administered to children and adults in the age range 8-65 years. Selective 
attention is measured with this test.4, 5 
Dot cancellation test: this paper and pencil test measures sustained selective attention and 
concentration in terms of speed and accuracy. It consists of a paper on which figures made 
of 3, 4 or 5 dots are displayed in 33 rows. The child is instructed to cross off all figures with 
4 dots, as precise and as fast as they can.6 
Verbal memory 
WISC-III-NL – subtest digit span: the digit span consists of random number sequences that 
increase in length and that the examiner reads aloud at the rate of 1 number per second. 
The child has to reproduce these numbers in the same order. Next, the sequences must be 
recalled backwards (3-5-7 becomes 7-5-3). The first part of the test measures short-term 
auditory memory and short-term retention capacity. The second part measures auditory 
working memory. A difference of ≥4 points between forward and backward digit span in 
favor of forward is indicative of a working memory problem.7 
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recall of a 15-word list, a sixth recall trial after 30 minutes, and a seventh recognition trial. 
This test measures memory span, short- and long-term verbal memory, verbal recognition, 
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measures short-term visuospatial memory and short-term retention capacity.  The second 
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Rey complex figure test (RCFT): the RCFT consist of three trials. First the child has to copy 
a complex figure. Then after 3 and after 30 minutes the figure must be drawn from memory. 
Next, different figures are shown and the child has to indicate whether these figures were 
in the original figure. The last two trials measure short- and long-term visual-spatial memory, 
and visuospatial recognition. This test can be completed by children and adults in the age 
range 6-89 years.11, 12 




Key search: a test of strategy formation. The child is asked to demonstrate how they would 
search a field for a set of lost keys and their strategy is scored according to its functionality.13 
Modified six elements: the child is asked to work on six different tasks for which they have 
5 minutes. There are some rules the child has to obey during the task, while making sure 
that by the end of the 5 minutes, all six of the tasks have been done and the child has done 
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monitoring.13 
Visuospatial processing 
Rey complex figure test (RCFT): the RCFT consists of three trials. First the child has to copy 
a complex figure. Then after 3 and after 30 minutes the figure must be drawn from memory. 
Next, different figures are shown and the child has to indicate whether these figures were 
in the original figure. The first trial measures visual integration. This test can be completed by 
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Supplementary figure 1. Flowchart of the study population
Eligible, n=83
Tested with neuropsychological protocol implemented in 2014
 n=65
Died1, n=28 (21%)
 Neonatal ECMO and/or CDH patients born between Jan. 2006-Mar. 2009
n=127
Eligible but not included, n=18 
· Lost to follow-up/refused follow-up, n=14
· Tested with old protocol, n=1
· Tested elsewhere, n=3
Not eligible, n=23 
· Not testable2, n=9 
· Late diagnosis of CDH, n=10
· Paraesophageal hernia, n=4 
Eligible, n=7
· Initially treated in other center but 
follow-up in our center, n=6
· Earlier follow-up visit, n=1
1 ECMO-other group: n=12; ECMO-CDH-group: n=10; CDH-non-ECMO group: n=6.
2 Severe neurologic or developmental impairments (n=5; 3 patients had primary hemorrhage at cranial ultrasound performed 
after the ECMO run); Simpson-Golabi-Behmel Syndrome (n=2); Down Syndrome (n=1); mitochondriopathy (n=1).
Abbreviations: CDH=congenital diaphragmatic hernia; ECMO=extracorporeal membrane oxygenation.
Chapter 7
124
Supplementary table 1. Patient characteristics and neuropsychological outcome at 8 years of age
Intelligence Sustained attention Verbal memory 
immediate
Verbal memory delayed Visuospatial memory immediate Visuospatial memory delayed
Univariable analyses with medical predictors
CDH-non-ECMO1 B=9.84, p=0.031
(CI: 0.96 to 18.72)
B=1.73, p=0.016
(CI: 0.34 to 3.12)
B=0.70, p=0.068
(CI: -0.05 to 1.46)
B=0.86, p=0.145
(CI: -0.31 to 2.02)
B=0.31, p=0.257
(CI -0.23 to 0.86)
B=0.30, p=0.302
(CI: -0.28 to 0.88)
CDH-ECMO2 B=-14.11, p=0.016
(CI: -25.48 to -2.74)
B=-1.84, p=0.060
(CI: -0.08 to 3.76)
B=-0.73, p=0.144
(CI: -1.73 to 0.26)
B=-0.97,  p=0.204
(CI: -2.48 to 0.54)
B=-0.45,  p=0.205
(CI: -1.16 to 0.26)
B=-0.37, p=0.328
(CI: -1.12 to 0.38)
ECMO-other3 B=-1.59, p=0.745
(CI: -11.37 to 8.19)
B=-0.77, p=0.312
(CI: -2.30 to 0.75)
B=-0.29, p=0.475
(CI: -1.11 to 0.53)
B=-0.31, p=0.622
(CI: -1.55 to 0.94)
B=-0.48, p=0.868
(CI: -0.63 to 0.53)
B=-0.09, p=0.772
(CI: -0.70 to 0.53)
VA-ECMO4 B=-12.59, p=0.002
(CI: -19.97 to -5.20)
B=-0.42, p=0.670
(CI: -2.46 to 1.61)
B=-0.38, p=0.457
(CI: -1.41 to 0.66)
B=-0.25, p=0.677
(CI: -1.47 to 0.97)
B=-0.23, p=0.530
(CI: -0.97 to 0.51)
B=-0.26, p=0.499
(CI: -1.02 to 0.51)
Sepsis5 B=-12.36, p=0.064
(CI: -25.46 to 0.74)
B=-0.86, p=0.451
(CI: -1.42 to 3.15)
B=-0.52, p=0.363
(CI: -1.65 to 0.62)
B=-0.93, p=0.281
(CI: -2.63 to 0.78)
B=-0.23, p=0.565
(CI: -1.04 to 0.57)
B=-0.25, p=0.556
(CI: -1.10 to 0.60)
VIS6 B=-0.08, p=0.105
(CI: -0.17 to 0.02)
B=-0.01, p=0.217
(CI: 0.01 to -0.03)
B=-0.01, p=0.014
(CI: -0.02 to -0.002)
B=-0.02, p=0.004
(CI: -0.03 to -0.01)
B=-0.01, p=0.028
(CI: -0.01 to -0.001)
B=-0.01, p=0.006
(CI: -0.01 to -0.002)
Ventilator-free days7 B=0.70, p=0.006
(CI: 0.22 to 1.19)
B=0.07, p=0.098
(CI: 0.16 to -0.01)
B=0.04, p=0.035
(CI: 0.00 to 0.09)
B=0.08, p=0.025
(CI: 0.01 to 0.14)
B=0.03, p=0.040
(CI 0.00 to 0.06)
B=0.03, p=0.043
(CI: 0.01 to 0.07)
Initial hospital stay (days) B=-0.16, p=0.004
(CI: -0.27 to -0.06)
B=-0.01, p=0.133
(CI: 0.00 to -0.03)
B=-0.01, p=0.045
(CI: -0.02 to 0.000)
B=-0.01, p=0.133
(CI: -0.03 to 0.004)
B=-0.00, p=0.281
(CI: -0.01 to 0.003)
B=-0.00, p=0.347
(CI: -0.01 to 0.004)
Anesthetics8 B=-2.92,  p=0.027
(CI: -5.49 to -0.35)
B=-0.44, p=0.036
(CI: -0.03 to -0.85)
B=-0.15, p=0.179
(CI: -0.37 to 0.72)
B=-0.23, p=0.175
(CI: -0.57 to 0.11)
B=-0.04, p=0.615
(CI: -0.20 to 0.12)
B=-0.04, p=0.626
(CI: -0.21 to 0.13)
Univariable analyses with growth predictors
Weight-for-height z-score at 1 year B=6.41, p=0.002
(CI: 2.48 to 10.33)
B=0.42, p=0.275
(CI: -0.35 to 1.19)
B=0.35, p=0.053
(CI: -0.01 to 0.69)
B=0.29, p=0.323
(CI: -0.30 to 0.89)
B=0.23, p=0.087
(CI: -0.03 to 0.49)
B=0.22, p=0.112
(CI: -0.05 to 0.50)
Height-corrected-for-target height z-score at 
1 year
B=0.54, p=0.835
(CI: -4.70 to 5.79)
B=0.21,  p=0.639
(CI: 0.68 to 1.10)
B=0.28, p=0.203
(CI: -0.16 to 0.71)
B=0.38, p=0.287
(CI: -0.33 to 1.09)
B=-0.01, p=0.936
(CI: -0.34 to 0.31)
B=-0.05, p=0.766
(CI: -0.39 to 0.29)
Head circumference-for-age z-score at 1 year B=3.98, p=0.060
(CI: -0.18 to 8.13)
B=0.27,  p=0.413
(CI: -0.39 to 0.94)
B=0.21, p=0.237
(CI: -0.14 to 0.55)
B=0.23, p=0.445
(CI: -0.37 to 0.83)
B=0.13, p=0.351
(CI: -0.14 to 0.40)
B=0.11, p=0.423
(CI: -0.17 to 0.39)
Multivariable analyses
CDH-non-ECMO1 B=7.33, p=0.213
(CI: -4.42 to 19.07)
B=1.29, p=0.110
(CI: -2.90 to 0.31)
CDH-ECMO2 B=-1.66, p=0.851
(CI: -19.51 to 16.18)
VA-ECMO3 B=-8.03, p=0.131
(CI: -18.83 to 2.76)
VIS6 B=-0.01, p=0.055
(CI: -0.02 to -0.000)
B=-0.02, p=0.026
(CI: -0.03 to -0.002)
B=-0.01, p=0.084
(CI: -0.01 to -0.001)
B=-0.01, p=0.024
(CI: -0.02 to -0.001)
Ventilator-free days7 B=-0.28, p=0.571
(CI: -1.29 to 0.72)
B = 0.02, p=0.580
(CI -0.06 to 0.10)
B=0.02, p=0.555
(CI: -0.06 to 0.10)
B= 0.01, p=0.587
(CI: -0.03 to 0.05)
B=0.00, p=0.813
(CI: -0.03 to 0.04)
Initial hospital stay (days) B = -0.14, p=0.225
(CI: -0.36 to 0.09)
B=0.00, p=0.784
(CI: -0.01 to 0.02)
Anesthetics8 B=0.40, p=0.831
(CI: -3.36 to 4.15)
B=0.25, p=0.285
(CI: -0.22 to 0.72)
Weight-for-height at 1 year B=3.85, p=0.180
(CI: -1.88 to 9.58)
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Multivariable analyses
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(CI: -4.42 to 19.07)
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Initial hospital stay (days) B = -0.14, p=0.225
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Chapter 7
126
Maternal education level, ethnicity and gender were adjusted for in all models. 
Variables found to be significant predictors in the univariable analyses were added into the multivariable model. Only those variables 
found to be significant in the multivariable analyses are reported. 
Results indicate significant associations at p-value<0.05. 
1 CDH non-ECMO patients were compared to patients treated with ECMO. 
2 CDH-ECMO patients were compared to patients treated with ECMO following other diagnoses and to CDH patients not 
treated with ECMO. 
3 ECMO patients following other diagnosis were compared to CDH patients treated with and without ECMO.
4 Patients treated with VA-ECMO were compared to patients treated with VV-ECMO. 
5 Sepsis during initial hospital stay (clinical suspicion of sepsis with positive blood culture).
6 The maximum VIS recorded during pediatric intensive care unit stay up until ECMO cannulation for the ECMO-treated patients 
or up until hernia repair for the CDH non-ECMO patients. 
7 Ventilator-free days in the first 28 days of life. 
8 Number of anesthetic procedures in the first year of life.
Abbreviations: CDH=congenital diaphragmatic hernia; CI=95% confidence interval; ECMO=extracorporeal membrane oxygen-
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Objectives: Growth problems are reported in patients with congenital diaphragmatic hernia 
(CDH) during the first years of life. However, it is unknown if poor growth persists during 
childhood. We therefore evaluated growth of patients longitudinally until 12 years.
Methods: This prospective study included 172 patients (43 treated with extracorporeal 
membrane oxygenation (ECMO)) born from 1999 to 2014. Z-scores of height-for-age, 
weight-for-height, and distance-to-target height were calculated at 6 months of age and at 1, 
2, 5, 8, and 12 years of age. Data were analyzed by using general linear models.
Results: At 1 year of age, the mean weight-for-height z-score had declined in ECMO (-1.30, 
95% confidence interval: -1.62 to -0.97) and non-ECMO patients (-0.72, 95% confidence 
interval: -0.91 to -0.54; p<0.05).  Thereafter in ECMO patients, the mean height-for-age 
z-score deteriorated between 1 year (-0.43, 95% confidence interval: -0.73 to -0.13) and 5 
years of age (-1.08, 95% confidence interval: -1.38 to -0.78; p<0.01). In non-ECMO patients, 
the mean height-for-age z-score deteriorated between 2 years (-0.35, 95% confidence inter-
val: -0.53 to -0.17) and 5 years of age (-0.56, 95% confidence interval: -0.75 to -0.37; p=0.002). 
At 12 years of age, the mean height-for-age z-score was still less than the norm in both 
groups: ECMO (-0.67, 95% confidence interval: -1.01 to -0.33) versus non-ECMO (-0.49, 
95% confidence interval: -0.77 to -0.20; p<0.01). Adjusting for target height improved the 
mean height z-scores but did not bring them to normal.
Conclusions: Poor linear growth persisted at 12 years of age. The pattern of early deteriora-
tion of weight gain followed by a decline in linear growth is suggestive of inadequate nutrition 
during infancy.  Therefore, nutritional assessment and intervention should be started early, 
and should be continued during childhood.




Patients with congenital diaphragmatic hernia (CDH) may suffer from long-term morbidities 
that could affect development later in life, including obstructive lung function,1 gastroesopha-
geal reflux,2 and impaired physical growth.3  This indicates the need for long-term follow-up 
of patients with CDH. Therefore, in 2008 the American Academy of Pediatrics published 
guidelines for structured long-term follow-up.4 Growth problems are an important issue in 
patients with CDH. Prevalence rates of wasting, indicating acute malnutrition, vary between 
8% and 69% at 1 year of age.5, 6 Malnutrition in infancy has been associated with adverse 
long-term outcomes such as impaired neurodevelopment in otherwise healthy children.7, 
8 Previous studies reported growth problems in CDH survivors during the first months of 
life with catch-up growth starting after the first 6 months.6, 9 Still, a recent longitudinal study 
showed that growth failure persisted in 13.5% of patients at 6 years of age.10
Growth problems are worse among patients who were treated with neonatal extra-
corporeal membrane oxygenation (ECMO), possibly because they have more severe lung 
hypoplasia and, consequently, higher energy needs to compensate for the increased work 
of breathing.3, 11 So far, growth of patients with CDH after the age of 6 years has not been 
studied longitudinally. 
We aimed to evaluate growth longitudinally until 12 years of age in patients with CDH 
who were treated with and without ECMO. We hypothesized that patients were at risk for 
impaired growth in the long-term, especially those treated with neonatal ECMO. Further-





In 1999, we started a prospective longitudinal follow-up program to monitor growth, lung 
function and neurodevelopment of patients with CDH until 18 years of age.12 This pro-
spective longitudinal study was conducted within the framework of our follow-up program 
and included surviving patients with CDH admitted to the Erasmus MC-Sophia Children’s 
Hospital between January 1999 and December 2014. For the purposes of this evaluation, 
we excluded data from patients diagnosed after 7 days of age, those with paraesophageal 
diaphragmatic defects, those with a diaphragmatic eventration, and those with genetic syn-
dromes that affect physical growth. ECMO treatment was applied in case of reversible severe 
respiratory failure by using the entry criteria reported by Stolar et al.13 until November 2007. 
After November 2007, children were treated according to the standardized CDH EURO 
Consortium Consensus treatment protocol.14 
The Erasmus MC Medical Ethical Review Board stated that the ‘Medical Research in Human 
Subjects Act does not apply to this study,’ and waived institutional review board approval 
(MEC-2016-111). 
Data collection
The following data were collected: gestational age; birth weight; sex; ethnicity; side and type 
of repair of the diaphragmatic defect; age at repair ; duration of initial mechanical ventilation; 
ECMO treatment; duration of pediatric intensive care unit (PICU) stay; presence of chronic 
lung disease (oxygen dependency at 28 days of life)15; need for supplemental oxygen at 
discharge; and presence of cardiac anomalies; gastroesophageal reflux disease (GERD) or 
Nissen fundoplication.  All patients were treated with antireflux medication until evaluation 
of GERD by using 24-hour pH-metry. Until 2013, GERD was evaluated by 24-hour pH-metry 
only; afterwards, we used 24-hour pH-metry with impedance.
Growth was evaluated at each routine outpatient visit at 6 months of age and at 1, 2, 5, 
8, and 12 years of age. At each follow-up visit, we recorded the use of tube feeding, calorie 
enriched feeds, and GERD medication. 
Growth measurements
Growth parameters were expressed as z-scores in relation to Dutch norms by using the 
reference data from the Fifth Dutch Growth study.16 Reference values for Dutch children 
of Moroccan or Turkish origin were used where applicable.17 Height-for-age (HFA) and 
weight-for-height (WFH) z-scores were calculated.18 Target height (TH) and TH z-scores 
were calculated using parental heights.19 To correct HFA z-score for TH, we calculated dis-
tance-to-target height (DTH) z-score as follows: DTH z-score=HFA z-score minus TH 
z-score. Stunting was defined as HFA z-score <-2.20 Wasting was defined as WFH z-score 
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<-2.20 Stunting corrected for TH was defined as DTH z-score <-2. 
Pilot study: indirect calorimetry 
To assess the role of increased energy expenditure in 11 patients with growth problems, we 
measured resting energy expenditure (REE) by indirect calorimetry (Cosmed Quark RMR 
with Canopy,  Tulipmed, Nieuwegein, the Netherlands). In addition, these patients had dietary 
consultations. For more details, see supplemental methods. 
Statistical Analyses
To evaluate differences in patient characteristics between ECMO and non-ECMO patients, 
we performed chi-square or Fisher’s exact tests for categorical variables. Independent sam-
ples t-tests were used for normally distributed variables, and Mann-Whitney U tests for 
variables not normally distributed. 
To evaluate growth longitudinally and compare growth of patients with the norm pop-
ulation (z-score=0), we used general linear models. This method can account for within 
subject correlations and allows for missing values in the dependent variable. We compared 
ECMO and non-ECMO patients with the norm population by using general linear models 
that included z-scores for HFA, WFH and DTH as dependent variables, and time-point, 
ECMO, and the interaction between time-point and ECMO as independent variables. Paired 
sample t-tests were used to compare mean z-scores of HFA and DTH at each time-point. To 
find associations between growth and clinical variables, we estimated general linear models 
in which the following independent variables were considered, in addition to ECMO and 
time-point: gestational age, patch repair, presence of cardiac anomalies, duration of initial 
mechanical ventilation, duration of PICU stay, supplemental home oxygen at discharge, the 
presence of Nissen fundoplication, the use of tube feeding, the use of calorie-enriched feeds, 
and the presence of a new treatment protocol (after November 2007). We used a stepwise 
backward approach to select the independent variables from this list of variables, with a 
p-value cut-off of p=0.20 for removal of independent variables. Two-way interaction effects 
were then added to the resulting model if the interaction effect was statistically significant. 
Pearson correlation coefficients between independent variables were calculated to assess 
the level of multicollinearity.  All correlations among the included independent variables were 
lower than 0.6. To account for within-subject correlations, all general linear models were 
estimated with an unstructured error covariance matrix for the repeated measurements of 
each patient. The results of general linear models were summarized by using the estimated 
marginal means, which are the predicted values of the dependent variable adjusted for the 
effects of the independent variables. 
Analyses were performed using SPSS 21.0 (IBM Corporation, Armonk, New York, USA). 





Of 298 patients with CDH, 78 (26%) died before hospital discharge (figure 1). Forty-eight 
of the 220 patients who survived were excluded for various reasons. Therefore, the study 
group consisted of 172 patients, of whom 43 (25%) received ECMO treatment. None of 
the 172 included children had a Morgagni-Larrey hernia.
Table 1 shows patient characteristics. Of all 172 patients, 138 (80%) underwent 24-hour 
pH-metry at the median age of 2.9 months (interquartile range (IQR): 1.7-4.4), and 53 
patients (38%) were diagnosed with GERD. Twenty-three patients were asymptomatic; the 
30 others had the following symptoms: regurgitation (n=11), regurgitation with feeding diffi-
culties (n=18), and oxygen saturation dips (n=1).  Twenty patients (12%) underwent a Nissen 
fundoplication at the median age of  0.7 years (IQR: 0.3-2.6). Nineteen patients experienced 
regurgitation with feeding difficulties and one asymptomatic patient had histologically proven 
esophagitis despite adequately dosed drug therapy. Seventeen patients (10%) had a gastros-
tomy placement at the median age of 0.5 year (IQR: 0.3-0.9; 12 of these patients underwent 
Nissen fundoplication). Supplementary table 1 shows the numbers of patients who were 
tube fed at follow-up. None of the patients were tube fed at the age of 8 and 12 years.
Height measurements
The mean HFA was less than the norm at all ages in ECMO and non-ECMO patients (all 
p<0.05; figure 2). ECMO-treated patients were significantly shorter than non-ECMO patients 
at 2, 5 and 8 years of age (p=0.048, p=0.004 and p=0.02, respectively). In non-ECMO 
patients, the mean HFA declined from the ages of 2 to 5 years (p=0.002). In ECMO patients, 
the mean HFA declined from the ages of 1 year to 2 years and 2 years to 5 years (p=0.01 
and p<0.001, respectively). From 8 to 12 years of age, the mean HFA significantly improved 
in the ECMO patients (p=0.002). 
Target heights were available for 160 patients. In ECMO patients, the mean DTH was 
higher than the mean HFA at 2 years of age (table 2). In non-ECMO patients, the mean DTH 
was higher than the mean HFA from 6 months to 8 years of age. The mean DTH was still less 
than the norm from 2 to 12 years of age in both groups. The prevalence of stunting remained 
high in ECMO patients, but correcting for TH decreased stunting rates (figures 3A and 3B).
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Figure 1. Flowchart of the study population
CDH survivors 
n=220 (74%) 





































CDH patients admitted between 











The enrollment of patients with CDH was n=172. For each routine visit, the actual number of patients of whom growth data 
were obtained and the number of patients who were eligible for follow-up are shown. 
1 ECMO patients (n=58); non-ECMO patients (n=20).
2 16p11.2 deletion syndrome (n=1); Cohen syndrome (n=1); Down syndrome (n=2); Loeys-Dietz syndrome (n=1); Ohtahara 
syndrome (n=1); Simpson-Golabi-Behmel syndrome (n=3); Wolf-Hirschhorn syndrome (n=1)
3 CDH correction at the median age of 8.1 months (IQR: 1.5-19.9) 
4 No follow-up visit because of organizational reasons: n=2.
5 No follow-up visit because of the following reasons: organizational reasons: n=9; refused follow-up: n=4.
6 No follow-up visit because of the following reasons: organizational reasons: n=9; refused follow-up: n=6; emigration: n=2; lost 
to follow-up: n=1; died: n=1.
7 No follow-up visit because of the following reasons: organizational reasons: n=2; refused follow-up: n=11; emigration: n=2; lost 
to follow-up: n=1; died: n=1.
8 No follow-up visit because of the following reasons: refused follow-up: n=4; emigration: n=1; died: n=1.
9 No follow-up visit because of the following reasons: refused follow-up: n=2; died: n=1.
Abbreviations: CDH=congenital diaphragmatic hernia; ECMO=extracorporeal membrane oxygenation.
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Gestational age (weeks) 38.6±1.8 39.0±1.5 38.4±1.8 0.08
Birth weight (kilograms) 3.1±0.5 3.2±0.5 3.0 ±0.5 0.08
Male 98 (57%) 27 (63%) 71 (55%) 0.37
Ethnicity
     Dutch








Prenatal diagnosis 107 (62%) 21 (49%) 86 (67%) 0.04
Left sided hernia 151 (88%) 36 (84%) 115 (89%) 0.35
Age at surgery (days) 4 (3-6) 6 (4-13) 3 (2-4) <0.001
Patch repair 126 (73%) 39 (91%) 87 (67%) 0.003
Days of mechanical ventilation 11 (6-23) 31 (19-51) 8 (5-15) <0.001
Days of PICU stay 21 (13-43) 67 (33-99) 17 (10-29) <0.001
Days of initial hospital stay 39 (21-70) 90 (58-143) 30 (20-51) <0.001
Presence of chronic lung disease 76 (44%) 33 (77%) 43 (33%) <0.001
Need for Nissen fundoplication 20 (12%) 12 (28%) 8 (6%) <0.001
Gastrostomy placement 17 (10%) 9 (21%) 8 (6%) 0.011
Data are presented as mean±standard deviation, median (interquartile range) or number (percentage), as appropriate.
1 Fisher’s exact test was used.
Abbreviations: ECMO=extracorporeal membrane oxygenation; PICU=pediatric intensive care unit.
Figure 2. Height-for-age in patients with congenital diaphragmatic hernia treated with and without 
extracorporeal membrane oxygenation until 12 years of age











Estimated marginal means with error bars representing 95% confidence intervals were plotted, and the presentation of data is 
based on a general linear model, with time-point, ECMO and their interaction effect as independent variables.
The solid line represents the ECMO patients; the dashed line represents the non-ECMO patients.
* The data indicate a significant difference between ECMO and non-ECMO patients.
Abbreviation: ECMO=extracorporeal membrane oxygenation.
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Table 2. Height-for-age and distance-to-target height in patients with congenital diaphragmatic hernia 
treated with and without extracorporeal membrane oxygenation until 12 years of age
Age ECMO patients Non-ECMO patients
HFA z-score DTH z-score p-value1 HFA z-score DTH z-score p-value1






















































Data are presented as estimated marginal means (95% confidence intervals), and the presentation of data is based on a general 
linear model, with time-point, ECMO and their interaction effect as independent variables. 
1 P-values are based on a comparison of mean z-scores of HFA and DTH using paired sample t-tests.
Abbreviations: DTH=distance-to-target height; ECMO=extracorporeal membrane oxygenation ; HFA=height-for-age.
Weight measurements
The mean WFH was less than the norm until the age of 5 years in non-ECMO patients 
and until the age of 8 years in ECMO patients (all p<0.05; figure 4). ECMO patients had 
lower mean WFH than non-ECMO patients from 6 months to 8 years of age (all p<0.05). 
The mean WFH declined from 6 months to 1 year of age in ECMO patients (p=0.01) and 
non-ECMO patients (p=0.001). In ECMO patients, the mean WFH improved from 8 to 12 
years of age (p<0.001). In non-ECMO patients, the mean WFH improved from 5 to 8 years 
of age, and from 8 to 12 years of age (p=0.03 and p=0.02, respectively). The prevalence of 
wasting remained high in both groups (figure 3C). 
Associations between growth measurements and clinical variables
Associations between HFA, DTH, and WFH z-scores and clinical variables are shown in supple-
mentary table 2. HFA was negatively associated with the duration of PICU stay and positively 
associated with gestational age. DTH was negatively associated with the duration of PICU stay 
and patch repair. There were significant interaction effects between time-point and ECMO, 
which showed that ECMO had a negative association with HFA and DTH from 1 to 8 years of 
age. Tube feeding at follow-up had a positive association with HFA, DTH, and WFH.  There was 
a significant interaction effect between time-point and tube feeding on WFH, which showed the 
highest positive association between tube feeding and WFH at 6 months of age. WFH had a 
negative association with ECMO, patch repair, and the use of calorie-enriched feeds at follow-up.
Chapter 8
138
Figure 3. Prevalence rates of wasting and stunting in patients with congenital diaphragmatic hernia 
treated with and without extracorporeal membrane oxygenation until 12 years of age
A. Prevalence rates of stunting (height-for-age z-score <-2)
























B. Prevalence rates of stunting corrected for target height (distance-to-target height z-score <-2)



















C. Prevalence rates of wasting (weight-for-height z-score <-2)

























Bars show the percentages of stunting or wasting at follow-up, calculated as: the number of cases / the total number of patients 
seen at each time-point. The numbers within the bars represent the number of cases at each time-point.
The white bars represent the ECMO patients; the gray bars represent the non-ECMO patients.
* The data indicate a significant difference between ECMO and non-ECMO patients.
Abbreviation: ECMO=extracorporeal membrane oxygenation
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Figure 4. Weight-for-height in patients with congenital diaphragmatic hernia treated with and without 
extracorporeal membrane oxygenation until 12 years of age















Estimated marginal means with error bars representing 95% confidence intervals were plotted, and the presentation of data is 
based on a general linear model, with time-point, ECMO and their interaction effect as independent variables. 
The solid line represents the ECMO patients; the dashed line represents the non-ECMO patients.
* The data indicate a significant difference between ECMO and non-ECMO patients.
Abbreviation: ECMO=extracorporeal membrane oxygenation.
Pilot study: indirect calorimetry 
At the median age of 8.2 years (IQR: 4.4-12.1), 11 patients underwent indirect calorimetry 
(supplementary table 3). REE was profoundly increased in 4 (36%) patients. Seven (64%) 
patients had a disturbed eating pattern (they could only eat small portions and/or it took 




In this longitudinal study, we observed growth impairments in patients with CDH. High 
prevalence rates of wasting and stunting were found, especially in ECMO-treated patients. 
Furthermore, from 6 months to 1 year of age, the mean WFH z-score declined, which was 
followed by a decline in the mean HFA z-score until age 5 years. We assume that the decline 
in growth during infancy might be explained by inadequate nutritional intake to meet energy 
needs, and this possible cause should be explored as an initial step. In patients with CDH, 
feeding difficulties and increased resting and activity energy expenditure due to respiratory 
morbidity contribute to impaired growth. Although results seemed more favorable after 
correcting for TH, the mean DTH was less than normal at 12 years of age in both groups. 
Recently, Terui et al.10 retrospectively evaluated growth in 174 patients with CDH at 1.5, 3, 
and 6 years of age. They found wasting and/or stunting in 19.5% at 1.5 years of age. Weight 
improved from 1.5 to 3 years of age, although stunting remained in 13.5% at 6 years of age. 
Similar to what we found, chronic malnutrition seemed to develop via acute malnutrition. It is 
difficult to compare the prevalence rates of  Terui et al.10 with our prevalence rates because 
they used different definitions for wasting and stunting than we did. In addition, we had a 
higher number of ECMO-treated patients (6% versus 25%). We assume that feeding difficul-
ties and increased energy expenditure occur especially in ECMO-treated patients who are 
the most critically ill and have the most hypoplastic lungs. Therefore, this subgroup of patients 
is more prone to persistent growth problems. Interestingly, we observed a catch-up of height 
in ECMO-treated patients from 8 to 12 years of age, which is reassuring. This catch-up growth 
may be explained by improvement of clinical problems over time, including lower rates of 
respiratory infections, hospitalizations, and feeding difficulties. Nevertheless, future studies 
should evaluate whether this catch-up growth is sustained into adolescence and adulthood. 
Terui et al.10 also summarized results of previous longitudinal studies that retrospectively 
evaluated growth in patients with CDH until 1 to 2 years of age.5, 6, 9, 11 Some studies reported 
catch-up growth from the age of 6 months to 1 year ;6, 9 others from the age of 1 to 2 years.5, 
11 However, it is difficult to compare our results with these studies because of differences 
in study populations, which included the selection of  less severe9 or more severe5 patients 
with CDH, and retrospective study designs with potential selection bias due to relatively 
high numbers of patients lost to follow-up. In addition, nutritional management strategies 
differ among centers.
Multiple factors are thought to be involved in growth problems in patients with CDH, 
including feeding problems and an increased metabolism due to the increased work of 
breathing.11 Previous studies identified different variables associated with impaired growth 
including lower birth weight,6, 10 prematurity,6 ECMO treatment,3, 11 patch repair,10 use of 
inhaled nitric oxide,10 lower protein intake during PICU stay,6 longer duration of mechanical 
ventilation9, 10 and hospital stay,10 need for supplemental oxygen at discharge,6, 10, 11 and GERD 
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therapy at discharge.6 In our study, HFA and DTH were negatively associated with ECMO 
and the duration of PICU stay. WFH was negatively associated with ECMO, patch repair and 
the use of calorie-enriched feeds. ECMO treatment, patch repair, and a longer PICU stay are 
indicators of more severe CDH, which can explain the negative association between these 
clinical variables and growth. In addition, during PICU stay critically ill neonates are subjected 
to factors that may generate a poor growth status, including mechanical ventilation, surgery, 
feeding interruptions, and prolonged hospitalization.21-23 A recent trial found that not starting 
parenteral nutrition up to one week in the PICU was superior to an early start of parenteral 
nutrition.24 This means that one has to be cautious in administering parenteral feeding in 
the first week of PICU stay. Nevertheless, nutritional support is important for recovery and 
growth after the acute phase of critical illness. Growth and nutritional assessments and inter-
ventions should therefore be considered in the different phases of disease during PICU stay.25 
Malnutrition has been associated with negative effects on long-term outcomes in different 
groups such as premature infants and children in developing countries. It is associated with 
immune dysfunction,26 impaired neurodevelopment,7, 8 behavioral problems,27 lower educa-
tional achievement,28 and lower economic status in adulthood.28 In patients with CDH, lower 
weight and smaller head circumference at 2 years of age were associated with increased risk 
of borderline or delayed neurological outcome at this age.29  Therefore, we think malnutrition 
should ideally be prevented, and, if present, should be treated at an early stage.
Tube feeding had a positive association with HFA, DTH and WFH z-scores. More liberal 
and longer use of tube feeding could be considered in patients with impaired growth. How-
ever, initiating oral feeding in an early phase is important to avoid feeding difficulties and 
oral aversion.30 Therefore, a tailor made approach for each patient with CDH managed by 
a multidisciplinary nutritional support team is recommended. In addition to the American 
Academy of Pediatrics guideline recommendations of long-term follow-up,4 we propose a 
risk stratification flowchart that can be used during follow-up to select patients who need 
dietary consultation and intervention (figure 5). This flowchart is based on the Screening 
Tool for Risk on Nutritional status and Growth (STRONGkids).31, 32
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Figure 5. Flowchart for dietary consultation and intervention in patients with congenital diaphragmatic 
hernia
Determine
DTH or HFA z-score1
WFA z-score if < 1 year of age 
WFH z-score if ≥ 1 year of age 
1 - 4 years of age< 1 year of age
DTH1 or WFA z-score < -2 
OR
Decline in WFA z-score > 1 in 3 months
> 4 years of age
DTH1 or WFH z-score < -2 
OR
Decline in DTH1 z-score > 0.5 in 1 year
DTH1 or WFH z-score < -2
OR
Decline in DTH1 z-score > 0.25 in 1 year
No Yes





























1 Use HFA if DTH is not available.
2 Nutritional risk screening tool STRONGkids (screening tool for risk on nutritional status and growth)31
Score if yes
Subjective clinical assessment:
Is the patient in a poor nutritional status judged by subjective clinical assessment (diminished subcutaneous 
fat and/or muscle mass and/or hollow face)?
1 point
High risk disease state, are one of the following items present:
-Extracorporeal membrane oxygenation treatment?
-Chronic lung disease?
-Recurrent (pulmonary) infections requiring antibiotics or hospitalization?
-Recent major surgery?
-High risk CDH judged by clinical assessment of physician?
2 points
Nutritional intake and losses, are one of the following items present: 
-Excessive diarrhea (≥5 times per day) and/or vomiting (>3 times per day) the last few days?
-Pre-existing dietetically advised nutritional intervention (for example calorie-enriched feeds or tube 
feeding)?
-Obvious reduced food intake during the last few days?
-Inability to consume adequate intake (for example due to GERD)?
1 point
Weight loss or poor weight gain:
Is there weight loss or no weight gain (infants <1 year) during the last weeks/months?
1 point
Abbreviations: CDH=congenital diaphragmatic hernia; DTH=distance-to-target height; ECMO=extracorporeal 
membrane oxygenation; GERD=gastroesophageal reflux disease; HFA=height-for-age; PICU=pediatric intensive 
care unit; WFA=weight-for-age; WFH=weight-for-height.
An increased REE and feeding difficulties may contribute to impaired growth. In a pilot 
study with REE measurements, we found an increased measured REE in four (36%) patients 
and a disturbed eating pattern in seven (64%). These results emphasize the importance of 
care by a multidisciplinary nutritional support team. Dietary consultation with REE measure-
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ment could serve as a first step to identify possible causes of poor growth. All children with 
REE measurements were older than 3 years of age. REE may be even higher in the first 2 
years of life because of an increased rate of breathing after correction of the defect. Indeed, 
Haliburton et al.33 reported that 10 (59%) of 17 patients were hypermetabolic at the median 
age of 32 days. Longitudinal studies including more patients should be performed to assess 
metabolic needs in patients with CDH over time.
This is the largest prospective cohort study following growth of patients with CDH up 
to 12 years of age. Other study strengths are the high follow-up rate of 96% and the use 
of z-scores for growth by using recently established reference values for Dutch children.16 
In addition, this is the first study to report DTH z-scores in patients with CDH. Because 
adjusting for TH improved height z-scores, it seems important to calculate DTH z-scores 
when evaluating growth parameters in patients with CDH.
Our study has some limitations. Birth weight of most patients was estimated. Therefore, 
we used growth measurements at 6 months of age as the reference point in the general 
linear model analyses. Secondly, as this is a longitudinal study, not all children had yet reached 
the age of 12 years. Although general linear models can account for missing data values, the 
limited number of children assessed at 12 years of age may have contributed to not finding 
a significant difference in the mean HFA z-scores between ECMO and non-ECMO patients 
(type II error). Ongoing assessment of growth into adolescence is therefore recommended. In 
addition, management of CDH changed during the study period, which could have influenced 
our results. However, we did not find a significant association between HFA, DTH and WFH 
z-scores and the change in treatment protocol. In our pilot study, nutritional assessments were 
performed in a limited number of patients, however, our results support previous findings.33 
In addition, our study highlights the importance of early initiation of nutritional assessment 
and intervention by a multidisciplinary nutritional team.
Conclusions
We found impaired growth in patients with CDH, especially in those who had received 
ECMO treatment. A decline in weight gain was followed by a decline in linear growth 
suggestive of inadequate nutritional intake to meet energy needs during infancy. This study 
shows the importance for early risk stratification for poor growth to identify patients with 
a high risk, such as those who required ECMO treatment. Early risk stratification should be 
combined with nutritional assessments and interventions, as well as long-term follow-up of 
growth. Further studies are needed to determine the relation between growth problems 




1. Spoel M, Laas R, Gischler SJ, Hop WJ, Tibboel D, de Jongste JC, et al. Diagnosis-related deterioration of 
lung function after extracorporeal membrane oxygenation. Eur Respir J. 2012;40:1531-1537.
2. Caruso AM, Di Pace MR, Catalano P, Farina F, Casuccio A, Cimador M, et al. Gastroesophageal reflux in 
patients treated for congenital diaphragmatic hernia: short- and long-term evaluation with multichannel 
intraluminal impedance. Pediatr Surg Int. 2013;29:553-559.
3. Gischler SJ, van der Cammen-van Zijp MH, Mazer P, Madern GC, Bax NM, de Jongste JC, et al. A pro-
spective comparative evaluation of persistent respiratory morbidity in esophageal atresia and congenital 
diaphragmatic hernia survivors. J Pediatr Surg. 2009;44:1683-1690.
4. American Academy of Pediatrics Section on S, American Academy of Pediatrics Committee on F, New-
born, Lally KP, Engle W. Postdischarge follow-up of infants with congenital diaphragmatic hernia. Pediatrics. 
2008;121:627-632.
5. Cortes RA, Keller RL, Townsend T, Harrison MR, Farmer DL, Lee H, et al. Survival of severe congenital 
diaphragmatic hernia has morbid consequences. J Pediatr Surg. 2005;40:36-45; discussion 45-36.
6. Bairdain S, Khan FA, Fisher J, Zurakowski D, Ariagno K, Cauley RP, et al. Nutritional outcomes in survivors 
of congenital diaphragmatic hernia (CDH)-factors associated with growth at one year. J Pediatr Surg. 
2015;50:74-77.
7. Corbett SS, Drewett RF. To what extent is failure to thrive in infancy associated with poorer cognitive 
development? A review and meta-analysis. J Child Psychol Psychiatry. 2004;45:641-654.
8. Nyaradi A, Li J, Hickling S, Foster J, Oddy WH. The role of nutrition in children’s neurocognitive develop-
ment, from pregnancy through childhood. Front Hum Neurosci. 2013;7: doi: 10.3389/fnhum.2013.00097.
9. Leeuwen L, Walker K, Halliday R, Karpelowsky J, Fitzgerald DA. Growth in children with congenital dia-
phragmatic hernia during the first year of life. J Pediatr Surg. 2014;49:1363-1366.
10. Terui K, Nagata K, Hayakawa M, Okuyama H, Goishi K, Yokoi A, et al. Growth Assessment and the Risk 
of Growth Retardation in Congenital Diaphragmatic Hernia: A Long-Term Follow-Up Study from the 
Japanese Congenital Diaphragmatic Hernia Study Group. Eur J Pediatr Surg. 2016;26:60-66.
11. Muratore CS, Utter S, Jaksic T, Lund DP, Wilson JM. Nutritional morbidity in survivors of congenital dia-
phragmatic hernia. J Pediatr Surg. 2001;36:1171-1176.
12. Gischler SJ, Mazer P, Duivenvoorden HJ, van Dijk M, Bax NM, Hazebroek FW, et al. Interdisciplinary 
structural follow-up of surgical newborns: a prospective evaluation. J Pediatr Surg. 2009;44:1382-1389.
13. Stolar CJ, Snedecor SM, Bartlett RH. Extracorporeal membrane oxygenation and neonatal respiratory 
failure: experience from the extracorporeal life support organization. J Pediatr Surg. 1991;26:563-571.
14. Reiss I, Schaible T, van den Hout L, Capolupo I, Allegaert K, van Heijst A, et al. Standardized postnatal 
management of infants with congenital diaphragmatic hernia in Europe: the CDH EURO Consortium 
Consensus. Neonatology. 2010;98:354-364.
15. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723-1729.
16. Schonbeck Y, Talma H, van Dommelen P, Bakker B, Buitendijk SE, HiraSing RA, et al. The world’s tallest nation 
has stopped growing taller : the height of Dutch children from 1955 to 2009. Pediatr Res. 2013;73:371-377.
17. Schonbeck Y, van Dommelen P, HiraSing RA, van Buuren S. Trend in height of Turkish and Moroccan 
children living in the Netherlands. PLoS One. 2015;10:e0124686.
18. Talma H. Groeidiagrammen 2010: Handleiding bij het meten en wegen van kinderen en het invullen van 
groeidiagrammen.: TNO; 2010.
19. van Dommelen P, Schonbeck Y, van Buuren S. A simple calculation of the target height. Arch Dis Child. 
2012;97:182.
Follow-up of growth in CDH patients until 12 years
 145
8
20. Use and interpretation of anthropometric indicators of nutritional status. WHO Working Group. Bull 
World Health Organ. 1986;64:929-941.
21. Hulst J, Joosten K, Zimmermann L, Hop W, van Buuren S, Buller H, et al. Malnutrition in critically ill children: 
from admission to 6 months after discharge. Clin Nutr. 2004;23:223-232.
22. Mehta NM, McAleer D, Hamilton S, Naples E, Leavitt K, Mitchell P, et al. Challenges to optimal enteral 
nutrition in a multidisciplinary pediatric intensive care unit. JPEN J Parenter Enteral Nutr. 2010;34:38-45.
23. Mehta NM, Bechard LJ, Cahill N, Wang M, Day A, Duggan CP, et al. Nutritional practices and their rela-
tionship to clinical outcomes in critically ill children--an international multicenter cohort study*. Crit Care 
Med. 2012;40:2204-2211.
24. Fivez T, Kerklaan D, Mesotten D, Verbruggen S, Wouters PJ, Vanhorebeek I, et al. Early versus Late Parenteral 
Nutrition in Critically Ill Children. N Engl J Med. 2016;374:1111-1122.
25. Joosten KF, Kerklaan D, Verbruggen SC. Nutritional support and the role of the stress response in critically 
ill children. Curr Opin Clin Nutr Metab Care. 2016;19:226-233.
26. Bourke CD, Berkley JA, Prendergast AJ. Immune Dysfunction as a Cause and Consequence of Malnutrition. 
Trends Immunol. 2016: pii: S1471-4906(16)30006-0.
27. Liu J, Raine A, Venables PH, Mednick SA. Malnutrition at age 3 years and externalizing behavior problems 
at ages 8, 11, and 17 years. Am J Psychiatry. 2004;161:2005-2013.
28. Victora CG, Adair L, Fall C, Hallal PC, Martorell R, Richter L, et al. Maternal and child undernutrition: 
consequences for adult health and human capital. Lancet. 2008;371:340-357.
29. Danzer E, Gerdes M, D’Agostino JA, Partridge EA, Hoffman-Craven CH, Bernbaum J, et al. Preschool 
neurological assessment in congenital diaphragmatic hernia survivors: outcome and perinatal factors 
associated with neurodevelopmental impairment. Early Hum Dev. 2013;89:393-400.
30. Mason SJ, Harris G, Blissett J. Tube feeding in infancy: implications for the development of normal eating 
and drinking skills. Dysphagia. 2005;20:46-61.
31. Hulst JM, Zwart H, Hop WC, Joosten KF. Dutch national survey to test the STRONGkids nutritional risk 
screening tool in hospitalized children. Clin Nutr. 2010;29:106-111.
32. Joosten K, van der Velde K, Joosten P, Rutten H, Hulst J, Dulfer K. Association between nutritional status and 
subjective health status in chronically ill children attending special schools. Qual Life Res. 2016;25:969-977.
33. Haliburton B, Chiang M, Marcon M, Moraes TJ, Chiu PP, Mouzaki M. Nutritional Intake, Energy Expenditure, 





Supplementary methods. Indirect calorimetry
Indirect calorimetry (Cosmed Quark RMR with Canopy, Tulipmed, Nieuwegein, the Neth-
erlands) is an accurate method of estimating the basal metabolic rate in awake patients. The 
Cosmed Quark RMR measures resting energy expenditure (REE) using a canopy dilution 
technique. Before each measurement, gas and pressure calibrations were performed. All 
patients were spontaneously breathing without supplementary oxygen. Patients had to lay 
down for 5 minutes in advance to keep their breathing as calm as possible. After that, they 
had to breathe calmly for 20 minutes with an air-tight transparent plastic canopy hood over 
their head. The flow rate was directly measured with a digital turbine flowmeter. Expired air 
was extracted by a pump and analyzed by metabolic cart sensors. The oxygen consump-
tion (VO2 in ml/min) and carbon dioxide production (VCO2 in ml/min) were measured by 
oxygen and carbon dioxide gas analyzers. The respiratory quotient was calculated: VCO2/
VO2.  Software used the Weir equation to calculate the REE from oxygen consumption and 
carbon dioxide production.1, 2  REE was calculated with the Schofield equation for weight 
and height.3 Increased energy expenditure was defined as an increase in measured REE of 
>10% compared with the calculated REE (( measured REE calculated REE  
 
TEN =
measured REE * activity factor + disease factor-1 *growth factor 
energy absorption coefficient
       
	
 -1)x100%).  Total energy need (TEN, 






measured REE * activity factor + disease factor-1 *growth factor 
energy absorption coefficient
       
	
      
Total energy intake was calculated from the entries in a three-day food diary, which intake 
was compared with the estimated TEN. A total energy intake of ≥95% of  TEN was consid-
ered as sufficient. The eating pattern was categorized as normal or disturbed (deviant from 
healthy peers) judged by the patients, parents and/or dietician.
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Supplementary table 1. Number of patients with tube feeding at follow-up
Age ECMO Non-ECMO p-value
0.5 year 56% (23/41) 15% (19/129) <0.001
1 year 53% (20/38) 13% (16/121) <0.001
2 years 20% (7/35) 9% (9/98) 0.131
5 years 9% (3/33) 1% (1/67) 0.101
1 Fisher’s exact test was used.
Abbreviation: ECMO=extracorporeal membrane oxygenation.
Supplementary table 2. Associations between growth measurements and clinical variables




0.5 year of age 
1 year of age
2 years of age
5 years of age
8 years of age



















ECMO 0.21 -0.19 to 0.61 0.30
Patch repair -0.22 -0.52 to 0.08 0.15
Gestational age (weeks) 0.08 0.001 to 0.15 0.047
Days of PICU stay -0.005 -0.008 to -0.001 0.004
Tube feeding at follow-up 0.25 0.06 to 0.44 0.009
Calorie-enriched feeds at follow-up -0.16 -0.34 to 0.02 0.08
Interaction term: 
ECMO*Follow-up time-point:
0.5 year of age 
1 year of age
2 years of age
5 years of age
8 years of age




















Days of PICU stay*Follow-up time-point:
0.5 year of age 
1 year of age
2 years of age
5 years of age
8 years of age






















0.5 year of age 
1 year of age
2 years of age
5 years of age
8 years of age



















ECMO 0.32 -0.11 to 0.75 0.14
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Supplementary table 2. Continued
Variable Estimated coefficient 95% confidence interval p-value
Patch repair -0.31 -0.60 to -0.02 0.04
Gestational age (weeks) 0.05 -0.02 to 0.13 0.15
Days of PICU stay -0.006 -0.009 to -0.003 0.001
Tube feeding at follow-up 0.29 0.09 to 0.49 0.004
Interaction term: 
ECMO*Follow-up time-point:
0.5 year of age 
1 year of age
2 years of age
5 years of age
8 years of age




















Days of PICU stay*Follow-up time-point:
0.5 year of age 
1 year of age
2 years of age
5 years of age
8 years of age






















0.5 year of age 
1 year of age
2 years of age
5 years of age
8 years of age



















ECMO -0.57 -0.94 to -0.20 0.003
Patch repair -0.50 -0.81 to -0.20 0.001
Days of PICU stay 0.002 -0.001 to 0.005 0.14
Tube feeding at follow-up 0.66 0.35 to 0.96 <0.001
Calorie-enriched feeds at follow-up -0.30 -0.55 to -0.05 0.02
New treatment protocol 0.21 -0.08 to 0.50 0.15
Interaction term: 
Tube feeding*Follow-up time-point:
0.5 year of age 
1 year of age
2 years of age
5 years of age
8 years of age



















Abbreviations: DTH=distance-to-target height; ECMO=extracorporeal membrane oxygenation; HFA=height-for-age;
PICU=pediatric intensive care unit; WFH=weight-for-height.
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Supplementary table 3. Results of dietary consultations and indirect calorimetry measurements 













measured REE and 
calculated REE
TEN (kcal/day) Caloric intake 
(% of TEN)
Eating pattern
1 M Yes No 5.3 -2.36 -1.33 -1.23 881 824 +7% 1456 80 Disturbed
2 F Yes No 3.3 -2.13 -1.51 -0.94 765 727 +5% 1509 93 Disturbed
3 M Yes Yes 12.1 -2.88 -2.55 -1.96 1309 1090 +20%1 2680 60 Disturbed
4 M Yes No 15.6 -1.11 -1.02 -0.29 2082 1585 +31%1 3500 96 Normal
5 M Yes No 8.2 -2.10 -1.98 -0.94 1159 953 +22%1 2325 76 Normal
6 F No No 12.3 -1.61 -0.85 -0.72 1136 1158 -2% 2000 102 Normal
7 F Yes Yes 10.3 0.15 0.12 -4.36 1152 1086 +6% 2150 75 Disturbed
8 M No No 4.4 -1.72 -2.33 -0.18 773 829 -7% 1840 98 Normal
9 F Yes No 8.2 -2.81 -2.27 -1.82 896 862 +4% 1520 63 Disturbed
10 M Yes Yes 12.1 -1.45 -2.26 -3.86 1207 1135 +6% 1776 89 Disturbed
11 F Yes No 3.3 -2.20 -2.39 1.41 993 770 +29%1 1260 94 Disturbed
1 Increased energy expenditure. 
Abbreviations: DTH=distance-to-target height; ECMO=extracorporeal membrane oxygenation; F=female; HFA=height-for-age; 
M=male; REE=resting energy expenditure; TEN=total energy need; WFH=weight-for-height.
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Supplementary table 3. Results of dietary consultations and indirect calorimetry measurements 













measured REE and 
calculated REE
TEN (kcal/day) Caloric intake 
(% of TEN)
Eating pattern
1 M Yes No 5.3 -2.36 -1.33 -1.23 881 824 +7% 1456 80 Disturbed
2 F Yes No 3.3 -2.13 -1.51 -0.94 765 727 +5% 1509 93 Disturbed
3 M Yes Yes 12.1 -2.88 -2.55 -1.96 1309 1090 +20%1 2680 60 Disturbed
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1 Increased energy expenditure. 
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The primary objective of this thesis was to evaluate the postnatal risks and outcomes of 
patients with congenital diaphragmatic hernia (CDH). We investigated early outcomes, includ-
ing disturbed thyroid function during the neonatal period (chapters 2 and 3) and persistent 
pulmonary hypertension during the first year of life (chapter 4). In addition, we studied the 
long-term risks of growth failure (chapters 5 and 8) and impaired neurodevelopmental and 
neuropsychological outcomes (chapters 6 and 7) until school age. We also aimed to identify 
determinants of patient outcomes in these studies. Subjects were CDH patients treated in 
the Netherlands (chapters 2, 3, 4, 7 and 8) or Australia (chapters 5 and 6). Both countries 
have a standardized long-term follow-up program for CDH patients in place. The studies’ 
most important conclusions are shown in figure 1. Here, we will discuss the main findings of 
our studies and relate these to the current literature. We also make recommendations for 
future research and implementation of our findings for patient care.
Figure 1. Main conclusions about the early and long-term outcomes of patients with congenital 
diaphragmatic hernia following the studies in this thesis
Neonatal age Pre-school age School age
Early outcomes
Long-term outcomes
Thyroid function: Non-thyroidal illness syndrome was a frequent, short-term problem in congenital diaphragmatic patients treated 
with neonatal extracorporeal membrane oxygenation that was related to the severity of illness.  
Pulmonary hypertension: Persistent pulmonary hypertension was found in only a minority (<10%) of congenital diaphragmatic hernia 
patient at 6 and 12 months of age, and was related to the severity of neonatal illness. 
Growth: Impaired linear growth persisted in congenital diaphragmatic hernia patients at school age. Growth outcomes were related 
to the severity of neonatal illness.
Neuropsychological outcome: Problems in the area of selective attention, verbal memory and visuospatial memory were found in 
congenital diaphragmatic hernia patients at school age. Neuropsychological outcome was related to the severity of neonatal illness.  
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Early outcomes and risks 
Thyroid function
From the first breath of life, neonates with CDH are at a high risk of mortality1, 2 and 
morbidity.3, 4 Difficulties with breathing start soon after birth due to pulmonary hypoplasia 
and pulmonary hypertension associated with the diaphragmatic defect. Although there is 
no univocal definition of neonatal or pediatric critical illness,5 neonates with CDH can 
be considered critically ill from birth onwards as they have a life-threatening illness that 
requires support of vital organ functions to prevent death.6 Those with the greatest severity 
of  illness even require extracorporeal membrane oxygenation (ECMO) treatment. During 
critical illness, the body reacts with a stress response that causes endocrine, metabolic and 
immunologic changes.6, 7 
In chapters 2 and 3, we focused specifically on the disturbed endocrine response of the 
hypothalamic-pituitary-thyroid (HPT) axis, which can occur in CDH patients during critical 
illness. This disturbed thyroid function during critical illness is called non-thyroidal illness syn-
drome (NTIS).8-10 NTIS is characterized by low thyroxine (T4) and triiodothyronine (T3) 
concentrations, an increased reverse T3 concentration, and a normal or low thyroid-stimu-
lating hormone (TSH) concentration.8-10 One of the first occasions to find disturbed thyroid 
hormone levels is during the neonatal heel prick screening for congenital hypothyroidism. 
In chapter 2, we found that more than half of the ECMO-treated neonates had an aberrant 
screening result for congenital hypothyroidism before the start (73.1%) and during (67.3%) 
ECMO, which incidence was significantly higher than that of aberrant screening results after 
ECMO treatment (31.4%). Neonatal screening results showed a low total T4 concentration 
in combination with a low TSH concentration in almost all patients, which normalized in all 
survivors after recovery of critical illness. Eventually, none of the survivors with an aberrant 
screening result was diagnosed with congenital hypothyroidism. We, therefore, believe that 
these aberrant screening results are most likely due to NTIS. 
Previous studies have also found disturbed thyroid hormone levels in other groups of 
critically ill neonates treated with11 or without12-14 ECMO. Other groups of critically ill neo-
nates will presumably also have a high incidence of aberrant screening results for congenital 
hypothyroidism.15 Clinicians should be aware that an aberrant congenital hypothyroidism 
screening result in a critically ill neonate is likely due to NTIS. Further, other contributing 
factors, including the use of medication such as dopamine, should be taken into account.16 
Neonatal screening for congenital hypothyroidism in such a patient can best be repeated 
after clinical recovery of critical illness. However, it is equally important to repeat screening 
before the age of 14 days as thyroxine treatment should be started before the first two 
weeks of life to prevent intellectual disabilities.17 
To further characterize the disturbances in thyroid hormone concentrations during ECMO, 




aspiration syndrome at six fixed time-points before, during, and after ECMO (chapter 3).  This 
study confirmed that low thyroid hormone concentrations, as is seen in NTIS, were already 
present in critically ill neonates before the start of ECMO. Immediately after the start of 
ECMO, thyroid hormone concentrations further declined, possibly due to hemodilution11, 18 
and the global inflammatory response occurring during the initial phases of cardiopulmonary 
bypass and ECMO.19-21 Soon thereafter, first the TSH concentration significantly increased 
followed by an increase in total T4 and total T3 concentrations. This is in line with previous 
studies showing that restoration of the HPT axis after NTIS starts with an increase in TSH 
followed by increases in total  T4 and total  T3,22, 23 which suggests that restoration of the 
HPT axis already occurs during neonatal ECMO. 
Another potential factor contributing to the increase in TSH is the discontinuation of dopa-
mine administration during ECMO as TSH is known to be suppressed by dopamine, and after 
dopamine is discontinued, TSH level again increases.24 However, we think that this is not the 
most important factor involved, because dopamine levels were not associated with an aberrant 
screening result or with thyroid hormone concentrations in our studies (chapters 2 and 3). 
In chapter 2, we found an association between an aberrant screening result for congenital 
hypothyroidism and the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score,25 which is 
a score for the severity of illness. This suggests that the occurrence of NTIS is related to the 
severity of neonatal illness. On the other hand, we could not confirm an association between 
the PELOD-2 score and thyroid hormone concentrations in chapter 3. Explanations for this 
equivocal result are the low number of patients included and the limitations of the PELOD-2 
score in assessing the severity of illness in this specific group of ECMO-treated neonates. 
Although the PELOD-2 score is validated for a broad group of pediatric intensive care unit 
(PICU) patients,25, 26 its relative significance and performance in ECMO-treated neonates is 
currently unknown. Further, the score is affected by treatment such as ventilator settings 
and use of vasoactive drugs, and therefore it does not solely reflect the severity of illness. 
Impaired neuropsychological outcomes have been found in CDH and ECMO-treated 
patients at school age (chapter 7).27, 28 As thyroid hormones are essential for brain devel-
opment during early life,29, 30 disturbances of thyroid function during this period may have 
important consequences for neurodevelopmental outcome later in life. In the first 16 to 
20 weeks of gestation, thyroid hormone influences neuronal proliferation and migration 
of neurons in the cerebral cortex, hippocampus and medial ganglionic eminence.31-35 The 
second stage occurs during the remainder of pregnancy, when thyroid hormone is involved 
in neurogenesis, neuron migration, axonal outgrowth, dendritic branching and synaptogenesis, 
together with the initiation of glial cell differentiation and migration and the onset of myelin-
ation.35-39 During the neonatal period, thyroid hormones influence migration of granule cells 
in the hippocampal dentate gyrus and cerebellum, migration of pyramidal cells in the cortex 
and migration of Purkinje cells in the cerebellum, and thyroid hormone-dependent gliogen-
esis and myelination continues.35, 39-41 In chapter 3, we found normal cognitive outcomes in a 
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small sample of neonatal ECMO survivors (n=16) compared with the norm population at 2 
years of age. Recent research has mainly focused on the effect of maternal thyroid function 
on children’s neurodevelopment instead of neonatal thyroid function. Ghassabian et al.42 
found an adverse effect of maternal hypothyroxinemia on children’s nonverbal intelligence 
quotient (IQ) at 6 years of age but no effect on brain morphology. Nevertheless, Korevaar 
et al.43 showed that both low and high maternal free T4 were associated with lower child IQ 
and smaller grey matter and cortex volumes at school age. It is difficult to compare these 
results to ours as thyroid hormone-dependent neurological development differs between 
the fetal and neonatal periods.
The effect of temporarily low thyroid hormone levels during the neonatal period has been 
mostly studied in premature neonates with transient hypothyroxinemia.44 Studies investigating 
the impact of hypothyroxinemia of prematurity on neurodevelopmental outcomes later in life 
have found contradictory results. One study found a significant association between thyrox-
ine concentrations and psychomotor development at 2 years of age.45 Another found that 
children with transient hypothyroxinemia had lower cognitive and verbal scores than children 
without transient hypothyroxinemia at 5 years of age.46 However, a more recent study did 
not confirm this association between transient hypothyroxinemia of prematurity and adverse 
neurodevelopmental outcomes in young adults.47 All three studies adjusted for possible con-
founders such as the degree of prematurity and the severity of neonatal illness. In contrast to 
low T4 levels, high T4 levels may also impair brain development. For example, Scratch et al.48 
found that higher T4 levels after very preterm birth were associated with lower scores on 
verbal learning and verbal memory at 7 years of age, whereas they did not find associations 
between T4 levels and brain volumes. As stated above, we did not find impaired cognitive 
scores in ECMO-treated neonates with NTIS at the age of 2 years. At school age, however, 
CDH and neonatal ECMO survivors experienced mainly problems in the areas of selective 
attention, verbal and visuospatial memory (chapter 7), which has been associated with injury 
in the area of the hippocampus.49-54 As thyroid hormone concentrations are essential for 
the development of brain circuits in general, it is likely that other mechanisms are involved 
in determining neuropsychological outcome in survivors of neonatal critical illness later in 
life. Nevertheless, smaller hippocampal volumes and reduced memory functioning have 
also been found in children of mothers diagnosed with hypothyroidism,55, 56 and in children 
and adolescents with congenital hypothyroidism.57 From our studies, we cannot exclude 
an effect of thyroid hormone concentrations on neuropsychological outcomes at school 
age. Thus, future longitudinal studies assessing the impact of temporarily decreased thyroid 
hormone concentrations on specific neuropsychological outcome in the areas of attention 
and memory at school age as well as brain morphology should be performed to make a 
definite conclusion regarding this issue. 
Apart from brain development, thyroid hormones are important for physical growth.58 




growth in our studies. As thyroid hormone concentrations normalized after the period of 
neonatal critical illness, we assume that this temporarily phase of reduced thyroid hormone 
concentrations does not substantially affect growth in childhood. 
Persistent pulmonary hypertension
Persistent pulmonary hypertension is an important determinant of mortality and morbidity 
in CDH patients.59-61 It develops on account of a reduced number of pulmonary arteries 
in combination with altered vasoreactivity and abnormal pulmonary vascular remodeling.62 
Over the years, different definitions for and classifications of pulmonary hypertension have 
been used to study the risk of persistent pulmonary hypertension in CDH patients.59-61, 63-65 
One of the reasons for the use of these different definitions is the challenge of obtaining 
a well-performed echocardiogram as the heart of CDH patients is often in an abnormal 
position and no single reliable quantitative measure of pulmonary artery pressure and/
or right ventricular function exists. To be able to compare study results and standardize 
pulmonary hypertension follow-up and treatment, we should avoid the use of different 
definitions. Therefore, a standardized protocol using validated echocardiography measures 
is needed for the echocardiographic diagnosis of pulmonary hypertension in CDH patients. 
In addition, echocardiography should be performed by ultrasound specialists who are well 
trained in echocardiography of CDH patients. In our study, all patients with persistent pul-
monary hypertension were treated with sildenafil. Current guidelines advise to treat severe 
pulmonary hypertension with pulmonary vasodilators such as inhaled nitric oxide, sildenafil, 
and/or bosentan,66 although there is no evidence for the use of these drugs from properly 
designed randomized controlled trials. Therefore, well-powered randomized controlled trials 
should be performed that investigate the effectiveness of these treatments in CDH patients. 
A multicenter, randomized controlled trial, the CoDiNOS trial, will start shortly to evalu-
ate whether inhaled nitric oxide or intravenous sildenafil is superior in treating pulmonary 
hypertension in CDH patients.
Patients with persistent pulmonary hypertension during infancy had a longer duration of 
mechanical ventilation and hospital stay than patients without persistent pulmonary hyper-
tension.  This indicates that persistent pulmonary hypertension is associated with the severity 
of illness in early life, as previous studies also have shown. Lusk et al.60 found an association 
between persistent pulmonary hypertension at 2 weeks of age and mortality or adverse 
respiratory outcomes (prolonged intubation (≥28 days) or prolonged respiratory support 
(≥56 days)). Wynn et al.61 found that prenatal diagnosis, patch repair, post-operative compli-
cations, and ECMO were associated with worse pulmonary hypertension at 1 month of age. 
At 3 months of age, patch repair, non-isolated CDH, a genetic diagnosis and a lower birth 
weight were associated with worse pulmonary hypertension.61
Persistent pulmonary hypertension may also have important consequences for neurode-
velopmental outcome later in life. Both pulmonary hypoplasia and pulmonary hypertension 
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can have important consequences for gas exchange.  A lung with severe hypoplasia has fewer 
branching points and therefore fewer airways, arteries, veins and alveolar structures than 
a normal lung resulting in a fixed increased vascular resistance and decreased surface area 
for gas exchange,67, 68 with a high risk of hypoxemia. This hypoxemia can lead to inadequate 
cerebral oxygenation, which may result in hypoxic-ischemic and eventually reperfusion injury 
in vulnerable areas such as the hippocampus.69, 70 As stated above, this can lead to attention 
and memory problems later in life,49-53 which we found in over 50% of CDH patients at 8 
years of age (chapter 7). Still, we think that persistent pulmonary hypertension during infancy 
is not the main cause of these attention and memory problems in CDH patients at school 
age, seeing that more than 90% of CDH survivors in our study recovered from pulmonary 
hypertension during the first year of life. It may well be, however, that very early occurrence 
of pulmonary hypertension, which we found in 71% of the surviving CDH patients pediatric 
intensive care unit admission, has an effect on neuropsychological outcomes at school age. 
An important long-term issue in patients with persistent pulmonary hypertension is ensur-
ing adequate growth. These children may have an increased risk of growth failure due to a 
greater severity of illness in the neonatal period and possibly also due to other factors such 
as feeding difficulties due to an increased work of breathing, an increased resting energy 
expenditure and gastroesophageal reflux disease (GERD) (chapter 8). Indeed, we found 
that all patients with persistent pulmonary hypertension required tube feeding at follow-up 
(chapter 4). Therefore we think it is important to closely monitor these children’s nutrition 
and growth.
We found that 71% of the CDH survivors had pulmonary hypertension on the first day of 
pediatric intensive care unit admission. However, more than 90% of the survivors recovered 
from pulmonary hypertension during the first year of life, and none showed relapse during 
follow-up after stopping medication for pulmonary hypertension. This is why we think that 
routine structured follow-up for pulmonary hypertension in CDH patients is unnecessary. 
Echocardiographic follow-up seems necessary only when pulmonary hypertension is still 
present at hospital discharge and/or patients still require treatment with sildenafil and/or 




Long-term outcomes and risks 
Growth and nutrition
In chapters 5 and 8, we focused on physical growth in CDH patients.  After the infant period, 
CDH patients remain at risk for long-term morbidities including growth failure.71 In the study 
presented in chapter 8, we found poor weight gain during the first 2 years of life, followed 
by a decline in linear growth. Although catch-up in weight occurred after 2 years of age, at 
12 years of age linear growth was still below the norm. Therefore, the risk of growth failure 
seems especially high in the first years of life and incomplete catch-up growth occurs later 
in life. Previous studies have also reported growth problems in CDH survivors during the 
first years of life,72-74 with prevalence rates of growth failure ranging from 8.2% to 68.8%.72, 73 
This wide range is due to differences in study populations, retrospective study designs with 
potential selection bias on account of the relatively high numbers of patients lost to follow-up, 
and differences in nutritional management strategies. The longest follow-up study so far found 
that growth failure (stunting: height z-score <-2) persisted in 13.5% of patients at 6 years of 
age.71 This study did not take into account parental heights. As there is a strong genetic deter-
minant influencing growth,75 we considered it important to also calculate children’s target 
height and adjust for this when assessing linear growth. We then found significant differences 
in linear growth, with a higher height z-score after adjustment for target height. Therefore, 
we think it is important to calculate distance-to-target height z-scores when assessing linear 
growth in CDH patients, and possibly also in other patient groups. As in our study both 
height-for-age and distance-to-target height were still below the norm at 12 years of age, we 
think it is important to continue growth assessments in CDH patients. Studies in premature 
infants have found an increased risk for metabolic syndrome later in life as a consequence of 
catch-up growth.76, 77 Because catch-up growth also occurred in CDH patients, it is important 
to combine these growth assessments with assessment of the metabolic profile, including 
body composition measurements, in early adulthood. 
We found that measures of severity of illness such as the need for ECMO, patch repair 
and the duration of PICU stay were negatively associated with growth (chapter 8). Addi-
tionally, mechanical ventilation was predictive of failure to thrive (weight-for-age and/or 
weight-for-length z-score <-2) at 6 months of age (chapter 5). This association with severity 
of illness and growth is in line with previous studies in which different indicators of severity 
of illness were associated with impaired growth. These included ECMO treatment,74, 78 patch 
repair,71 use of inhaled nitric oxide,71 longer duration of mechanical ventilation and hospital 
stay,71, 79 and need for supplemental oxygen at discharge.71, 72, 74 In a recent study in 12 CDH 
patients, increased postnatal weight gain was associated with increased ipsilateral lung volume 
growth measured by infant pulmonary MRI.80 This result in combination with our results of 
early growth failure highlights the importance of early start of nutritional assessment and 
interventions in high risk CDH patients. Therefore, early risk stratification to prevent growth 
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failure is indicated in CDH patients. In chapter 8, we propose a risk stratification flowchart 
that can be used to select patients who need early dietary consultation and intervention. 
Ideally, nutritional assessments and interventions should already be started in the PICU. It is 
also important to make parents aware of the risk of growth failure and involve them early in 
the nutritional care of their child. In the infant period, breastmilk feeding should be encour-
aged,81 for example through family-centered care with kangaroo mother care. This may aid in 
establishing successful breastmilk feeding and improves parent-child attachment.82-84 In CDH 
patients with a high risk of growth failure, calorie-enriched feeds should already be started 
during hospital admission to prevent early growth failure. Additionally, tube feeding should 
be considered if an increased work of breathing is causing feeding difficulties or stagnation in 
growth occurs. Still, it remains important to continue oral feeding to avoid feeding difficulties 
and oral aversion.85 
Another frequent source of feeding difficulties is the presence of GERD, which occurs 
frequently in CDH patients.86-89 Therefore in the Erasmus MC-Sophia Children’s Hospital, all 
neonates with CDH are treated with antireflux medication until evaluation of GERD has 
been performed. In chapter 8, 53 (38%) patients were diagnosed with GERD using 24-hour 
pH-metry at the median age of 3 months and 20 (12%) patients underwent a Nissen fun-
doplication at the median age of 8 months. Additionally in chapter 5, 42% of CDH patients 
required treatment for GERD. Previous studies have also reported a high prevalence rate 
of gastroesophageal reflux, affecting up to 83% of CDH patients at 6 months of age.90 It is 
difficult to compare the prevalence rates of GERD in the CDH population due to different 
definitions, different diagnostic methods used in studies including pH monitoring, upper gas-
trointestinal contrast studies or clinical diagnosis of GERD, as well as thresholds for initiating 
treatment. As GERD can contribute to growth failure in CDH patients, this should always 
be considered in CDH patients with feeding and/or growth problems. If present, it should 
be optimally treated using antireflux medication as a first step.
To unravel possible causes of poor growth, we performed indirect calorimetry measure-
ments and nutritional assessments in a subgroup of 11 CDH patients with growth failure. 
Four (36%) of them had an increased energy expenditure, which suggests that increased 
energy expenditure plays a role in growth failure. Haliburton et al.89 even found that 10 
(59%) of 17 patients were hypermetabolic at the median age of 32 days. We assume that 
resting energy expenditure of CDH patients is higher in the first 2 years of life due to an 
increased rate of breathing after correction of the defect. Seven (64%) of the 11 patients 
with growth failure also had a disturbed eating pattern.  Therefore, we think that both an 
increased resting energy expenditure and feeding difficulties were involved in growth failure. 
However, as these problems were not universal in patients with growth failure, the causes for 
poor growth in CDH patients are probably multifactorial also including the severity of illness 
during the neonatal period and presence of GERD. Limitations of the indirect calorimetry 




only one time-point, and the absence of activity energy expenditure measurements. Future 
studies should perform longitudinal resting and activity energy expenditure measurements in 
a large group of CDH patients, which can help in understanding the causes of growth failure.
Poor growth may negatively affect neurodevelopmental outcomes. Previous studies in 
premature infants91 and CDH patients92 have found that growth during infancy was nega-
tively associated with neurodevelopmental outcomes later in life. The exact relation between 
poor growth and neurodevelopmental outcome in premature infants remains controversial, 
however, as many studies have not taken into account the severity of illness.91 Additionally, 
no nutritional intervention trial that aimed to increase postnatal growth in premature infants 
has reported a long-term benefit of faster growth on neurodevelopmental outcome,91 
and a more recent study in children with extremely low birth weight showed no effect of 
catch-up-growth in the first 2 years of life on neurocognitive outcome at 11 years of age.93 
Although neuropsychological outcomes were not available for the patients included in our 
longitudinal growth study (chapter 8), we determined the association between growth at 1 
year and neuropsychological outcome at school age in chapter 7. Only weight-for-height at 
1 year of age was positively associated with IQ. In the multivariable analyses, however, only 
the maximum vasoactive-inotropic score (VIS), which is a measure of the dose of vasoactive 
medication needed and therefore also of the severity of illness, remained associated with 
verbal and visuospatial memory. These results suggest that the severity of neonatal illness 
has a greater impact on neurodevelopmental outcome than growth in the first year of life. 
Neuropsychological outcome
In chapters 6 and 7, we found that neurodevelopmental and neuropsychological outcomes 
were impaired in a high number of CDH patients, and these problems varied with age. In 
line with the findings of Gischler et al.78 and Danzer et al.,94 gross motor skills were below 
average at one year of age (chapter 6). This is possibly the consequence of prolonged 
hospitalization with little physical activity and therefore fewer opportunities to obtain early 
gross motor skills in the first year of life. At 3 years of age, gross motor skills were normal 
in all patients indicating that CDH patients with delays in gross motor skills catch-up with 
their peers after the first year of life. However at 3 years of age, 27% of CDH patients 
experienced a mild delay on the expressive or receptive language scale. It is possible that 
subtle neurocognitive problems will become more evident with age, and therefore are only 
diagnosed at a later age. Similarly, previous studies found neuropsychological problems in 
the areas of attention and concentration in CDH and neonatal ECMO patients at 8 years of 
age, despite a normal IQ,27, 28, 95 which is referred to as a growing-into-deficit phenomenon. 
To increase our understanding about the neuropsychological domains that are affected on 
the long-term, we performed extended neuropsychological assessments in eight-year-old 
CDH and neonatal ECMO patients. Further, we determined clinical factors that were asso-
ciated with specific neuropsychological functions. In line with previous findings of our study 
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group,27, 28, 95 we found that intelligence fell within the normal range at 8 years of age, except 
in CDH patients treated with neonatal ECMO (chapter 7). Further, sustained attention, verbal 
memory (immediate and delayed recall) and visuospatial memory (immediate and delayed 
recall as well as recognition) were below average compared to the general population. As 
these deficits in memory function can have a profound effect on everyday life and academic 
achievement,50, 96 we think it is important to continue follow-up of neuropsychological out-
come and academic achievement of CDH patients into adulthood.     
Neuropsychological outcome at 8 years of age was associated with the severity of neona-
tal illness indicated by the need for ECMO, treatment with veno-arterial ECMO, maximum 
VIS, ventilator-free days in the first 28 days of life, and duration of initial hospital stay. In the 
multivariable model, the maximum VIS remained the only predictor of delayed verbal and 
visuospatial memory scores. As mentioned above, brain areas susceptible for hypoxic-isch-
emic and reperfusion injury, such as the hippocampus and other limbic system regions, 
are altered following critical illness in early life and these areas are specifically related to 
impaired memory and attention.49-54 Although our study does not show a causative effect 
of vasoactive medication on memory problems, the requirement of high levels of vasoactive 
medication in the first period of life could be an indirect marker of (regional) inadequate 
brain perfusion resulting in memory problems later in life. As monitor devices and clinical 
predictors for regional cerebral perfusion and oxygenation are not yet available for clinical 
use, the maximum VIS could be a useful component in estimating severity of illness and 
risk of memory problems in CDH and neonatal ECMO survivors at school age. Although 
the maximum VIS is a measure of pharmacologic cardiovascular support and therefore can 
be easily influenced by the treating physician, the VIS has already been validated to predict 
clinical outcomes in infants who require cardiac surgery.97, 98 Future studies are needed to 
validate this score in other survivors of critical illness. We acknowledge that prediction of 
neuropsychological outcome after neonatal critical illness will remain challenging because 
multiple factors are involved in neuropsychological development (figure 2). These include 
medical factors such as severity of neonatal illness and treatment effects,27, 28, 99, 100 as well 
as non-medical factors such as parental education,95, 99-102 parental income,100, 102-104 parental 
care,102, 103, 105, 106 cognitive stimulation,102, 105 stressful life events,103 and neighborhood.106 Ideally, 
all these factors are taken into account when predicting neuropsychological outcome in 
survivors of neonatal critical illness.
In addition to identification of predictors, it is important to design interventions to improve 
neuropsychological outcomes. Over the past years, there has been a growing interest in 
cognitive training programs that improve neuropsychological outcomes. However, only a 
few studies have assessed the effectiveness of these cognitive training programs in children. 
A working memory training program that has been studied most frequently is Cogmed,107 
which is a computerized training program designed to improve working memory by effec-




com). Its effectiveness is disputed, however, Klingberg et al.108 found that Cogmed training had 
improved visuospatial and working memory in children with attention deficit hyperactivity 
disorder (ADHD) at 3 months follow-up. Nevertheless, a more recent study did not confirm 
improvements on neurocognitive tasks in ADHD children after Cogmed training.109 Studies in 
very low birth weight preschoolers found positive effects of Cogmed on working memory, 
visual learning and verbal learning 4 weeks110 and 7 months111 after training. Furthermore, in 
ex-premature adolescents, Cogmed also improved verbal and visuospatial working memory 
immediately after training and at 6 months follow-up.112 However, the authors of a recent 
meta-analytic review concluded that working memory training programs appear to produce 
short-term, specific training effects that do not generalize to measures of ‘real world’ cognitive 
skills.113 Currently, the effectiveness of Cogmed is assessed in a randomized controlled trial of 
school aged survivors of neonatal ECMO and CDH (trial registration number: NTR4571). 
To prevent neuropsychological problems in the future, it is important to identify the 
pathophysiological mechanism underlying neuropsychological problems in survivors of neo-
natal critical illness. Advanced neuroimaging techniques such as diffusion tensor imaging may 
increase our understanding of pathophysiological concepts of early brain development and 
injury. Therefore, studies using standardized advanced neuroimaging both at neonatal age 
and school age should be carried out. Furthermore, noninvasive neuromonitor devices that 
can monitor regional cerebral perfusion and oxygenation in vulnerable brain areas such as 
the hippocampus should be developed. Monitoring can result in early signaling of perfusion 
and oxygenation problems and thus enable early start and guidance of management, which 
can hopefully prevent adverse outcomes in the future. However, in addition to ischemia, the 
hippocampus is vulnerable for many other conditions such as neuroinflammation and chronic 
stress,70 and therefore it might be hard to prevent hippocampal injury at all. 
Figure 2. Multiple factors play a role in determining neuropsychological outcome of patients with 
congenital diaphragmatic hernia
Severity of neonatal illness
Neuropsychological
 outcome
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In this thesis we focused on non-respiratory morbidities in CDH patients. We found that all 
ECMO-treated neonates recovered from NTIS after critical illness. Pulmonary hypertension 
only persisted in a small subgroup of CDH patients with the greatest severity of illness. 
Therefore, NTIS and pulmonary hypertension appear to be mainly short-term problems. In 
contrast, we found persistent problems in the areas of physical growth and neuropsycho-
logical outcome at school age. Continuing longitudinal long-term follow-up could make clear 
whether these problems persist during adolescence and adulthood.
We found multiple determinants of outcomes including the need for ECMO treatment, 
the duration of mechanical ventilation, duration of PICU and initial hospital stay, and severity 
of illness scores such as the PELOD-2 score and the maximum VIS. These variables are all 
related to the severity of illness in the neonatal period, which suggests that this in itself is an 
important predictor of outcome in CDH patients. The building of a prediction model in our 
studies was hampered by the relatively small sample sizes, which is a common problem in 
follow-up studies including patients with rare diagnoses. Multicenter research could ensure 
sufficient patient enrollment to reach adequate statistical power in future studies. This will 
give opportunities to develop prediction models and improve patient care.
Multicenter research can be implemented by collaborations between multiple CDH 
treatment centers such as those collaborating within the CDH EURO Consortium. The 
CDH EURO Consortium is a collaboration between 22 tertiary European centers with 
an expertise in the treatment of CDH. In November 2007, the CDH EURO Consortium 
issued a protocol for standardized postnatal management of CDH patients.114  Thereafter, 
the VICI-trial was the first randomized controlled trial in which these centers participated.115 
This trial has resulted in an update of the standardized postnatal management protocol.66 
It would be valuable to extend this agreement of compliance with standardized postnatal 
management to new long-term follow-up studies and further standardization of the long-
term follow-up care of CDH patients. In these new long-term follow-up studies, the use 
of standardized clinical assessment and management plans (SCAMPs) would be valuable. 
A SCAMP is a dynamic clinical care algorithm designed to eliminate unnecessary resource 
utilization, decrease practice variation and improve patient outcomes, which undergoes 
iterative updates based on periodic data collection and review.116, 117 SCAMPs have been 
found successful in pediatric cardiology,118, 119 and we assume that they can also be beneficial 
in the care for CDH patients. The use of SCAMPs in the follow-up care of CDH patients is 
currently being implemented within the CDH Euro Consortium. In order to collaborate in 
long-term follow-up research and care, several aspects are important: standardization of data 
collection and data storage, availability of a good research infrastructure in the collaborating 
centers, the use of standardized definitions, standardized assessments, and standardized 




Another interesting research area is the development of intervention strategies that could 
lead to better outcomes. Intervention-based studies should be established for the different 
organ systems in which problems occur. Possible topics are the effectiveness of drugs for 
the treatment of pulmonary hypertension, the effectiveness of early nutritional interven-
tions to improve physical growth, and the use of attention and memory training programs 
for neuropsychological outcomes. These intervention strategies should be investigated in 
well-powered randomized controlled trials. 
Additionally, future studies should focus on identifying the pathophysiology behind adverse 
outcomes. This will help develop effective intervention strategies to improve outcomes, and 
hopefully in the future may prevent adverse outcomes. It has become apparent that adverse 
neuropsychological outcomes following neonatal critical illness are not limited to the group 
of CDH patients, as attention and memory problems have also been found in other groups 
of critically ill neonates such as ECMO-treated neonates,28, 95, 121 premature neonates122, 123 
and neonates with congenital heart disease.124-126 This suggests the existence of a common 
pathophysiologic mechanism underlying these neuropsychological problems. Inclusion of 
other groups of neonatal critical illness survivors in follow-up studies using advanced neu-
romonitoring and neuroimaging techniques could make clear whether there is a common 




The studies in this thesis show that CDH is a complex condition, which not only affects the 
respiratory system. On the short-term, we found a high incidence of NTIS in the first week 
of life, with normalization of thyroid function after the period of critical illness. Pulmonary 
hypertension on the first day of hospital admission was common, but the risk of persistent 
pulmonary hypertension during the first year of life was low. On the long-term, we found 
impaired physical growth and neuropsychological problems in the areas of sustained atten-
tion, verbal and visuospatial memory at school age. These findings illustrate the need for 
long-term follow-up care for CDH patients, and continuing follow-up of these CDH through 
adolescence and adulthood. All outcomes were associated with variables related to the 
severity of neonatal illness. Therefore, it seems that the severity of illness in the neonatal 
period is the most important factor in determining outcomes of CDH patients. In the future, 
multicenter research using standardized treatment and outcome measures can lead to the 
development of multivariable prediction models.  Additionally, multicenter collaborations 
with the use of SCAMPs may yield clues to improve the long-term follow-up care for CDH 
patients. Development of intervention strategies as well as identification of the underlying 
cause of adverse outcomes is also important to improve patient outcomes. Furthermore, it 
would be interesting to combine CDH patients with other groups of critically ill neonates in 
future follow-up studies to examine whether a common pathophysiologic mechanism exists 
that leads to similar outcomes of these patients.
Future research directions
-To investigate and improve long-term follow-up care for CDH patients, SCAMPs should be 
used in a large, multicenter cohort.
-To improve the prediction of adverse outcomes, multicenter studies should be instituted to 
design a multivariable prediction model, which can enable early risk stratification.
-To improve patient outcomes, intervention strategies, such as memory training programs, 
should be designed and investigated.
-To increase our understanding and possibly prevent adverse outcomes in the future, studies 






1. Brindle ME, Cook EF, Tibboel D, Lally PA, Lally KP, Congenital Diaphragmatic Hernia Study G. A clin-
ical prediction rule for the severity of congenital diaphragmatic hernias in newborns. Pediatrics. 
2014;134:e413-419.
2. van den Hout L, Schaible T, Cohen-Overbeek TE, Hop W, Siemer J, van de Ven K, et al. Actual outcome 
in infants with congenital diaphragmatic hernia: the role of a standardized postnatal treatment protocol. 
Fetal Diagn Ther. 2011;29:55-63.
3. Putnam LR, Harting MT, Tsao K, Morini F, Yoder BA, Luco M, et al. Congenital Diaphragmatic Hernia Defect 
Size and Infant Morbidity at Discharge. Pediatrics. 2016;138: pii: e20162043.
4. American Academy of Pediatrics Section on S, American Academy of Pediatrics Committee on F, New-
born, Lally KP, Engle W. Postdischarge follow-up of infants with congenital diaphragmatic hernia. Pediatrics. 
2008;121:627-632.
5. Watson RS, Hartman ME. Epidemiology of critical illness. In: Wheeler DS, Whong HR, Shanley TP, editors. 
Pediatric Critical Care Medicine. London: Springer ; 2014. p. 125-131.
6. Boonen E, Van den Berghe G. Endocrine responses to critical illness: novel insights and therapeutic impli-
cations. J Clin Endocrinol Metab. 2014;99:1569-1582.
7. Cuesta JM, Singer M. The stress response and critical illness: a review. Crit Care Med. 2012;40:3283-3289.
8. Van den Berghe G. Non-thyroidal illness in the ICU: a syndrome with different faces. Thyroid. 2014;24:1456-
1465.
9. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. Lancet Diabetes 
Endocrinol. 2015;3:816-825.
10. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflamma-
tion and infection. Endocr Rev. 2011;32:670-693.
11. Stewart DL, Ssemakula N, MacMillan DR, Goldsmith LJ, Cook LN. Thyroid function in neonates with severe 
respiratory failure on extracorporeal membrane oxygenation. Perfusion. 2001;16:469-475.
12. Kurt A, Aygun AD, Sengul I, Sen Y, Citak Kurt AN, Ustundag B. Serum thyroid hormones levels are signifi-
cantly decreased in septic neonates with poor outcome. J Endocrinol Invest. 2011;34:e92-96.
13. Goldsmit GS, Valdes M, Herzovich V, Rodriguez S, Chaler E, Golombek SG, et al. Evaluation and clinical 
application of changes in thyroid hormone and TSH levels in critically ill full-term newborns. J Perinat 
Med. 2011;39:59-64.
14. Lim DJ, Herring MK, Leef KH, Getchell J, Bartoshesky LE, Paul DA. Hypothyroxinemia in mechanically 
ventilated term infants is associated with increased use of rescue therapies. Pediatrics. 2005;115:406-410.
15. Kempers MJ, Lanting CI, van Heijst AF, van Trotsenburg AS, Wiedijk BM, de Vijlder JJ, et al. Neonatal 
screening for congenital hypothyroidism based on thyroxine, thyrotropin, and thyroxine-binding globulin 
measurement: potentials and pitfalls. J Clin Endocrinol Metab. 2006;91:3370-3376.
16. Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med. 1995;333:1688-1694.
17. Leger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, et al. European Society for Paediatric 
Endocrinology Consensus guidelines on screening, diagnosis, and management of congenital hypothy-
roidism. J Clin Endocrinol Metab. 2014;99:363-384.
18. Agus MS, Jaksic T. Critically low hormone and catecholamine concentrations in the primed extracorporeal 
life support circuit. Asaio J. 2004;50:65-67.
19. Fortenberry JD, Bhardwaj V, Niemer P, Cornish JD, Wright JA, Bland L. Neutrophil and cytokine activation 
with neonatal extracorporeal membrane oxygenation. J Pediatr. 1996;128:670-678.
20. Kozik DJ, Tweddell JS. Characterizing the inflammatory response to cardiopulmonary bypass in children. 
Ann Thorac Surg. 2006;81:S2347-2354.
Chapter 9
170
21. Seghaye MC, Grabitz RG, Duchateau J, Busse S, Dabritz S, Koch D, et al. Inflammatory reaction and capillary 
leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations. J Thorac 
Cardiovasc Surg. 1996;112:687-697.
22. Murzi B, Iervasi G, Masini S, Moschetti R, Vanini V, Zucchelli G, et al. Thyroid hormones homeostasis in 
pediatric patients during and after cardiopulmonary bypass. Ann Thorac Surg. 1995;59:481-485.
23. Hamblin PS, Dyer SA, Mohr VS, Le Grand BA, Lim CF, Tuxen DV, et al. Relationship between thyrotropin 
and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. J Clin Endocrinol 
Metab. 1986;62:717-722.
24. Van den Berghe G, de Zegher F, Lauwers P. Dopamine suppresses pituitary function in infants and children. 
Crit Care Med. 1994;22:1747-1753.
25. Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F, et al. PELOD-2: an update of the 
PEdiatric logistic organ dysfunction score. Crit Care Med. 2013;41:1761-1773.
26. Leteurtre S, Duhamel A, Deken V, Lacroix J, Leclerc F, Groupe Francophone de Reanimation et Urgences 
P. Daily estimation of the severity of organ dysfunctions in critically ill children by using the PELOD-2 
score. Crit Care. 2015;19:324.
27. Madderom MJ, Toussaint L, van der Cammen-van Zijp MH, Gischler SJ, Wijnen RM, Tibboel D, et al. Con-
genital diaphragmatic hernia with(out) ECMO: impaired development at 8 years. Arch Dis Child Fetal 
Neonatal Ed. 2013;98:F316-322.
28. Madderom MJ, Reuser JJ, Utens EM, van Rosmalen J, Raets M, Govaert P, et al. Neurodevelopmental, 
educational and behavioral outcome at 8 years after neonatal ECMO: a nationwide multicenter study. 
Intensive Care Med. 2013;39:1584-1593.
29. Oppenheimer JH, Schwartz HL. Molecular basis of thyroid hormone-dependent brain development. 
Endocr Rev. 1997;18:462-475.
30. Zoeller RT, Rovet J. Timing of thyroid hormone action in the developing brain: clinical observations and 
experimental findings. J Neuroendocrinol. 2004;16:809-818.
31. Narayanan CH, Narayanan Y. Cell formation in the motor nucleus and mesencephalic nucleus of the 
trigeminal nerve of rats made hypothyroid by propylthiouracil. Exp Brain Res. 1985;59:257-266.
32. Lucio RA, Garcia JV, Ramon Cerezo J, Pacheco P, Innocenti GM, Berbel P. The development of auditory 
callosal connections in normal and hypothyroid rats. Cereb Cortex. 1997;7:303-316.
33. Cuevas E, Auso E, Telefont M, Morreale de Escobar G, Sotelo C, Berbel P. Transient maternal hypothy-
roxinemia at onset of corticogenesis alters tangential migration of medial ganglionic eminence-derived 
neurons. Eur J Neurosci. 2005;22:541-551.
34. Auso E, Lavado-Autric R, Cuevas E, Del Rey FE, Morreale De Escobar G, Berbel P. A moderate and tran-
sient deficiency of maternal thyroid function at the beginning of fetal neocorticogenesis alters neuronal 
migration. Endocrinology. 2004;145:4037-4047.
35. Williams GR. Neurodevelopmental and neurophysiological actions of thyroid hormone. J Neuroendocrinol. 
2008;20:784-794.
36. de Escobar GM, Obregon MJ, del Rey FE. Maternal thyroid hormones early in pregnancy and fetal brain 
development. Best Pract Res Clin Endocrinol Metab. 2004;18:225-248.
37. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Role of thyroid hormone during early brain 
development. Eur J Endocrinol. 2004;151:U25-37.
38. Obregon MJ, Calvo RM, Del Rey FE, de Escobar GM. Ontogenesis of thyroid function and interactions 
with maternal function. Endocr Dev. 2007;10:86-98.
39. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Is neuropsychological development related to 
maternal hypothyroidism or to maternal hypothyroxinemia? J Clin Endocrinol Metab. 2000;85:3975-3987.
40. Bernal J, Guadano-Ferraz A, Morte B. Perspectives in the study of thyroid hormone action on brain 




41. Porterfield SP, Hendrich CE. The role of thyroid hormones in prenatal and neonatal neurological devel-
opment--current perspectives. Endocr Rev. 1993;14:94-106.
42. Ghassabian A, El Marroun H, Peeters RP, Jaddoe VW, Hofman A, Verhulst FC, et al. Downstream effects 
of maternal hypothyroxinemia in early pregnancy: nonverbal IQ and brain morphology in school age 
children. J Clin Endocrinol Metab. 2014;99:2383-2390.
43. Korevaar TI, Muetzel R, Medici M, Chaker L, Jaddoe VW, de Rijke YB, et al. Association of maternal thyroid 
function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based 
prospective cohort study. Lancet Diabetes Endocrinol. 2016;4:35-43.
44. Fisher DA. Thyroid system immaturities in very low birth weight premature infants. Semin Perinatol. 
2008;32:387-397.
45. Meijer WJ, Verloove-Vanhorick SP, Brand R, van den Brande JL. Transient hypothyroxinaemia associated 
with developmental delay in very preterm infants. Arch Dis Child. 1992;67:944-947.
46. Delahunty C, Falconer S, Hume R, Jackson L, Midgley P, Mirfield M, et al. Levels of neonatal thyroid hor-
mone in preterm infants and neurodevelopmental outcome at 5 1/2 years: millennium cohort study. J 
Clin Endocrinol Metab. 2010;95:4898-4908.
47. Hollanders JJ, Israels J, van der Pal SM, Verkerk PH, Rotteveel J, Finken MJ, et al. No association between 
transient hypothyroxinaemia of prematurity and neurodevelopmental outcome in young adulthood. J 
Clin Endocrinol Metab. 2015;100:4648-4653.
48. Scratch SE, Hunt RW, Thompson DK, Ahmadzai ZM, Doyle LW, Inder TE, et al. Free thyroxine levels after 
very preterm birth and neurodevelopmental outcomes at age 7 years. Pediatrics. 2014;133:e955-963.
49. Schiller RM, van den Bosch GE, Muetzel RL, Smits M, Dudink J, Tibboel D, et al. Neonatal critical illness 
and development: white matter and hippocampus alterations in school age neonatal extracorporeal 
membrane oxygenation survivors. Dev Med Child Neurol. 2017;59:304-310.
50. Nosarti C, Froudist-Walsh S. Alterations in development of hippocampal and cortical memory mecha-
nisms following very preterm birth. Dev Med Child Neurol. 2016;58:35-45.
51. Thompson DK, Adamson C, Roberts G, Faggian N, Wood SJ, Warfield SK, et al. Hippocampal shape vari-
ations at term equivalent age in very preterm infants compared with term controls: perinatal predictors 
and functional significance at age 7. Neuroimage. 2013;70:278-287.
52. Cooper JM, Gadian DG, Jentschke S, Goldman A, Munoz M, Pitts G, et al. Neonatal hypoxia, hippocampal 
atrophy, and memory impairment: evidence of a causal sequence. Cereb Cortex. 2015;25:1469-1476.
53. Munoz-Lopez M, Hoskote A, Chadwick MJ, Dzieciol AM, Gadian DG, Chong K, et al. Hippocampal damage 
and memory impairment in congenital cyanotic heart disease. Hippocampus. 2017;27:417-424.
54. Schiller RM, H IJ, Madderom MJ, Rietman AB, Smits M, van Heijst AFJ, et al. Neurobiologic Correlates of 
Attention and Memory Deficits Following Critical Illness in Early Life. Crit Care Med. 2017: doi: 10.1097/
CCM.0000000000002553.
55. Willoughby KA, McAndrews MP, Rovet JF. Effects of maternal hypothyroidism on offspring hippocampus 
and memory. Thyroid. 2014;24:576-584.
56. Willoughby KA, McAndrews MP, Rovet JF. Accuracy of episodic autobiographical memory in children with 
early thyroid hormone deficiency using a staged event. Dev Cogn Neurosci. 2014;9:1-11.
57. Wheeler SM, Willoughby KA, McAndrews MP, Rovet JF. Hippocampal size and memory functioning in 
children and adolescents with congenital hypothyroidism. J Clin Endocrinol Metab. 2011;96:E1427-1434.
58. Zimmermann MB. The role of iodine in human growth and development. Semin Cell Dev Biol. 2011;22:645-
652.
59. Dillon PW, Cilley RE, Mauger D, Zachary C, Meier A. The relationship of pulmonary artery pressure and 
survival in congenital diaphragmatic hernia. J Pediatr Surg. 2004;39:307-312; discussion 307-312.
60. Lusk LA, Wai KC, Moon-Grady AJ, Steurer MA, Keller RL. Persistence of pulmonary hypertension 




61. Wynn J, Krishnan U, Aspelund G, Zhang Y, Duong J, Stolar CJ, et al. Outcomes of congenital diaphragmatic 
hernia in the modern era of management. J Pediatr. 2013;163:114-119.e1.
62. Thebaud B, Mercier JC, Dinh-Xuan AT. Congenital diaphragmatic hernia. A cause of persistent pulmonary 
hypertension of the newborn which lacks an effective therapy. Biol Neonate. 1998;74:323-336.
63. Valfre L, Braguglia A, Conforti A, Morini F, Trucchi A, Iacobelli BD, et al. Pulmonary hypertension in neo-
nates with high-risk congenital diaphragmatic hernia does not affect mid-term outcome. Eur J Pediatr 
Surg. 2011;21:154-158.
64. Egan MJ, Husain N, Stines JR, Moiduddin N, Stein MA, Nelin LD, et al. Mid-term differences in right 
ventricular function in patients with congenital diaphragmatic hernia compared with controls. World J 
Pediatr. 2012;8:350-354.
65. Datta J, Phillips SE, Yang EY. Association of high ventilator pressures with the development of chronic 
pulmonary hypertension in congenital diaphragmatic hernia patients requiring ECMO. Pediatr Surg Int. 
2012;28:977-982.
66. Snoek KG, Reiss IK, Greenough A, Capolupo I, Urlesberger B, Wessel L, et al. Standardized Postnatal 
Management of Infants with Congenital Diaphragmatic Hernia in Europe: The CDH EURO Consortium 
Consensus - 2015 Update. Neonatology. 2016;110:66-74.
67. Kitagawa M, Hislop A, Boyden EA, Reid L. Lung hypoplasia in congenital diaphragmatic hernia. A quantitative 
study of airway, artery, and alveolar development. Br J Surg. 1971;58:342-346.
68. Hislop A, Reid L. Persistent hypoplasia of the lung after repair of congenital diaphragmatic hernia. Thorax. 
1976;31:450-455.
69. Back SA, Riddle A, McClure MM. Maturation-dependent vulnerability of perinatal white matter in prema-
ture birth. Stroke. 2007;38:724-730.
70. Bartsch T, Wulff P. The hippocampus in aging and disease: From plasticity to vulnerability. Neuroscience. 
2015;309:1-16.
71. Terui K, Nagata K, Hayakawa M, Okuyama H, Goishi K, Yokoi A, et al. Growth Assessment and the Risk 
of Growth Retardation in Congenital Diaphragmatic Hernia: A Long-Term Follow-Up Study from the 
Japanese Congenital Diaphragmatic Hernia Study Group. Eur J Pediatr Surg. 2016;26:60-66.
72. Bairdain S, Khan FA, Fisher J, Zurakowski D, Ariagno K, Cauley RP, et al. Nutritional outcomes in survivors 
of congenital diaphragmatic hernia (CDH)-factors associated with growth at one year. J Pediatr Surg. 
2015;50:74-77.
73. Cortes RA, Keller RL, Townsend T, Harrison MR, Farmer DL, Lee H, et al. Survival of severe congenital 
diaphragmatic hernia has morbid consequences. J Pediatr Surg. 2005;40:36-45; discussion 45-36.
74. Muratore CS, Utter S, Jaksic T, Lund DP, Wilson JM. Nutritional morbidity in survivors of congenital dia-
phragmatic hernia. J Pediatr Surg. 2001;36:1171-1176.
75. Preece MA. The genetic contribution to stature. Horm Res. 1996;45 Suppl 2:56-58.
76. Embleton ND, Korada M, Wood CL, Pearce MS, Swamy R, Cheetham TD. Catch-up growth and metabolic 
outcomes in adolescents born preterm. Arch Dis Child. 2016;101:1026-1031.
77. Kerkhof GF, Willemsen RH, Leunissen RW, Breukhoven PE, Hokken-Koelega AC. Health profile of 
young adults born preterm: negative effects of rapid weight gain in early life. J Clin Endocrinol Metab. 
2012;97:4498-4506.
78. Gischler SJ, van der Cammen-van Zijp MH, Mazer P, Madern GC, Bax NM, de Jongste JC, et al. A pro-
spective comparative evaluation of persistent respiratory morbidity in esophageal atresia and congenital 
diaphragmatic hernia survivors. J Pediatr Surg. 2009;44:1683-1690.
79. Vu LT, McFarland C, Bratton B, Lee H. Closer Look at the Nutritional Outcomes of Patients After Primary 
Repair of Congenital Diaphragmatic Hernia. J Pediatr Gastroenterol Nutr. 2017;65:237-241.
80. Schopper MA, Walkup LL, Tkach JA, Higano NS, Lim FY, Haberman B, et al. Evaluation of Neonatal Lung 
Volume Growth by Pulmonary Magnetic Resonance Imaging in Patients with Congenital Diaphragmatic 




81. Section on B. Breastfeeding and the use of human milk. Pediatrics. 2012;129:e827-841.
82. Gooding JS, Cooper LG, Blaine AI, Franck LS, Howse JL, Berns SD. Family support and family-centered care 
in the neonatal intensive care unit: origins, advances, impact. Semin Perinatol. 2011;35:20-28.
83. Conde-Agudelo A, Diaz-Rossello JL. Kangaroo mother care to reduce morbidity and mortality in low 
birth weight infants. Cochrane Database Syst Rev. 2016:CD002771.
84. Moore ER, Bergman N, Anderson GC, Medley N. Early skin-to-skin contact for mothers and their healthy 
newborn infants. Cochrane Database Syst Rev. 2016;11:CD003519.
85. Mason SJ, Harris G, Blissett J. Tube feeding in infancy: implications for the development of normal eating 
and drinking skills. Dysphagia. 2005;20:46-61.
86. Van Meurs KP, Robbins ST, Reed VL, Karr SS, Wagner AE, Glass P, et al. Congenital diaphragmatic 
hernia: long-term outcome in neonates treated with extracorporeal membrane oxygenation. J Pediatr. 
1993;122:893-899.
87. Chiu PP, Sauer C, Mihailovic A, Adatia I, Bohn D, Coates AL, et al. The price of success in the management 
of congenital diaphragmatic hernia: is improved survival accompanied by an increase in long-term mor-
bidity? J Pediatr Surg. 2006;41:888-892.
88. Peetsold MG, Kneepkens CM, Heij HA, H IJ, Tibboel D, Gemke RJ. Congenital diaphragmatic hernia: long-
term risk of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2010;51:448-453.
89. Haliburton B, Chiang M, Marcon M, Moraes TJ, Chiu PP, Mouzaki M. Nutritional Intake, Energy Expenditure, 
and Growth of Infants Following Congenital Diaphragmatic Hernia Repair. J Pediatr Gastroenterol Nutr. 
2016;62:474-478.
90. Caruso AM, Di Pace MR, Catalano P, Farina F, Casuccio A, Cimador M, et al. Gastroesophageal reflux in 
patients treated for congenital diaphragmatic hernia: short- and long-term evaluation with multichannel 
intraluminal impedance. Pediatr Surg Int. 2013;29:553-559.
91. Ong KK, Kennedy K, Castaneda-Gutierrez E, Forsyth S, Godfrey KM, Koletzko B, et al. Postnatal growth 
in preterm infants and later health outcomes: a systematic review. Acta Paediatr. 2015;104:974-986.
92. Danzer E, Gerdes M, D’Agostino JA, Partridge EA, Hoffman-Craven CH, Bernbaum J, et al. Preschool 
neurological assessment in congenital diaphragmatic hernia survivors: outcome and perinatal factors 
associated with neurodevelopmental impairment. Early Hum Dev. 2013;89:393-400.
93. Raaijmakers A, Jacobs L, Rayyan M, van Tienoven TP, Ortibus E, Levtchenko E, et al. Catch-up growth in 
the first two years of life in Extremely Low Birth Weight (ELBW) infants is associated with lower body 
fat in young adolescence. PLoS One. 2017;12:e0173349.
94. Danzer E, Gerdes M, D’Agostino JA, Hoffman C, Bernbaum J, Bebbington MW, et al. Longitudinal neuro-
developmental and neuromotor outcome in congenital diaphragmatic hernia patients in the first 3 years 
of life. J Perinatol. 2013;33:893-898.
95. Schiller RM, Madderom MJ, Reuser JJCM, Steiner K, Gischler SJ, Tibboel D, et al. Neuropsychological fol-
low-up after neonatal ECMO. Pediatrics. 2016;138: pii: e20161313.
96. Alloway TP, Alloway RG. Investigating the predictive roles of working memory and IQ in academic attain-
ment. J Exp Child Psychol. 2010;106:20-29.
97. Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-inotropic score as a 
predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 
2010;11:234-238.
98. Gaies MG, Jeffries HE, Niebler RA, Pasquali SK, Donohue JE, Yu S, et al. Vasoactive-inotropic score is 
associated with outcome after infant cardiac surgery: an analysis from the Pediatric Cardiac Critical Care 
Consortium and Virtual PICU System Registries. Pediatr Crit Care Med. 2014;15:529-537.
99. Mussatto KA, Hoffmann R, Hoffman G, Tweddell JS, Bear L, Cao Y, et al. Risk Factors for Abnormal Devel-
opmental Trajectories in Young Children With Congenital Heart Disease. Circulation. 2015;132:755-761.
100. Subedi D, DeBoer MD, Scharf RJ. Developmental trajectories in children with prolonged NICU stays. 
Arch Dis Child. 2017;102:29-34.
Chapter 9
174
101. Voss W, Jungmann T, Wachtendorf M, Neubauer AP. Long-term cognitive outcomes of extremely low-birth-
weight infants: the influence of the maternal educational background. Acta Paediatr. 2012;101:569-573.
102. Hackman DA, Farah MJ, Meaney MJ. Socioeconomic status and the brain: mechanistic insights from human 
and animal research. Nat Rev Neurosci. 2010;11:651-659.
103. Luby J, Belden A, Botteron K, Marrus N, Harms MP, Babb C, et al. The effects of poverty on childhood brain 
development: the mediating effect of caregiving and stressful life events. JAMA Pediatr. 2013;167:1135-
1142.
104. Hair NL, Hanson JL, Wolfe BL, Pollak SD. Association of Child Poverty, Brain Development, and Academic 
Achievement. JAMA Pediatr. 2015;169:822-829.
105. Wolke D, Jaekel J, Hall J, Baumann N. Effects of sensitive parenting on the academic resilience of very 
preterm and very low birth weight adolescents. J Adolesc Health. 2013;53:642-647.
106. Whittle S, Vijayakumar N, Simmons JG, Dennison M, Schwartz O, Pantelis C, et al. Role of Positive Par-
enting in the Association Between Neighborhood Social Disadvantage and Brain Development Across 
Adolescence. JAMA Psychiatry. 2017;74:824-832.
107. Klingberg T, Forssberg H, Westerberg H. Training of working memory in children with ADHD. J Clin Exp 
Neuropsychol. 2002;24:781-791.
108. Klingberg T, Fernell E, Olesen PJ, Johnson M, Gustafsson P, Dahlstrom K, et al. Computerized training of 
working memory in children with ADHD--a randomized, controlled trial. J Am Acad Child Adolesc Psy-
chiatry. 2005;44:177-186.
109. Gray SA, Chaban P, Martinussen R, Goldberg R, Gotlieb H, Kronitz R, et al. Effects of a computerized work-
ing memory training program on working memory, attention, and academics in adolescents with severe 
LD and comorbid ADHD: a randomized controlled trial. J Child Psychol Psychiatry. 2012;53:1277-1284.
110. Grunewaldt KH, Lohaugen GC, Austeng D, Brubakk AM, Skranes J. Working memory training improves 
cognitive function in VLBW preschoolers. Pediatrics. 2013;131:e747-754.
111. Grunewaldt KH, Skranes J, Brubakk AM, Lahaugen GC. Computerized working memory training has posi-
tive long-term effect in very low birth weight preschool children. Dev Med Child Neurol. 2016;58:195-201.
112. Lohaugen GC, Antonsen I, Haberg A, Gramstad A, Vik T, Brubakk AM, et al. Computerized working 
memory training improves function in adolescents born at extremely low birth weight. J Pediatr. 
2011;158:555-561 e554.
113. Melby-Lervag M, Redick TS, Hulme C. Working Memory Training Does Not Improve Performance on 
Measures of Intelligence or Other Measures of “Far Transfer”: Evidence From a Meta-Analytic Review. 
Perspect Psychol Sci. 2016;11:512-534.
114. Reiss I, Schaible T, van den Hout L, Capolupo I, Allegaert K, van Heijst A, et al. Standardized postnatal 
management of infants with congenital diaphragmatic hernia in Europe: the CDH EURO Consortium 
Consensus. Neonatology. 2010;98:354-364.
115. Snoek KG, Capolupo I, van Rosmalen J, Hout Lde J, Vijfhuize S, Greenough A, et al. Conventional Mechan-
ical Ventilation Versus High-frequency Oscillatory Ventilation for Congenital Diaphragmatic Hernia: A 
Randomized Clinical Trial (The VICI-trial). Ann Surg. 2016;263:867-874.
116. Farias M, Jenkins K, Lock J, Rathod R, Newburger J, Bates DW, et al. Standardized Clinical Assessment 
And Management Plans (SCAMPs) provide a better alternative to clinical practice guidelines. Health Aff 
(Millwood). 2013;32:911-920.
117. Farias M, Friedman KG, Lock JE, Rathod RH. Gathering and learning from relevant clinical data: a new 
framework. Acad Med. 2015;90:143-148.
118. Friedman KG, Kane DA, Rathod RH, Renaud A, Farias M, Geggel R, et al. Management of pediatric chest 
pain using a standardized assessment and management plan. Pediatrics. 2011;128:239-245.
119. Porras D, Brown DW, Rathod R, Friedman K, Gauvreau K, Lock JE, et al. Acute outcomes after introduction 
of a standardized clinical assessment and management plan (SCAMP) for balloon aortic valvuloplasty in 




120. Snoek KG, Capolupo I, Braguglia A, Aite L, van Rosmalen J, Valfre L, et al. Neurodevelopmental Outcome 
in High-Risk Congenital Diaphragmatic Hernia Patients: An Appeal for International Standardization. 
Neonatology. 2016;109:14-21.
121. Madderom MJ, Schiller RM, Gischler SJ, van Heijst AF, Tibboel D, Aarsen FK, et al. Growing Up After Crit-
ical Illness: Verbal, Visual-Spatial, and Working Memory Problems in Neonatal Extracorporeal Membrane 
Oxygenation Survivors. Crit Care Med. 2016;44:1182-1190.
122. Luu TM, Ment L, Allan W, Schneider K, Vohr BR. Executive and memory function in adolescents born very 
preterm. Pediatrics. 2011;127:e639-646.
123. Aarnoudse-Moens CS, Duivenvoorden HJ, Weisglas-Kuperus N, Van Goudoever JB, Oosterlaan J. The 
profile of executive function in very preterm children at 4 to 12 years. Dev Med Child Neurol. 2012;54:247-
253.
124. Schaefer C, von Rhein M, Knirsch W, Huber R, Natalucci G, Caflisch J, et al. Neurodevelopmental outcome, 
psychological adjustment, and quality of life in adolescents with congenital heart disease. Dev Med Child 
Neurol. 2013;55:1143-1149.
125. Gerstle M, Beebe DW, Drotar D, Cassedy A, Marino BS. Executive Functioning and School Performance 
among Pediatric Survivors of Complex Congenital Heart Disease. J Pediatr. 2016;173:154-159.
126. Sanz JH, Berl MM, Armour AC, Wang J, Cheng YI, Donofrio MT. Prevalence and pattern of executive 









Congenital diaphragmatic hernia (CDH) is a severe congenital anomaly of the diaphragm and 
both lungs, which occurs in approximately 1 per 2,500 births. Most CDH patients will have 
difficulty breathing directly after birth, and need immediate mechanical ventilatory support. 
Advanced postnatal treatment options with standardized treatment improved the survival 
outlook, even of CDH patients with most severe pulmonary hypoplasia and pulmonary 
hypertension. So far, previous studies have mainly focused on short-term and respiratory 
outcomes. Given the improved survival rate, it is important that research now also focuses on 
long-term outcomes including non-respiratory outcomes.  This thesis describes the postnatal 
risks and short- and long-term outcomes of CDH patients from neonatal age until school 
age. Early outcomes include the risk of disturbed thyroid hormone concentrations during 
the neonatal period and the risk of persistent pulmonary hypertension in the first year of 
life. Long-term outcomes include the risk of growth failure and neuropsychological problems 
until school age. Six studies were performed in the Sophia Children’s Hospital in Rotterdam, 
the Netherlands (chapters 2, 3, 4, 7, and 8), and two in the Westmead Children’s Hospital 
in Sydney, Australia (chapters 5 and 6). Both countries use a structured program for the 
long-term follow-up of CDH patients. 
Chapter 1
In chapter 1, we presented an overview of the current knowledge regarding postnatal 
management of CDH patients and the survivors’ risk of developing short- and long-term 
morbidities. We gave a short overview of the history of CDH with the introduction of new 
treatment options over the years. New treatment options include delayed surgical repair after 
stabilization, gentle ventilation with permissive hypercapnia, and the use of inhaled nitric oxide, 
high frequency oscillation ventilation and extracorporeal membrane oxygenation (ECMO) 
as rescue therapies. These advances in treatment options and standardized evidence-based 
management have increased survival rates, which makes it now important to investigate 
long-term outcomes of CDH survivors. 
Chapter 2
Chapter 2 described the results of a nationwide study among 168 ECMO-treated neonates 
screened by the newborn screening protocol.  Aberrant screening results for congenital 
hypothyroidism were found in 73% of the neonates screened before ECMO, in 67% screened 
during ECMO, and in 31% screened after ECMO.  Almost all (>98%) patients had a low total 
thyroxine concentration in combination with a low thyroid-stimulating hormone concen-
tration. These thyroid hormone concentrations normalized in all survivors after recovery of 
critical illness, and none of the survivors with an aberrant screening result was diagnosed 
with congenital hypothyroidism. Therefore, aberrant screening results for congenital hypothy-
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roidism in these neonates are likely due to non-thyroidal illness syndrome, which can occur 
during critical illness. Non-thyroidal illness syndrome is characterized by low thyroxine and 
low triiodothyronine concentrations, an increased reverse triiodothyronine concentration, 
and a normal or low thyroid-stimulating hormone concentration. Children screened before 
or during ECMO or those who had a higher Pediatric Logistic Organ Dysfunction-2 score 
(measure of severity of illness) had a higher risk of an aberrant screening result for congenital 
hypothyroidism. Mortality was not different between neonates with an aberrant screening 
result and neonates with a normal screening result.
Chapter 3
In chapter 3, we further investigated the disturbances in thyroid hormone concentrations 
occurring during neonatal ECMO.  Thyroid hormone concentrations were measured at 
six fixed time-points before, during, and after ECMO in 10 neonates with CDH and 11 
neonates with meconium aspiration syndrome. Before the start of ECMO, we found low 
concentrations of free thyroxine, total thyroxine, total triiodothyronine, and thyroid-stim-
ulating hormone, with a high concentration of reverse triiodothyronine, which pattern is 
suggestive of non-thyroidal illness syndrome. One hour after the start of ECMO, all thyroid 
hormone concentrations, except free thyroxine, significantly declined. After this initial decline, 
first thyroid-stimulating hormone increased followed by increases in total thyroxine and total 
triiodothyronine. These changes suggest that restoration of the hypothalamic-pituitary-thy-
roid axis occurs during neonatal ECMO. In contrast, the concentration of free thyroxine 
remained constant within the normal range during the entire ECMO course, which suggests 
that thyroxine therapy is not required during neonatal ECMO. At the follow-up examina-
tion at 2 years of age, cognitive outcomes of survivors did not differ from that of the norm 
population.
Chapter 4
In chapter 4, we assessed the usefulness of routine follow-up for pulmonary hypertension 
by echocardiography and electrocardiography in 52 CDH patient during the first year of 
life. At 6 months of age, persistent pulmonary hypertension was found in three of them. 
At 12 months of age, two had persistent pulmonary hypertension. Patients with persistent 
pulmonary hypertension had been ventilated and admitted to the hospital for longer than 
patients without persistent pulmonary hypertension, and had all been treated with inhaled 
nitric oxide, sildenafil and bosentan. This indicates that patients with persistent pulmonary 
hypertension are more severely ill during the neonatal period than those without per-
sistent pulmonary hypertension. Echocardiography was superior to electrocardiography in 
diagnosing pulmonary hypertension. Because over 90% of patients did not have persistent 
pulmonary hypertension at ages 6 and/or 12 months, we think follow-up for pulmonary 




nary hypertension at hospital discharge and those treated with medication for pulmonary 
hypertension at hospital discharge.
Chapter 5
Chapter 5 described the physical growth and the presence of feeding problems in 38 CDH 
patients during the first year of life. Low weight, height, and head circumference were found 
at 3 months of age, with weight being most affected. However, catch-up growth for weight, 
height and head circumference occurred from 3 to 12 months of age. Duration of mechanical 
ventilation was the only clinical variable predictive of failure to thrive at 6 months of age. No 
predictors for failure to thrive were found at 12 months of age. One fifth of the patients had 
feeding problems, which included: poor suck-swallowing reflex, immature oral skills, feeding diffi-
culties owing to increased work of breathing, oral aversion and gastroesophageal reflux disease.
Chapter 6
In chapter 6, we described the neurodevelopmental outcome of 18 CDH patients who were 
longitudinally assessed at 1 year and 3 years of age. Neurodevelopmental outcomes of CDH 
patients were compared with a healthy age- and gender-matched control group. At one year 
of age, gross motor skills were mildly delayed in one patient and severely delayed in three 
patients. At 3 years of age, expressive language scores were mildly delayed in three patients, 
and receptive language score was mildly delayed in one patient. All the other outcome scores 
were normal at 3 years of age. We found no difference in neurodevelopmental outcome 
between CDH patients and the control group at 1 year and 3 years of age.
Chapter 7
In chapter 7, we determined the neuropsychological outcome at 8 years of age in 40 patients 
with CDH (10 treated with neonatal ECMO) and 25 patients treated with neonatal ECMO 
following other diagnoses.  Additionally, we aimed to identify variables associated with neu-
ropsychological outcomes. We found specific impairments in the areas of sustained attention, 
verbal memory and visuospatial memory at 8 years of age in CDH and neonatal ECMO 
survivors, despite an overall average intelligence quotient (IQ). ECMO-treated CDH patients 
had the lowest IQ. We found that various severity of illness indicators were independently 
associated with neuropsychological outcome: treatment with ECMO, use of veno-arterial 
ECMO, a higher maximum vasoactive-inotropic score (maximum dose of vasoactive med-
ication required), a lower number of ventilator-free days in the neonatal period, and a 
longer duration of initial hospital stay.  Additionally, the number of anesthetic procedures 
and weight at 1 year of age were associated with neuropsychological outcome. However, 
only the maximum vasoactive-inotropic score remained negatively associated with delayed 
verbal and visuospatial memory when all contributing factors were taken into account in the 
multivariable model. This suggests that this measure of severity of illness, possibly indicating 
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(cerebral) hypoperfusion during early life, is related to specific memory problems at 8 years 
of age following CDH and/or neonatal ECMO.
Chapter 8
In chapter 8, we described the longitudinal physical growth of 172 CDH patients (43 treated 
with neonatal ECMO) until 12 years of age. Additionally, we wanted to find clinical variables 
associated with growth and unravel possible causes of growth failure. We found that weight gain 
declined from 6 months to 1 year of age, followed by a decline in linear growth until 5 years 
of age. This pattern of early deterioration of weight gain followed by a decline in linear growth 
is suggestive of inadequate nutrition during infancy. Overall, CDH patients treated with ECMO 
had a lower weight and height than CDH patients not treated with ECMO. At 12 years of age, 
height of CDH patients was still below the norm. Adjusting for target height improved height 
z-scores but not to normal. ECMO treatment, the need for patch repair and the duration of 
pediatric intensive care unit stay were negatively associated with height. ECMO treatment, the 
need for patch repair and the need for calorie-enriched feeds at follow-up were negatively 
associated with weight. Tube feeding at follow-up had a positive association with weight and 
height. We found an increased resting energy expenditure in four of the 11 patients with 
growth failure, and a disturbed eating pattern in seven of them. Therefore, both factors seem 
involved in growth failure. Our study results highlight the importance of early risk stratification 
in combination with nutritional assessments and interventions in preventing growth failure, as 
well as the importance of continuing long-term follow-up of growth.
Chapter 9
In chapter 9, we discussed the study results, put them into perspective, and made recommen-
dations for future research and patient care. The studies in this thesis showed that CDH is a 
complex condition that does not only affect the respiratory system. In the short-term, there 
is a high risk of non-thyroidal illness syndrome and pulmonary hypertension. In the long-term, 
we found impaired linear growth and neuropsychological problems in the areas of sustained 
attention, verbal and visuospatial memory at school age. These findings illustrate the need 
for long-term follow-up care for CDH patients, and continuing follow-up of these children 
throughout adolescence and adulthood. Outcomes were associated with variables related 
to the severity of neonatal illness. Therefore, it seems that the severity of neonatal illness 
is the most important factor in determining outcomes. The development of multivariable 
prediction models should be further investigated in multicenter studies. Further, multicenter 
collaborations with the use of standardized clinical assessment and management plans may 
yield clues to improve the long-term follow-up and care of CDH patients. To improve patient 
outcomes, research should also focus on developing intervention strategies, such as memory 
training programs, as well as identifying underlying causes of adverse outcomes, which hope-










Congenitale hernia diafragmatica ofwel een aangeboren middenrifbreuk, in het Engels ‘conge-
nital diaphragmatic hernia’ (CDH), is een ernstige aangeboren afwijking van het middenrif en 
de longen die bij 1 op de 2.500 pasgeborenen voorkomt. De meeste kinderen met deze aan-
doening hebben direct na de geboorte moeite met ademen waardoor ze meteen beademd 
moeten worden. Dankzij nieuwe behandelmethoden en gestandaardiseerde behandeling 
zijn hun overlevingskansen in de afgelopen jaren echter sterk verbeterd. Het is nu dan ook 
belangrijk dat er verder onderzoek wordt gedaan naar hun uitkomsten op de langere termijn. 
Dit proefschrift beschrijft onderzoek naar diverse uitkomsten van CDH patiënten, waaronder 
de schildklierfunctie, de aanwezigheid van pulmonale hypertensie (verhoogde bloeddruk in 
de longvaten), de fysieke groei en de neuropsychologische ontwikkeling. Zes studies werden 
verricht in het Erasmus MC-Sophia Kinderziekenhuis in Rotterdam (hoofdstukken 2, 3, 4, 7 
en 8) en twee studies in het Westmead Children’s Hospital in Sydney (hoofdstukken 5 en 
6). Zowel in Rotterdam als in Sydney worden CDH patiënten poliklinisch gevolgd tot aan 
de leeftijd van 18 jaar.
Hoofdstuk 1
In hoofdstuk 1 wordt een overzicht gegeven van de geschiedenis en de huidige kennis 
omtrent de behandeling en de risico’s van CDH. Na intubatie en opname op de kinder 
intensive care wordt gewacht met operatieve behandeling van de middenrifbreuk tot de 
patiënt klinisch stabiel is, waarbij beademd wordt met zo laag mogelijke piekdrukken. De 
meest zieke patiënten worden daarnaast behandeld met geïnhaleerde stikstofmonoxide, 
hoogfrequente beademing en extracorporele membraan oxygenatie (ECMO). ECMO is 
een behandeling waarbij een hart-longmachine het werk van de longen en het hart tijdelijk 
overneemt, waardoor deze organen kunnen herstellen. ECMO wordt alleen toegepast als 
uiterste redmiddel indien er zeer hoge kans is op overlijden als gevolg van ernstig longfalen. 
Eerdere studies hebben al laten zien dat longproblemen bij CDH patiënten langdurig aan-
wezig kunnen blijven. Op het ogenblik is er echter nog maar weinig bekend over de overige 
uitkomsten van CDH patiënten.
Hoofdstuk 2
In hoofdstuk 2 beschreven we de incidentie van een afwijkende screeningsuitslag op congeni-
tale hypothyreoïdie (aangeboren tekort aan schildklierhormoon) tijdens de hielprikscreening 
bij 168 ECMO-behandelde pasgeborenen.  Als de screening werd verricht voor ECMO werd 
bij 73% een afwijkende uitslag gevonden; als dit tijdens ECMO werd gedaan bij 67%; en als 
dit na ECMO werd gedaan bij 31%. Bijna alle patiënten met een afwijkende screeningsuitslag 
hadden een lage concentratie totaal thyroxine in combinatie met een normale concentratie 
thyroïd stimulerend hormoon in hun bloed. Uiteindelijk bleek geen van de pasgeborenen met 
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een afwijkende screeningsuitslag congenitale hypothyreoïdie te hebben. Deze bevindingen 
duiden erop dat de afwijkende screeningsuitslagen bij ECMO-behandelde pasgeborenen het 
meest waarschijnlijk het gevolg zijn van het zogenoemde ‘non-thyroidal illness syndroom’, 
welke kan optreden bij ernstig zieke patiënten. Deze schildklierfunctiestoornis wordt geken-
merkt door lage concentraties thyroxine en triiodothyronine, een hoge concentratie inactief 
triiodothyronine in combinatie met een normale of lage concentratie thyroïd stimulerend 
hormoon. Screening voor en tijdens ECMO en een hogere ‘Pediatric Logistic Organ Dysfunc-
tion-2’ score, een maat voor de ziekte-ernst, waren geassocieerd met een hoger risico op een 
afwijkende screeningsuitslag op congenitale hypothyreoïdie. We vonden echter geen verschil 
in sterfte tussen pasgeborenen met een afwijkende screeningsuitslag en pasgeborenen met 
een normale screeningsuitslag. 
Hoofdstuk 3
In hoofdstuk 3 deden we verder onderzoek naar de veranderingen in schildklierhormoon-
concentraties die optreden bij pasgeborenen tijdens ECMO. Op zes vaste tijdspunten (voor, 
tijdens en na ECMO) werden schildklierhormoonconcentraties in het bloed gemeten bij 
10 pasgeborenen met CDH en 11 pasgeborenen met meconium aspiratie syndroom. De 
metingen voor ECMO wezen wederom op schildklierfunctiestoornissen passend bij het 
bovengenoemde ‘non-thyroidal illness syndroom’. Na de start van de ECMO-behandeling, 
zagen we een verdere daling van de schildklierhormoonconcentraties, met uitzondering van 
de concentratie vrij thyroxine. Na deze daling namen de schildklierhormoonconcentraties 
gedurende de ECMO-behandeling weer toe.  Allereerst steeg de concentratie thyroïd sti-
mulerend hormoon, waarna ook de concentraties totaal thyroxine en totaal triiodothyronine 
toenamen. Dit patroon suggereert dat herstel van de hypothalamus-hypofyse-schildklier as 
optreedt tijdens de ECMO-behandeling. Omdat de vrij thyroxine concentratie stabiel en 
binnen de normaalwaarde bleef, lijkt behandeling met thyroxine tijdens ECMO niet nodig. 
Op de follow-up na 2 jaar, vertoonden overlevende kinderen normaal cognitief functioneren.
Hoofdstuk 4
In hoofdstuk 4 onderzochten we of routinematige follow-up voor pulmonale hypertensie 
(verhoogde bloeddruk in de longvaten) zinvol was bij CDH patiënten gedurende het eerste 
levensjaar.  Voor dit doel werd echocardiografie en elektrocardiografie uitgevoerd bij 52 
CDH patiënten op de leeftijd van 6 maanden en/of 12 maanden. Drie patiënten hadden op 
de leeftijd van 6 maanden nog tekenen van pulmonale hypertensie bij echocardiografie, en 
twee op de leeftijd van 12 maanden. Deze patiënten met persisterende pulmonale hyper-
tensie waren langer beademd tijdens de eerste ziekenhuisopname en verbleven langer in 
het ziekenhuis dan patiënten zonder persisterende pulmonale hypertensie. Ook waren al 
deze patiënten behandeld met geïnhaleerde stikstofmonoxide, sildenafil en bosentan, terwijl 




waren geweest. Dit duidt erop dat patiënten met persisterende pulmonale hypertensie 
ernstiger ziek zijn in de eerste levensweken. Omdat de diagnose pulmonale hypertensie bij 
twee van de drie patiënten gemist werd op het elektrocardiogram, lijkt elektrocardiografie 
niet geschikt voor de follow-up van pulmonale hypertensie bij CDH patiënten. Poliklinische 
follow-up van pulmonale hypertensie middels echocardiografie lijkt ons vooral zinvol bij 
patiënten met echocardiografische tekenen van pulmonale hypertensie bij ontslag naar huis 
en/of gebruik van medicatie voor pulmonale hypertensie ten tijde van ontslag.
Hoofdstuk 5
In hoofdstuk 5 evalueerden we de fysieke groei en de aanwezigheid van voedingsproble-
men bij 38 CDH patiënten gedurende het eerste levensjaar. Daarnaast onderzochten we 
mogelijke voorspellers voor het optreden van een groeiachterstand (failure to thrive). Op de 
leeftijd van 3 maanden hadden patiënten een lager gewicht, een kleinere lichaamslengte en 
een kleinere schedelomtrek dan normaal, waarbij het gewicht het meeste achterbleef. Op de 
leeftijd van 12 maanden was echter een inhaalgroei opgetreden, voor zowel gewicht, lengte 
als schedelomtrek. Een langere beademingsduur was de enige voorspeller voor een groeiach-
terstand op de leeftijd van 6 maanden. Eén vijfde van de kinderen had voedingsproblemen, 
waaronder onvoldoende ontwikkeling van de zuig- en slikreflex, onjuiste drinktechniek, voe-
dingsproblemen door ademhalingsmoeilijkheden, orale aversie en gastro-oesofageale reflux.
Hoofdstuk 6
In hoofdstuk 6 evalueerden we de ontwikkeling op het gebied van taal, motoriek en cognitie 
op 1-jarige en 3-jarige leeftijd bij 18 CDH patiënten, en vergeleken deze met een gezonde 
controlegroep. Op 1-jarige leeftijd, hadden twee patiënten een milde achterstand op het 
gebied van taalproductie of taalbegrip, en vier patiënten hadden een achterstand op het 
gebied van grove motoriek. Op 3-jarige leeftijd, hadden drie patiënten een milde achterstand 
op het gebied van taalproductie en één patiënt op het gebied van taalbegrip. De overige 
uitkomsten op het gebied van taal, motoriek en cognitie waren normaal op deze leeftijd. Er 
waren geen verschillen in ontwikkelingsuitkomsten (taal, motoriek en cognitie) tussen de 
CDH patiënten en de controlegroep op de leeftijd van 1 en 3 jaar.
Hoofdstuk 7
In hoofdstuk 7 onderzochten we de neuropsychologische uitkomsten op 8-jarige leeftijd 
bij 40 CDH patiënten (van wie 10 behandeld waren met ECMO) en 25 patiënten zonder 
CDH die kort na de geboorte met ECMO behandeld waren. Daarnaast analyseerden we 
mogelijke voorspellers van neuropsychologische uitkomsten. Kinderen hadden problemen 
met volgehouden aandacht, verbaal geheugen en visueel geheugen, ondanks de aanwezig-
heid van een normaal intelligentie quotiënt (IQ). Het IQ van CDH patiënten die behandeld 
waren met ECMO was het laagst. Ziekte-ernst indicatoren waren de belangrijkste voor-
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spellers voor neuropsychologische uitkomsten, wat erop wijst dat de meest ernstig zieke 
kinderen het hoogste risico lopen op een slechte neuropsychologische uitkomst. Meerdere 
ingrepen onder algehele narcose in het eerste levensjaar had ook een negatief effect op de 
neuropsychologische uitkomst. Daarnaast was er een positief verband tussen het gewicht 
op 1-jarige leeftijd en het IQ. Echter, na het invoeren van alle significante voorspellers in 
het voorspellingsmodel, bleef er alleen een negatief verband bestaan tussen de maximale 
‘vasoactive-inotropic’ score, een maat voor de benodigde hoeveelheid vasoactieve medicatie 
en ziekte-ernst, en verbaal en visueel lange termijn geheugen. Dit duidt erop dat kinderen die 
het meest ernstig ziek waren in de eerste levensdagen, met daarbij mogelijk een hoger risico 
op cerebrale hypoperfusie, meer risico hadden op geheugenproblemen op 8-jarige leeftijd. 
Hoofdstuk 8
In hoofdstuk 8 beschreven we de longitudinale groei tot aan de leeftijd van 12 jaar bij 172 
CDH patiënten (van wie 43 patiënten behandeld met ECMO). Daarnaast onderzochten 
we voorspellers voor fysieke groei en mogelijke oorzaken van een groeiachterstand. Een 
afbuiging van gewicht trad op van de leeftijd van 6 maanden tot 1 jaar, en hierna boog de 
lengtegroei af tot de leeftijd van 5 jaar. Dit groeipatroon met onvoldoende gewichtstoe-
name gevolgd door vertraagde lengtegroei duidt mogelijk op chronische ondervoeding 
in het eerste levensjaar. ECMO-behandelde patiënten hadden een lager gewicht en een 
kleinere lengte dan patiënten die niet behandeld waren met ECMO. De eerder opgetreden 
groeiachterstand van patiënten werd niet geheel ingehaald, en op 12-jarige leeftijd waren 
zij nog steeds kleiner dan de normpopulatie. De lengtescores van patiënten verbeterden na 
correctie voor de berekende streeflengte maar zelfs na deze correctie bleven zij kleiner dan 
de normpopulatie. Lengte en gewicht werden beide negatief beïnvloed door ECMO-be-
handeling en correctie van de middenrifbreuk met een patch (kunststoflapje). Sondevoeding 
had een positief effect op zowel het gewicht als de lengte. Bij vier van de 11 CDH patiënten 
met een groeiachterstand, vonden we een verhoogd rustmetabolisme en bij zeven patiën-
ten waren eetproblemen aanwezig. Beide factoren lijken dan ook een rol te spelen bij het 
ontstaan van een groeiachterstand. Ter voorkoming hiervan is vroegtijdige risicostratificatie 
nodig met regelmatige beoordeling van de voedingsstatus en het tijdig starten van voedings-
interventies.
Hoofdstuk 9
In hoofdstuk 9 bespraken we de studieresultaten en gaven we aanbevelingen voor verder 
onderzoek. Uit ons onderzoek blijkt dat CDH een complexe aandoening is die niet alleen 
gepaard gaat met longproblemen. Op de korte termijn hadden kinderen een hoog risico op 
het ‘non-thyroidal illness syndroom’ en pulmonale hypertensie. Op de lange termijn vonden 
we groeiproblemen en problemen met volgehouden aandacht, verbaal geheugen en visueel 




te blijven volgen. De ziekte-ernst in de eerste levensweken was de belangrijkste voorspeller 
van uitkomsten in onze studies. Voor de ontwikkeling van betere voorspellingsmodellen in de 
toekomst, is meer multicenter onderzoek nodig. Daarnaast denken wij dat de invoering van 
‘standardized clinical assessment and management plans’ waardevol kan zijn voor het verbe-
teren van de zorg voor CDH patiënten. Tot slot moet toekomstig onderzoek zich ook richten 
op het ontwikkelen van interventiestrategieën en het identificeren van de onderliggende 















BADS-C-NL Behavioral assessment of the dysexecutive syndrome children-Dutch 
version
Bayley-III Bayley scales of infant and toddler development-third edition





DCT Dot cancellation test
DTH Distance-to-target height
ECG Electrocardiograph
ECMO Extracorporeal membrane oxygenation
FFP Fresh frozen plasma
FiO2 Inspiratory oxygen fraction
FT4 Free thyroxine
FTT Failure to thrive
GERD Gastroesophageal reflux disease
H2O Water
HFA Height-for-age
HFOV High frequency oscillation ventilation
HPT Hypothalamic-pituitary-thyroid
iNO Inhaled nitric oxide
IQR Interquartile range
LHR Lung-to-head ratio
MAS Meconium aspiration syndrome
NTIS Non-thyroidal illness syndrome
PAPVR Partial anomalous pulmonary venous return
PEEP Positive end expiratory pressure
PELOD-2 Pediatric Logistic Organ Dysfunction-2
PH Pulmonary hypertension
PICU Pediatric intensive care unit
PIP Peak inspiratory pressure
PRISM III Pediatric Risk of Mortality III
RAVLT Rey auditory verbal learning test
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RCFT Rey complex figure test
REE Resting energy expenditure
rT3 Reverse triiodothyronine
SCAMPS Standardized clinical assessment and management plans
SD Standard deviation
SDS Standard deviation score
STRONGkids Screening Tool for Risk On Nutritional status and Growth




TEN Total energy need
TH Target height
TMT A Trail making test section A
TMT B Trail making test section B
TR Tricuspid regurgitation
TSH Thyroid-stimulating hormone or thyrotropin
TT4 Total thyroxine
TT3 Total triiodothyronine 
VA Veno-arterial





WISC-III-NL Wechsler intelligence scale for children-third edition-Dutch version








Leeuwen L*, Kraemer US*, Krasemann TB, Wijnen RMH, Tibboel D, IJsselstijn H.  Character-
istics of infants with congenital diaphragmatic hernia who need follow-up of
pulmonary hypertension. Provisionally accepted in Pediatr Crit Care Med.
Leeuwen L*, Schiller RS*, Rietman AB, van Rosmalen J, Wildschut ED, Houmes RJ, Tibboel D, 
IJsselstijn H. Risk factors of impaired neuropsychological outcome in school-aged
survivors of neonatal critical illness.  Accepted in Crit Care Med.
Leeuwen L, Mous DS, van Rosmalen J, Olieman JF, Andriessen L, Gischler SJ, Joosten KFM, 
Wijnen RMH, Tibboel D, IJsselstijn H, Spoel M. Congenital diaphragmatic hernia and growth. 
Pediatrics. 2017; 140: e20163659.
Leeuwen L, van Heijst AFJ, van Rosmalen J, de Rijke YB, Beurskens LWJE, Tibboel D, van den 
Akker ELT, IJsselstijn H. Changes in thyroid hormone concentrations during neonatal extra-
corporeal membrane oxygenation. J Perinatol. 2017; doi: 10.1038/jp.2017.56.
Leeuwen L, van Heijst AF, Vijfhuize S, Beurskens LW, Weijman G, Tibboel D, van den Akker 
EL, IJsselstijn H. A nationwide evaluation of congenital hypothyroidism during neonatal extra-
corporeal membrane oxygenation. Neonatology. 2017; 111: 93-99.
Leeuwen L, Walker K, Halliday R, Fitzgerald DA. Neurodevelopmental outcome in congenital 
diaphragmatic hernia survivors during the first three years. Early Hum Dev. 2014; 90: 413-415.
Leeuwen L, Walker K, Halliday R, Karpelowsky J, Fitzgerald DA. Growth in children with con-
genital diaphragmatic hernia during the first year of life. J Pediatr Surg. 2014; 49: 1363-1366.
Leeuwen L, Fitzgerald DA. Congenital diaphragmatic hernia. J Paediatr Child Health. 2014; 
50: 667-673.
Leeuwen L, Magoffin AK, Fitzgerald DA, Cipolli M, Gaskin KJ. Cholestasis and meconium ileus 
in infants with cystic fibrosis and their clinical outcomes. Arch Dis Child. 2014; 99: 443-447.






Leeuwen L, van Holten J, Loeffen JLCM, de Mol AC, Keyzer-Dekker CMG. Chronische buikpijn 








Name    Lisette Leeuwen
Department   Intensive care and pediatric surgery
PhD period   November 2014 - December 2017
Promotors   Prof. dr. D. Tibboel
    Prof. dr. R.M.H. Wijnen
Copromotor   Dr. H. IJsselstijn
Research school   Medical Genetic Center
1. PhD Training
General academic skills Year Workload
Systematical literature retrieval course Jan. 2015 1.0 ECTS
Research integrity course Apr. 2015 0.3 ECTS
Biomedical English writing and communication course Apr. 2015 3.0 ECTS
BROK course Sept. 2015 1.5 ECTS
Presenting skills for junior researchers Oct. 2016 1.0 ECTS
Biomedical English writing course June 2017 2.0 ECTS
Research skills Year Workload
Basic introduction on SPSS May 2015 1.0 ECTS
Biostatistical methods I: basic principles Oct. 2015 5.7 ECTS
Seminars and workshops Year Workload
Workshop: how to present your poster Feb. 2015 0.5 ECTS
Amsterdam pediatrics symposium 2015 Feb. 2015 0.3 ECTS
CPO Course: patient oriented research Apr. 2015 0.3 ECTS
Symposium: interdisciplinary care; an image of the future Apr. 2015 0.2 ECTS
Workshop: grant writing May 2015 0.1 ECTS
LNF conference 2015 June 2015 0.3 ECTS
Workshop: how to present your SLAM session June 2015 0.2 ECTS
COEUR course: congenital heart disease June 2015 1.5 ECTS
EUR course: presenting and pitching skills Nov. 2015 0.3 ECTS
TULIPS: child health symposium Mar. 2016 0.3 ECTS
Workshop: leading through conflict Nov. 2016 0.1 ECTS
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Erasmus MC PhD day 2015-2017 1.0 ECTS
Sophia Research Day 2015-2017 1.0 ECTS
Presentations Year Workload
‘Growth and neurodevelopmental outcomes in congenital 
diaphragmatic hernia survivors during the first three years 
of life’ 
Apr. 2013 0.5 ECTS
‘Deterioration of lung function and exercise capacity in 
congenital diaphragmatic hernia survivors over three 
decades’ 
Jan. 2015 0.5 ECTS
‘High incidence of abnormal screening results for 
congenital hypothyroidism in ECMO-treated neonates’ 
Mar. 2015 0.5 ECTS
‘Changes in thyroid hormone concentrations during 
neonatal ECMO’ 
Oct. 2016 0.5 ECTS
‘Growth in congenital diaphragmatic hernia patients until 
12 years of age’ 
Oct. 2016 0.5 ECTS
‘Memory problems following neonatal critical illness’ Nov. 2016 0.5 ECTS
International and national conferences Year Workload
European Respiratory Society Congress, Barcelona 
(poster presentation)
Sept. 2013 2.0 ECTS
Pediatric Association of the Netherlands Congress, 
Veldhoven  (oral presentation)
Nov. 2013 2.0 ECTS
International Student Congress of (bio)Medical Sciences, 
Groningen (oral presentation)
June 2014 2.0 ECTS
European Academy of Paediatric Societies Congress, 
Geneva (two oral presentations)
Oct. 2016 3.0 ECTS
Other activities Year Workload
Research meetings: department of respiratory medicine; 
department of intensive care and pediatric surgery; clinical 
PhD-students
2014-2017 1.5 ECTS
Organizing committee member Sophia Research Day 2014-2015 2.0 ECTS
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Lecturing talented primary school children 2014 0.5 ECTS
Coaching first- to third-year medical students 2015-2017 2.0 ECTS
Tutoring first-year medical students 2015-2017 3.0 ECTS
Didactic courses and workshops Year Workload
Training ‘Coaching of future Erasmusdoctors’ Feb. 2015 0.2 ECTS
E-learning symposium June 2015 0.2 ECTS
Training ‘Dealing with groups’ Aug. 2015 0.1 ECTS
ECTS=European Credit Transfer and Accumulation System






The breath of life, prana, ofwel onze ademhaling. Ademhalen begint onmiddellijk na de 
geboorte en is onlosmakelijk verbonden met het leven. Onze ademhaling ervaren we vaak 
als vanzelfsprekend maar dit is zeker niet voor iedereen het geval. In dit proefschrift heb ik 
laten zien dat ademhalen voor kinderen met een congenitale hernia diafragmatica vanaf het 
moment na de geboorte een probleem vormt. De problemen die optreden ten gevolge 
van het defect in hun diafragma gaan gepaard met een hoog risico op ziekte en zelfs sterfte. 
Vanaf de eerste ademhaling vechten deze kinderen met een buitengewone kracht voor 
hun leven. Het is ongelofelijk wat een herstel ze in deze vroege periode doormaken, maar 
hiervoor hebben ze een lange adem nodig. Ik heb enorm veel bewondering en respect voor 
de sterkte en veerkracht van deze patiënten en hun ouders. Allereerst wil ik dan ook alle 
patiënten en hun ouders bedanken. Zij zijn de reden dat ik ben begonnen met dit promotie 
onderzoek en ik hoop met mijn onderzoek te hebben bijgedragen aan het verbeteren van 
de zorg voor en uitkomsten van deze groep patiënten. Lieve patiënten en ouders, bedankt 
en ik wens jullie al het goede en heel veel geluk in de toekomst!
Het heeft even geduurd, maar nu is het eindelijk zover, het boekje is af! Zoals hierboven 
genoemd, hebben kinderen met een congenitale hernia diafragmatica een lange adem nodig 
voor hun herstel. Ik heb in de afgelopen jaren ervaren dat een lange adem ook essentieel is 
voor het schrijven van een proefschrift. Echter, ik had dit proefschrift nooit kunnen schrijven 
zonder de hulp van heel veel fantastische, mooie, lieve mensen die ik hier graag wil bedanken.
Beste Prof. Tibboel, beste Dick, bedankt voor de kans om dit promotietraject te combi-
neren met het werken in de kliniek, een hele leerzame ervaring. Dank ook voor uw blijvende 
geloof in mij als wetenschapper. Ik bewonder uw heldere visie en uw passie en inzet voor 
de wetenschap en hoop deze zelf ook te behouden, waardoor de zorg voor patiënten in de 
toekomst verder verbeterd kan worden.
Beste Prof.  Wijnen, beste René, bedankt voor het vertrouwen en alle leermomenten zowel 
op wetenschappelijk als klinisch gebied. Het is mooi en inspirerend om samen te werken met 
iemand die dezelfde passie en hartstocht voor de patiëntenzorg heeft. Ik hoop dat ik deze 
passie en hartstocht, net als u, blijf behouden in mijn verdere carrière. 
Beste Hanneke, bedankt voor je begeleiding vanaf het begin van mijn promotie. Ongeacht 
het tijdstip of de tijdzone, ik had op alle mails gegarandeerd een snel antwoord terug, waar-
door ik zo snel mogelijk weer verder kon. Bedankt voor je gedetailleerde kijk en nauwkeurige 
commentaar op alle artikelen, wat heeft geleid tot mooie publicaties. 
Dear Dominic, I could not have wished for a better supervisor to introduce me into 
the research world. You are such a great doctor and scientist! With your clear vision, never 
ending energy, enthusiasm and good sense of humor, you managed to keep me interested 
in research during my time in Sydney. This resulted in my first publications together with a 
good healthy tan and addictions to running, yoga, and Sydney’s beaches. I hope to catch up 
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with you and your family soon!
Beste leden van de kleine commissie, beste Dr. Erica van den Akker, beste Prof. Ivo de 
Blaauw, beste Prof. Irwin Reiss, bedankt voor het beoordelen van mijn proefschrift en deel-
nemen in de kleine commissie. Hartelijk dank ook Prof. Allegaert en Prof. Rings voor het 
zitting nemen in de grote commissie.
Beste coauteurs, beste Ulrike, Arno, Niels, André, Karen, Robert, Jonathan, Koen, Saskia, 
Marjolein, Thomas, Enno, Robert Jan, Yolanda, Joost, Gert, Sanne, Laura, Joanne, en natuurlijk 
Ko, heel erg bedankt voor al jullie inzet en hulp bij het schrijven van alle artikelen in dit 
proefschrift. Zonder jullie hulp was dit proefschrift er niet geweest en alle artikelen zijn 
echt zoveel beter geworden door jullie kritische blik. Het was fijn samenwerken, heel erg 
bedankt daarvoor!
Beste Evelien, wat een geluk dat ik jou ben tegengekomen, onwijs leuk om met zo’n cre-
atieve collega samen te werken aan het ontwerpen van mijn boekje, met ook een heel mooi 
resultaat. Super bedankt voor al je hulp!
Lieve Annemarie, Marie-Louise en Marja, ook jullie wil ik bedanken! Dankzij jullie hulp werd 
alles altijd zo snel mogelijk en nauwkeurig geregeld. Zelfs als beide professoren op reis waren 
en ik toch ‘echt, echt zo snel mogelijk’ verder moest met van alles en nog wat, regelden jullie 
het wel. Heel erg bedankt voor al jullie hulp en de leuke en gezellige tijd die ik met jullie in 
het Sophia heb gehad.
En dan natuurlijk de allerleukste kinderchirurgen, Claudia, Conny, Hester, John, Kees, Pim 
en Marco, wat ben ik blij dat ik in de kliniek met jullie heb mogen samenwerken. Tijdens mijn 
onderzoeksweken keek ik altijd weer uit naar het moment dat ik de kliniek in mocht. Dankzij 
jullie aanstekelijke enthousiasme, kennis en kunde heb ik met heel veel plezier in de kliniek 
gewerkt, enorm veel geleerd en me verder kunnen ontwikkelen als arts. Jullie zijn fantastische 
artsen en mensen, super bedankt voor de mooie tijd die ik bij jullie heb gehad!
Lieve arts-assistenten en verpleegkundig specialisten, Kitty, Daphne, Rhiana, Rosalie, Evelien, 
Chantal, Sergei, Ryan, Klarieke, Kayleigh, Irene, Susanna, Nicole, Alwin, Thirza, Sanne en Elvira, 
en natuurlijk alle lieve verpleegkundigen van alle Sophia afdelingen en de SEH, het was heel 
fijn om met jullie samen te werken. Bedankt voor alle gezelligheid en alle leermomenten in 
de kliniek, jullie zijn geweldige collega’s en ik ga jullie missen!
Alle (ex-)kamergenoten van SP-2430 en NA-1723, lieve Bianca, Annelieke, Tanja, Willem, 
Frank, Manuel, Shelley, Renate, Esther, Dorian, Alexandra, Marlous, Miriam, Nienke, Janneke, 
Ries en Aukje, bedankt voor alle supermooie en supergezellige momenten, echt te veel om 
hier allemaal op te noemen... Jullie maakten dat ik iedere dag weer met een lach naar het 
Sophia fietste, bedankt lieverds!
Lieve SOV-bestuursgenootjes, lieve Robin en Manouk, ik had me geen betere en lievere 
bestuursgenootjes kunnen wensen, wat ben ik blij dat ik met jullie het SOV-bestuur heb 
mogen doen en wat was het fijn om met jullie samen te werken. Lieve Paola, heel fijn dat jij 




nu al uit naar het eerste SOV Alumni Event!
Lieve Sophia Onderzoekers, wat een leuke, enthousiaste, inspirerende onderzoekers 
hebben we in het Sophia! Ik heb enorm veel van jullie geleerd en daarnaast natuurlijk heel 
veel gezellige en mooie momenten beleefd met alle koffietjes, lunches, borrels, weekendjes, 
workshops, Erasmus Tours en Sophia Research Days, bedankt voor deze mooie tijd!
Verhuizen van Groningen naar Sydney, van Sydney naar Galle, weer terug naar Groningen, 
en daarna naar Rotterdam. Dit, in combinatie met mijn passie voor reizen hebben ervoor 
gezorgd dat ik in de afgelopen jaren enorm veel inspirerende mensen ben tegengekomen 
en veel nieuwe vrienden heb gemaakt. Lieve familie, vrienden, (ex-)collega’s, yogi’s, hardloop-, 
sport- en reismaatjes, bedankt voor alle mooie en onvergetelijke momenten! Many thanks 
to all the creative, inspiring, lovely people I met during my travels and time abroad. You all 
made me feel so welcome in every corner of the world, and I would like to thank you for 
all the unforgettable moments! I feel truly blessed having so many amazing international 
friends all over the globe.
Lieve vriendinnen, de allerliefste en allerleukste vriendinnen, van wie je weet dat ze er 
altijd zullen zijn en blijven, die aan een half woord of alleen een blik al genoeg hebben, die 
altijd weer een lach op je gezicht weten te toveren, die altijd in zijn voor nieuw avonturen 
en uitdagingen, met wie het altijd vertrouwd en gezellig is, en die je altijd zullen steunen en 
achter je staan! Lieve Klaziena, Rose, Ella, Michelle en Willemke, bedankt voor jullie oneindige 
vriendschap!
Lieve Esther, 10 jaar geleden werden we vriendinnen tijdens het introductiekamp van de 
PanIC en ik had me geen beter en liever vriendinnetje kunnen wensen. Ontelbaar veel mooie 
ervaringen en momenten waren het resultaat! Op ieder uur van de dag en nacht ben je mijn 
onvoorwaardelijke steun en toeverlaat. Ik heb enorm veel bewondering voor wat je allemaal 
doet, onwijs knap! Ik hoop dat we nog heel lang vriendinnen blijven, lieve Es!
Lieve Raisa, ‘you are my person in het Sophia’! Vanaf het begin van mijn promotietraject 
stond je aan mijn zijde en wat ben ik daar blij om. Ik krijg alweer een lach op mijn gezicht als 
ik terugdenk aan alle leuke, mooie en hilarische momenten in het Sophia. Daarnaast waren 
we ook een super goed team met als resultaat een heel mooi artikel. Ik heb heel veel van 
je geleerd en er ook nog eens een hele goede vriendin bij gekregen. Ik heb nu al zin in alle 
mooie momenten die nog gaan volgen, lieve Rais!
Lieve Sieswerda’s, lieve Jeltina, Thijs, Wietse, Anna, Peter, Nynke, Jesper, Anna, Antje, Anke, 
Douwe, Annika, Johan en Ivonne, de allerliefste en allergezelligste familie die er is! Wat ben ik 
dankbaar dat jullie er altijd voor me zijn. Bedankt voor jullie liefde, steun, vertrouwen, humor, 
positieve instelling en heerlijke relativeringsvermogen, en nu dus eindelijk feest!
Lieve Jacob, Alex en Sanne, wat ben ik blij met jullie als stiefvader, stiefbroer en stiefzus. Vele 
jaren vol gezelligheid en mooie herinneringen en nog vele te gaan. Lieve Jacob, Alex, Sanne, 
Joke, Janiek, Arjan en Lieke, bedankt dat jullie er altijd voor me zijn. 
Lieve Will, wat ben ik gelukkig dat ik op mijn 15de jou als grote broer erbij kreeg, een 
Chapter 12
210
betere en lievere broer kan ik me niet voorstellen en ik ben dan ook enorm dankbaar! Lieve 
Will, Nienke, Semm en Sele, bedankt voor alle mooie momenten en op naar nog vele in 
de toekomst.
Lieve Pake en Beppe, van jongs af aan hebben jullie mij en Joey grootgebracht. En ook nu 
nog, ongeacht het tijdstip of de reden, we kunnen altijd bij jullie terecht. Met onvoorwaardeli-
jke liefde hebben jullie ons altijd gesteund, door dik en dun, en jullie zijn altijd in ons blijven 
geloven. Mijn dank en liefde is groot, lieve Pake en Beppe.
Lieve Joey, elkaars tegenpolen, maar altijd twee handen op één buik en vanaf het begin 
onafscheidelijk. Ontelbaar veel mooie momenten en herinneringen hebben we nu al en ik 
heb heel veel zin in de vele die nog gaan volgen. I will always have your back, broertje, hou 
van je!
Lieve Mam, ik had me geen mooiere, slimmere, sterkere of lievere moeder kunnen wensen. 
Bedankt dat je er altijd voor me bent, voor je oneindige vertrouwen en geloof in mij, altijd 
op elk moment, overal. Je bent mijn voorbeeld, hou van je lieve Mam!








1. The burden of congenital diaphragmatic hernia is far more extensive than only respi-
ratory morbidity. - this thesis 
2. The high incidence of aberrant screening results for congenital hypothyroidism in neo-
nates treated with extracorporeal membrane oxygenation is caused by non-thyroidal 
illness syndrome. - this thesis 
3. Routine screening of patients with congenital diaphragmatic hernia for pulmonary hyper-
tension in the first year is a waste of money, time and effort. - this thesis 
4. Neuropsychological outcome and physical growth of patients with congenital diaphrag-
matic hernia is determined by the severity of illness during the neonatal period. - this 
thesis 
5. Patients with congenital diaphragmatic hernia should receive standardized long-term 
follow-up during childhood, and ideally, follow-up should be problem-oriented and a 
moving target with regular updates according to the latest research findings. - this thesis 
6. Despite improved survival rates of critically ill children, pediatric intensive care has not 
become easier. - Rennick et al. Pediatrics. 2015
7. Physicians’ ‘gut feelings’ are a valuable skill, and these ‘gut feelings’ should not be ignored 
but used in medical decision making as well as in life. - Van den Bruel et al. BMJ. 2012
8. An open, curious mind is the sine qua non of success and achievement in any field, and 
therefore should always be encouraged. - Werner et al. Med Educ. 2011
9. Work experience abroad is very beneficial and valuable for the holistic develop-
ment of physicians. - Reardon et al. BMC Med Educ. 2015
10. A physician, though well versed in the knowledge and treatment of disease, who does 
not enter into the heart of the patient with the virtue of light and love, will not be able 
to heal the patient. - Charaka, ‘Father of Indian Medicine’
11. Be the change you want to see in the world. - Mahatma Gandhi 
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About this Thesis
Congenital diaphragmatic hernia (CDH) is a 
severe congenital anomaly of the diaphragm 
and both lungs, which occurs in approximately 
1 per 2,500 births. Most CDH patients will 
have difficulty breathing directly after birth, 
and need immediate mechanical ventilatory 
support. Advanced postnatal treatment op-
tions with standardized treatment improved 
the survival outlook, even of CDH patients 
with most severe pulmonary hypoplasia and 
pulmonary hypertension. 
This thesis describes the postnatal risks and 
short- and long-term outcomes of CDH 
patients from neonatal age until school age. 
Early outcomes include the risk of disturbed 
thyroid hormone concentrations during the 
neonatal period and the risk of persistent pul-
monary hypertension in the first year of life. 
Long-term outcomes include the risk of neu-
ropsychological problems and growth failure 
until school age. Six studies were performed 
in the Sophia Children’s Hospital in Rotter-
dam, the Netherlands (chapters 2, 3, 4, 7, and 
8), and two in the Westmead Children’s Hos-
pital in Sydney, Australia (chapters 5 and 6). 
Congenitale hernia diafragmatica ofwel een 
aangeboren middenrifbreuk, in het Engels 
‘congenital diaphragmatic hernia’ (CDH), is 
een ernstige aangeboren afwijking van het 
middenrif en de longen die bij 1 op de 2.500 
pasgeborenen voorkomt. De meeste kin-
deren met deze aandoening hebben direct 
na de geboorte moeite met ademen waar-
door ze meteen beademd moeten worden. 
Dankzij nieuwe behandelmethoden en ge-
standaardiseerde behandeling zijn hun over-
levingskansen in de afgelopen jaren echter 
sterk verbeterd. 
Dit proefschrift beschrijft onderzoek naar 
diverse uitkomsten van CDH patiënten, waar-
onder de schildklierfunctie, de aanwezigheid 
van pulmonale hypertensie (verhoogde bloed-
druk in de longvaten), de groei en neuropsy-
chologische ontwikkeling. Zes studies werden 
verricht in het Erasmus MC-Sophia Kinder-
ziekenhuis in Rotterdam (hoofdstukken 2, 3, 
4, 7 en 8) en twee studies in het Westmead 
Children’s Hospital in Sydney (hoofdstukken 
5 en 6). 
Do you ever think about the importance of our breathing? 
Life starts from the first breath we take in when we are born and continues until our 
last breath. Breathing is something we do naturally, most often without thinking about 
it, and without appreciating it. However, we cannot live without breathing: breath is life.
For children born with a diaphragmatic hernia, breathing is not so simple and self-
evident. They will have difficulty breathing immediately after birth due to the lung 
problems associated with the defect in their diaphragm. Consequently, from the first 
breath of life, these children are at a high risk of mortality and morbidity. Fortunately, 
more and more of them now survive. Little is known, however, about the risks and 
consequences of this condition when children grow up. 
This thesis describes the postnatal risks and outcomes of children with congenital 
diaphragmatic hernia from neonatal age until school age.
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